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Abstract  
 
Blastocystis spp. are the most common enteric parasites found in human stool and 
yet, the life cycle of the organism is unknown and the clinical relevance uncertain. Robust 
cysts transmit infection, and many animals carry the parasite.  Infection in humans has 
been linked to Irritable bowel syndrome (IBS). Although Blastocystis carriage is much 
higher in IBS patients, studies have not been able to confirm Blastocystis spp. are the 
direct cause of symptoms. Moreover, eradication is often unsuccessful. 
A number of approaches were utilised in order to investigate the clinical relevance 
of Blastocystis spp. in human IBS patients. Deconvolutional microscopy with time-lapse 
imaging and fluorescent spectroscopy of xenic cultures of Blastocystis spp. from IBS 
patients and healthy individuals was performed. Green autofluorescence (GAF), most 
prominently in the 557/576 emission spectra, was observed in the vacuolated, granular, 
amoebic and cystic Blastocystis forms. This first report of GAF in Blastocystis showed that 
a Blastocystis-specific fluorescein-conjugated antibody could be partially distinguished 
from GAF. Surface pores of 1m in diameter were observed cyclically opening and closing 
over 24 hours and may have nutritional or motility functions. Vacuolated forms, extruded a 
viscous material slowly over 12 hours, a process likely involving osmoregulation. Tear-
shaped granules were observed exiting from the surface of an amoebic form but their 
identity and function could not be elucidated. 
Seventeen different subtypes of Blastocystis based on the 18S subunit of ribosomal 
DNA have been described. Using subtyping techniques, the human and animal household 
contacts of 11 symptomatic Blastocystis-positive patients were studied.  All household 
contacts were found to be positive for Blastocystis spp. The specific subtypes within 
households had high similarity with the symptomatic patients (94% in human and 88% in 
animal contacts). Although 18S rDNA subtyping was not sufficient to discriminate 
genetically identical organisms, the ST findings suggest that intra-household transmission 
of Blastocystis is almost universal. 
 IBS is a common, heterogeneous condition with no objective biomarker. We 
studied eradication rates of Blastocystis following administration of different antimicrobial 
drug regimes. Currently recommended first line therapy for eradication, metronidazole 400 
mg three times daily or sulfamethozazole/trimethoprim 160/80mg were administered to 11 
symptomatic patients for 14 days. No patient was negative for Blastocystis carriage after 
therapy with either drug. In a later study 10 diarrhoea-predominant IBS Blastocystis-
positive patients were given 14 days of triple antimicrobial therapy, namely diloxanide 
furoate 500mg and secnidazole 400 mg three times daily, and trimethoprim-
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sulfamethoxazole 160/80 mg twice daily, with 60% of the patients eradicating the 
organism.  
It is not certain if particular Blastocystis organisms may have more pathogenic 
potential than others. Many different subtypes of Blastocystis were found in all 
symptomatic patients studied in this thesis and thus far there is no support for particular 
subtypes either being pathogenic or commonly transmitted from non-domestic animal 
contacts. Our study of household pets, combined with current knowledge in the literature, 
suggests that Blastocystis may well be a reverse zoonosis when it involves companion 
domestic pets such as dogs and cats.  
If there is no correlation between the Blastocystis subtype and pathogenic potential 
it is possible that the host immunological response determines symptomatology. The 
serological responses to infection in 40 symptomatic diarrhoea-predominant IBS patients 
(26 positive, 14 negative for Blastocystis) and 40 healthy controls (24 positive, 16 negative 
for Blastocystis) were examined. Low serum immunoglobulin A (IgA) levels were found to 
be associated with carriage of Blastocystis but not symptoms (p<0.001). All IBS patients, 
but more commonly the Blastocystis-positive group, had significantly greater reactivity with 
Blastocystis proteins of 27kDa (likely a cysteine protease), 50 and 75-95 kDa molecular 
weight. Specific anti-protease antibodies were shown to react with Blastocystis proteins 
suggesting that metalloproteases, as well as cysteine proteases, may be important 
Blastocystis antigens.   
The faecal microbiota (FM) is recognised to influence our health and is altered in 
IBS. We examined the FM in 40 patients with IBS (26 positive, 14 negative for 
Blastocystis) and 57 healthy controls (42 positive and 15 negative for Blastocystis). 
Characteristic changes in the FM profile of IBS patients at a phylum and genus level were 
observed. However, when the subgroups were analysed there were significant changes 
seen at different taxonomic levels between the Blastocystis positive and negative IBS 
groups. The lower serum IgA level present in Blastocystis carriers was hypothesised to 
result in changes in the FM that enable Blastocystis to flourish with increased epithelial cell 
contact. Other previously described host factors, such as cytokine polymorphisms in IBS 
patients that increase IL-8 production and decrease IL-10, may select subjects for immune 
activation and symptom development. 
In summary, Blastocystis spp. remain enigmatic organisms that are difficult to clear 
from our gastrointestinal tracts. Subtyping has increased our epidemiological 
understanding and infection within households is almost universal. Host immune 
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responses and FM are significantly different in Blastocystis-positive IBS patients 
suggesting that this organism may contribute to IBS in some subjects. 
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 3 
Review of Literature 
1.1 Why investigate Blastocystis species? 
Blastocystis sp. are often the most common faecal parasite identified 
worldwide and infection has been linked to human disease, most specifically 
chronic, watery diarrhoea, bloating and abdominal pain (Tan et al. 2010), 
typically irritable bowel syndrome (IBS) symptoms. The carriage rate in some 
developing countries has been reported to exceed 60% of the community 
(Tan 2008).  Faecal-oral transmission of the parasite likely occurs via 
ingestion of cysts indirectly in contaminated water sources or directly by 
contact with humans and domestic and non-domestic animals (Tan 2008). 
The parasite was under-diagnosed in commercial and research laboratory 
testing until the last 6 years, because identification of the parasite in wet 
faecal smears is unreliable. Molecular techniques have more than doubled the 
diagnostic accuracy (Stensvold et al. 2007a). The organism displays diverse 
morphological forms and the relationship and contribution of these forms in 
the life cycle of the parasite is not understood. Attempts at eradication with 
antimicrobials have a high failure rate (Stensvold et al. 2010). 
There are large gaps in our knowledge with regard to this parasite that 
are important to address, most notably whether the organism causes disease 
in humans or is simply an innocent bystander. Understanding how this 
organism contributes to the human faecal microbiome and any mechanism of 
pathogenicity of this apparently non-invasive organism may offer insights into 
the mechanism of mucosal damage in other gastrointestinal diseases such as 
Inflammatory Bowel Disease (IBD). If Blastocystis organisms are pathogenic 
to humans there are implications for the monitoring of safe water supplies and 
hygiene guidelines for humans and animal handling. It will be difficult to 
suggest preventative strategies or specific therapy until the life cycle of this 
parasite is understood. 
 
1. 2 Introduction to the faecal microbiota 
1.2.1 Defining the faecal microbiota 
The human gut is sterile at birth and during early infancy is colonised 
by organisms originating from the mother, diet and environment. The human 
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adult is host to 100 trillion species of commensal organisms that live in 
facilitative harmony with the 10 trillion cells in our body, the “faecal microbiota” 
(Bonfrate et al. 2013). Over 90% of the faecal mass is comprised of microbes 
namely bacteria (93%), viruses (5.8%), archaea (0.8%) and eukaryotes 
(0.5%)(Arumugam et al. 2011). Using molecular techniques thirty-seven 
eukaryotic species were identified in the faeces of a healthy adult including 
Blastocystis sp., 18 plant species and 18 fungal species (Gouba et al. 2013). 
However the vast majority of the FM (Garduno et al. 2002) comprises 
bacterial species that have not been cultured. The microbial density per gram 
of luminal content changes along the length of the gut from 101 in the 
relatively sterile stomach to 104 organisms in the jejunum, 108 in the ileum, 
1010 in the colon and 1012 in the faeces with anaerobes predominating in the 
colon (Bonfrate et al. 2013).  
The bacterial component of the FM has received most attention. The 
eukaryote contribution to the FM is small but most often includes Blastocystis 
spp. A recent study of 105 healthy adults in Ireland showed the prevalence of 
Blastocystis carriage to be 56%, with diverse subtypes and with stable 
carriage seen over 6-10 years (Scanlan et al. 2014). Blastocystis spp. in many 
people are one of the components of a healthy FM. 
 
1.2.2 Function of the faecal microbiota 
This intestinal microbiota is estimated to contain 3.3 million genes (the 
microbiome) vastly outnumbering our 20,000 human genes. The faecal 
microbiota/microbiome is increasingly recognised as an additional significant 
human organ with important neuroendocrine, metabolic, nutritional and 
protective functions (Albenberg & Wu 2014). The faecal microbiota produces 
micronutrients vitamin B and K and short chain fatty acids (SCFA) that are a 
primary energy source for colonic mucosal cells. The bacteria facilitate 
fermentation of food for host metabolism, produce neurotransmitters that are 
absorbed systemically, conduct immune priming, including differentiation of T 
helper cells, in the host and protect against other luminal pathogens 
(Furusawa et al. 2014).  
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1.2.3  Interaction with the host  
Normally a mucus layer ensures that there is little contact between the 
luminal biota and the host gut epithelial cells. The mucous glycoprotein layer 
in the small bowel is thin and discontinuous in contrast to the sterile, bi-
layered continuous thick mucus layer in the colon (Merga et al. 2014). 
Interaction between luminal bacteria and the host may occur directly with the 
epithelial cell and its glycocalyx, with the tight intercellular junctions between 
these cells or with Peyer’s patches comprising lymphoid cells topped with a 
dome epithelium of microfold (M) cells that are adapted for sampling/immune 
presentation of luminal antigens. The luminal microbiota may be very different 
to the mucosa-associated bacteria.  
 
1.2.4 Identification of the faecal microbiota 
Metagenomic analysis using culture-independent high throughput 16 
short subunit (SSU) ribosomal ribonucleic acid  (rRNA) quantitative gene 
sequencing and microarrays, has recently allowed genetic insights into faecal 
bacterial populations. This technology allows the bacteria to be classified 
according to Phylum, Class, Order, Genus and Species. Of the fifty bacterial 
phyla humans host ten are found in the gut, and 90% of the colonic microbiota 
consists of two dominant phyla, namely Bacteroidetes and Firmicutes with 
great individual variability seen at species and strain level. Three 
“enterotypes” based on genus have been described predominant in 
Bacteroides (of Bacteroidetes)  (Type 1), Prevotella (of Bacteroidetes)(Type 
2) and Ruminococcus (of Firmicutes)(Type 3)(Arumugam et al. 2011) 
although in reality graduated differences between these three groups are 
likely to be seen across the human population. 
 
1.2.5 Factors influencing the faecal microbiota 
In the newborn infant the gut microbiota is aerobic, but within days 
becomes anaerobic, and within 2 years is relatively stable till advanced age 
(Arrieta et al. 2014). Some of the factors that may change the human faecal 
microbiota include mode of delivery (vaginal versus Caesarean), feeding 
patterns in early infancy (breast feeding duration, time of introduction of 
foods), immunisation, antibiotic usage, sanitation (Arrieta et al. 2014), gender 
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(Aguirre de Carcer et al. 2011) and long term dietary choices. Prevotella 
species dominate in rural Africa where the diet is high in vegetables, fruit and 
fibre compared to Europe (De Filippo et al. 2010).  
The faecal microbiome is altered in various gastrointestinal diseases 
including IBS, IBD and colonic cancer (Table 1.1), raising the question of 
whether the disease is due to the abnormal microbiota or whether the disease 
is the end result of an abnormal immune response to normal faecal flora. 
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Table 1.1 Human bacterial faecal microbiome in heath and disease 
 
General 
description 
Level 1  
Phylum 
Level 2 
Class 
Level 3 
Order 
Level 4/5/6 
Class/Family/Gen
us/Species 
Diet, Age,
1,2
 
Gender,
3 
Enterotype
4 
IBS
1 
(Irritable bowel 
syndrome) 
 
IBD
5 
(Inflammatory 
bowel 
syndrome) 
(CD:Crohn’s disease 
UC:ulcerative colitis) 
General  
Comment 
Neonatal gut sterile 
Early bacteria 
aerobes 
 temporal instability 
 no. coliforms 
 aerobe:anaerobe ratio
 
Diversity in CD, UC 
mucosa assoc 
Bacteria  in CD 
Gram Positive 
 
Present in soil 
and freshwater 
Actinobacter 
 
(produce many bioactive 
molecules such as 
antibiotics,aminoglycosides, 
macrolides, teracyclines) 
     Actinobacter IBS  
Actinobacter Streptomyces     
Corynebacterineae Mycobacterium    M avium in CD 
Propionibacterineae     
Actinomycetaceae     
Bifidobacteriaceae 
(Lactobacillus bifidus) 
Bf.catenulation Bifidobacterium as 
teenagers 
IBS  CD, UC 
Coriobacteridae Collinsella   IBS  
Gram Negative 
 
Anaerobic 
Rod shaped 
No spores 
 
Bacteroidetes 
 
Widely found in 
environment, soil, sea, 
guts, skin 
   After age 5 years  Bacteroidetes IBS  
Bacteriodia Bacteroides  Enterotype 1  Baceroides IBS Bacteroides CD, UC 
 Porphyromonas     
 Prevotellaceae Prevotella 
Xylanibacter 
Enterotype 2 
(high fibre diet) 
Prevotella  IBS Prevotella CD, UC 
 M vs Females 
African children 
with high fibre diet 
with Firmicutes, 
Proteobacteria, 
lactobacillus vs 
European children 
 Rikenellaceae     
Gram  Positive 
 
Strong cell wall 
Round or rod 
Often produce 
endospores 
Firmicutes      Firmicutes  Firmicutes CD, UC 
Bacilli (aerobes) Bacillus     
(Bacillales Staphylococcus     
Lactobacillales Listeria     
Staphylococccacea) Lactobacillus  after 5 years age   IBS  CD, UC 
Clostridia Clostridium C. coccoides   IBS  
(anaerobes)  C. cocleatum   IBS  
 8 
  C.difficile    CD, UC 
  Coprococcus   IBS  
  Ruminococcus  Enterotype 3  IBS  Ruminocoocus 
gnavus CD 
 Clostridium iX Faecalobacterium 
prausnitzii 
(butyrate 
producer++) 
  CD, UC 
 Lachnospiraceae or 
Clos cluster XIV, b 
Roseburia in low carbohydrate 
diets 
  CD 
Mollicutes      
Negativicutes Veilonella   IBS-C CD deep ulcers 
Gram Negative  
 
 
Metabolism 
variable but 
most 
facultatively 
anaerobic, use 
photosynthesis, 
many have 
flagellae) 
 
 
Proteobacteria 
 
(purple bacteria capable of 
forming many shapes, outer 
membrane of 
lipopolysaccharides) 
     Proteobacteria IBS  Proteobacteria IBD 
Acidobacteria      
Deltaproteobacteria Desulfovibrionales Desulfovibrio    CD, UC 
Epsiloproteobacteria  Campylobacter    CD, epsiloproteoB 
  Helicobacter    
Alphaproteobacteria      
Zetaproteobacteria      
Gammaproteobacteri
a 
Enterobacteriales Ercherichia enterobacteria 
infants with 
necrotising 
enterocolitis 
enterobacteria IBS  enterobacteriaceae 
eg adherent invasive 
E.Coli  in CD 
 Proteus    
 Salmonella    
 Vibrio    
 Yersinia    
 Klebsiella    
 Pasteurellaceaea Haemophilus   CD deep ulcers 
Betaproteabacteria Neisseriales     CD 
Gram Negative 
Obligate 
anaerobe 
Non-spores 
Fusobacteria 
 
Asaccharolytic nature 
     CD 
Leptotrichiaceae Streptobacillus     
Fusobacteriacaea Fusobacterium  F. necrogenes 
  Clos.rectum 
   F.ulcerans    
   F.necrophorum    
 Deinococcus-Thermus       
Mucin loving 
5% of normal 
Bacteria in gut 
Verricomicrobia Verrucomicobia  Akkermansia 
mucinophila 
  in obesity 
(oral dose increases 
depth mucus layer) 
  CD, UC 
1 (Simren et al. 2013) 2 (Arrieta et al. 2014) 3(Aguirre de Carcer et al. 2011)  4(Berry & Reinisch 2013) 5 (Shanahan 2012)
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1.3 Irritable Bowel Syndrome 
1.3.1 Introduction  
 Irritable bowel syndrome (IBS) is a chronic heterogeneous disorder 
characterised by a symptom complex of abdominal pain, bloating and variable 
bowel habit in the absence of morphological, histological or inflammatory 
diagnostic markers (Drossman 2007). The disorder is divided into three types 
characterised by the change in bowel habit, namely diarrhoea-predominant   
(IBS-D), constipation-predominant (IBS-C) or alternating diarrhea and 
constipation (IBS-M). The IBS diagnostic criteria have been set out by a 
committee and the latest guidelines are the Rome III criteria (Drossman 2007) 
(Table 1.2). 
Table 1.2  Rome III diagnostic criteria for irritable bowel syndrome 
 
Recurrent abdominal pain or discomfort** at least 3 days per month in the last 3 
months, associated with 2 or more of the following: 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool 
 
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months   prior to diagnosis. 
 
1.3.2 Epidemiology   
IBS is reported worldwide and affects 3-20% of the population, usually 
occurring before the age of 45 years and has a female: male predominance of 
2:1 (Grundmann & Yoon 2010). IBS prevalence tends to be lower in Asian 
countries, highest in South America and the exact prevalence in developing 
countries is difficult to assess (Canavan et al. 2014a). The predominance of 
different types of IBS varies between countries.   
Socioeconomic status has no relationship to the prevalence of IBS but 
IBS is twice as common if there is a prior family history of IBS (Canavan et al. 
2014a). Depression, anxiety and insomnia are reported in 30% of IBS 
patients, more than twice the prevalence seen in the community (Grundmann 
& Yoon 2010). 
The onset is often reported after overseas travel (Tuteja et al. 2008) or 
infectious enteritis (Schwille-Kiuntke et al. 2011). Post-infectious IBS was first 
described in 1962 (Chaudhary & Truelove 1962) and has been reported to 
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occur following infection with many organisms including Shigella, 
Campylobacter, Salmonella, viruses and parasites at rates varying from 4-
36% (Schwille-Kiuntke et al. 2011). 
 
1.3.3 Costs of irritable bowel syndrome 
 Although IBS does not increase mortality, patients complain of 
diminished quality of life and 30% of people will seek medical attention, often 
at least twice a year for ten to fifteen years (Canavan et al. 2014b). IBS costs 
include direct medical costs (doctor and hospital visits and over two million 
prescriptions are reported to be written annually for IBS) and indirect costs 
related to loss of productivity (absenteeism and presenteeism) and have been 
estimated to amount to $1,350 million annually in the United States of 
America (Canavan et al. 2014b).  
 
1.3.3 Pathogenesis of irritable bowel syndrome 
 The pathophysiology of this disease is unknown and a number of 
different physiological aspects have been explored to investigate this disease. 
IBS links to the faecal microbiota have been suggested not only 
because post-infectious IBS is a common occurrence but because antibiotic 
and FM transplantation has been reported to be useful therapy for IBS 
(Kennedy et al. 2014). IBS is reported to be associated with small bowel 
bacterial overgrowth, increased temporal instability, increased 
aerobe:anaerobe ratio and an increased Firmicutes:Bacteroidetes phylum 
ratio in the FM (Simren et al. 2013). Various other differences at a species 
level have also been reported in IBS (Table 1.1), including an increase in 
Enterobacteriaea spp. (Proteobacteria phylum) and a decrease in 
Faecalobacterium prausnitzii spp (Firmicutes phylum) (Carroll et al. 2012), 
Lactobacillus and Bifidobacterium spp. (Firmicutes and Actinobacter genus 
respectively) (Malinen et al. 2005). A recent meta-analysis has shown that 
IBS patients are 2.3 times more likely to be infected with Blastocystis spp. and 
healthy male carriers of Blastocystis were found to have decreased numbers 
of Faecalibacterium prausnitzii (Nourrisson et al. 2014).  
Abdominal hypersensitivity (Ritchie 1973) and altered gut motility are 
typical of IBS and these symptoms may be due to a  dysregulated gut-brain 
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axis involving the enteric, autonomic and central nervous system (CNS) 
(Posserud et al. 2006). The communication from the central nervous system 
to the gut wall is bidirectional and influenced by neural, hormonal and 
immunological factors.  A number of studies have reported findings that 
suggest the FM is capable of influencing the CNS (Grenham et al. 2011). The 
enteric nervous system displays increased numbers of mast cells secreting 
serotonin adjacent to the dendritic cells in IBS patients (Matricon et al. 2012). 
Low level inflammation and immune activation is also reported in the 
gastrointestinal mucosa of patients with IBS, particularly increased numbers 
of mucosal mast cells and increased intestinal permeability (Chadwick et al. 
2002). Mast cell densities can be 50-100% higher, particularly in the ileum, 
caecum and colon of IBS patients compared to controls (Matricon et al. 2012) 
and higher intraluminal colonic levels of tryptase and histamine are seen in 
the IBS patients. Pro-inflammatory cytokines, including interleukin (IL)-6, IL-8 
and tumour necrosis factor- (TNF-α), have been reported to have higher 
levels in the plasma and peripheral blood mononuclear cells of IBS patients 
(Beatty et al. 2014). Increased levels of proteases are reported in the faeces 
of IBS patients but it is not clear if these are of human or bacterial origin 
(Gecse et al. 2008). Human beta-defensin HBD2 is an antimicrobial peptide 
produced by intestinal epithelial cells and higher levels have been found in the 
faeces of IBS patients (Matricon et al. 2012). 
 
1.3.4 Diagnosis 
 Many known clinical diseases mimic IBS and the diagnosis of IBS is 
contingent upon the exclusion of disorders including celiac disease, 
fermentable oligodisaccharide, monosaccharide and polyol intolerance 
(FODMAP intolerance) and inflammatory bowel disease (IBD). IBS 
(subcategorised clinically as either IBS-D, IBS-C or IBS-M) may be a 
heterogeneous disorder that has many different aetiological causes that 
clinically appear similar.  
It would be useful to identify biomarkers for IBS. Serum biomarkers for 
IBS have been investigated with a panel of ten (Lembo et al. 2009) and 
fourteen (Jones et al. 2014) markers and although diagnostic sensitivity was 
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above 80% specificity was poor at 50%. Interestingly, different biomarkers 
within the panel distinguished different clinical subtypes suggesting IBS-D and 
IBS-C may have a different biological cause. 
 
1.3.5: Therapy 
 No specific therapy is reliably efficacious in IBS. A number of therapies 
are used including dietary modification (low FODMAP diet and high fibre), 
specific management of constipation or diarrhoea, antispasmodic agents, bile 
acid binding agents, broad spectrum antibiotics such as rifaximin, probiotics 
and neuromodulators/antidepressants such as amitriptyline. 
 
1.4  Introduction to Blastocystis spp 
1.4.1 What are they? 
Blastocystis spp. are common, anaerobic, unicellular, eukaryotic, 
enteric protozoa found in man and most species of animals. They may have 
been described as early as 1849 during the infamous cholera outbreak in 
London (Parija & Jeremiah 2013) but Alexeieff first described this parasite as 
a distinct unicellular organism present in the gut of lizards and leeches in 
1911 (Zierdt 1991). A year later Brumpt described four species of Blastocystis 
including “Blastocystis hominis” (Dunn 1992). Over the last 100 years 
Blastocystis has been incorrectly classified as yeast, cyst of a flagellate, an 
amoebae, and a sporozoa. Zierdt identified protozoan attributes of the 
organism in 1976 (Zierdt & Tan 1976b) (Table1.3) and subsequent 
phylogenetic analysis of the 18 bit-piece subunit of the ribosomal gene (18S 
rDNA) has classified it as a eukaryote in the Stramenopile class (Silberman et 
al. 1996)(Figure 1.1). The accuracy of this classification has been confirmed 
with molecular analysis of other Blastocystis proteins (Arisue et al. 2002). 
Great genetic diversity (up to 7% variation in amino acid sequences) has been 
identified within the 18S DNA coding for ribosomal RNA (rDNA) subtypes 
(Noel et al. 2005). 
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Table 1.3 Blastocystis protozoan characteristics (Zierdt 1991) 
 
Figure 1.1 Taxonomic classification of Stramenopiles (Yoon 2002) 
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Stramenopiles, together with green plants, red algae, animals and 
fungi, separated nearly simultaneously 1,260 million years ago (Knoll 1994). 
The Stramenopile group, comprising 100,000 members, includes diverse uni- 
and multi-cellular organisms such as slime nets, water moulds and brown 
algae. Most Stamenopiles are characterised by mitochondria with tubular 
cristae, flagella and flagellar hairs. Uniquely Blastocystis does not possess 
hairs or flagellae and is the only stramenopile to live in the human intestine. 
Blastocystis is currently classified as  
 Kingdom Eukaryote 
 Phylum Chromista 
 Class  Stramenopiles 
 Order  Blastocystae 
 Genus Blastocystis 
 Species Blastocystis subtype 1-17 
 
1.4.2 Where are they found? 
Blastocystis spp. are found world-wide and have been described in the 
gut of every species of animal except Osteichthyes (fish with bony rather than 
cartilaginous skeletons) to date (Belova & Krylov 1994). 
 The organism is found in the gastrointestinal lumen and is not invasive. 
In humans it is found in the caecum and terminal ileum (Stenzel & Boreham 
1996) and no significant macroscopic mucosal changes are seen at 
endoscopy of small or large bowel (Zuckerman et al. 1994; Nagel et al. 2012). 
A recent study in pigs has reported Blastocystis organisms present 
predominantly in the lumen and adjacent to epithelial cells of the large bowel, 
with small bowel colonisation more common in immunosuppressed pigs, and 
no pathological changes seen in the underlying epithelial mucosa using light 
microscopy (Wang et al. 2014a). 
 
1.4.3 Prevalence  
The true prevalence of Blastocystis carriage is not known as methods 
of diagnosis and data collection are problematic. It has been estimated that 
over one billion people may carry the organism (Parija & Jeremiah 2013). An 
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Australian study reported a prevalence of 6% (Hellard et al. 2000) in the 
asymptomatic community and this accords with reported rates in other 
developed countries from 10-30% (Stenzel & Boreham 1996; Scanlan & 
Stensvold 2013). Prevalence rates of 19% have been reported in Sydney 
hospital inpatients (Roberts et al. 2012). The lowest community carriage rates 
have been reported in Japan (1.5%)  and Singapore (3.3%) (Yoshikawa 
2012). Carriage rates in developing countries from every continent have been 
reported to be much higher, ranging from 20-66% (Tan 2008) and even 100% 
in 93 children from Senegal (El Safadi et al. 2014). Marked variation in 
regional carriage rates within countries such as China, Thailand and Turkey 
have been documented. Higher rates of carriage have been reported in lower 
socioeconomic groups, those with lower standards of hygiene (Yamada et al. 
1987; Torres et al. 1992), and young adults (who tend to have a higher rate of 
infection compared to young children or older adults (Nimri 1993). 
 
1.4.4 Routes of transmission 
It is likely that the cystic form of Blastocystis transmits infection. The 
vacuolated form of Blastocystis was shown to have low infectivity (<20%) 
when delivered orally although intra-caecal inoculation resulted in consistent 
infection in germ free guinea pigs (Phillips & Zierdt 1976).  A robust cystic 
form was described in 1991 (Yamada et al. 1987; Stenzel & Boreham 1991) 
and subsequently shown to be infective when delivered orally to rats (Suresh 
et al. 1993), BALB/c mice (Moe et al. 1997) and birds (Tanizaki et al. 2005).  
The infection likely arises from indirect contamination of water supplies 
or by direct or indirect contact with humans or animals. Many studies suggest 
an association between Blastocystis infection and unfiltered or unboiled water 
(Leelayoova et al. 2004; Karanis et al. 2007) or water vegetable food 
contamination (Al-Binali et al. 2006; Li et al. 2007b). Blastocystis has been 
included as a microbial agent of interest in the 2008 water sanitation and 
health guidelines of the World Health Organisation (Organisation 2008). 
Exposure to animals is probably a risk factor as zookeepers and abattoir 
workers have also been reported to be associated with a higher rate of 
Blastocystis infection (Parkar et al. 2007). Influent and treated effluent sewage 
treatment samples both carry viable Blastocystis cysts (23% and 7%, 
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respectively) (Banaticla & Rivera 2011) and as few as 10-100 cysts may 
establish infection (Yoshikawa et al. 2004b). Direct and indirect (including 
water-borne) faecal-oral mode of transmission would be consistent with 
reports of frequent Blastocystis infection in campers or travellers returning 
from overseas destinations (particularly developing countries), children in day 
care centres and nursing home inpatients (Cirioni et al. 1999). 
 
1.4.5  Zoonotic potential 
Humans have been reported to carry 9 of the 17 subtypes identified to 
date (Stensvold 2013) and harbour the greatest diversity of subtypes (Figure 
1.2). Blastocystis subtypes 2, 4 and 7 but not 3 (all derived from human 
sources), were able to infect chickens and/or rats in a recent study (Iguchi et 
al. 2007) although some subtypes required larger inoculums of the parasite to 
establish infection.  
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Figure 1.2 Blastocystis subtypes in animals (Parkar et al. 2010) 
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Moderate animal host specificity is demonstrated in the various 
subtypes and subtypes from avian and non-avian hosts rarely overlap. 
Interestingly laboratory rats have been reported to have a high carriage of 
Blastocystis (60%) and in contrast laboratory mice were negative for 
Blastocystis (Chen et al. 1997; Chen XQ 1997). The carriage rate of 
Blastocystis has been reported to be as high as 71% in dogs and 67% in cats 
in Brisbane (Duda et al. 1998), although a later study has suggested that dogs 
are not a natural host and likely carry the parasite only when they have 
extensive contact with other reservoir hosts (Wang et al. 2013).  
Blastocystis carriage in zoo, farm and native animals is widespread 
and the prevalence of carriage in particular animals varies widely from country 
to country (Yoshikawa 2012). Zookeepers have been shown to carry unusual 
Blastocystis subtypes that are present in the animals they tend (Parkar et al. 
2010). Pigs mostly carry ST5 and two studies report infection in pig keepers 
with ST5 in China (Yan et al. 2007) and Australia (Wang et al. 2014c). 
However, it is unlikely that livestock are a major reservoir for Blastocystis 
infection in humans as the major ST in these animals seen around the world 
is ST5 and ST10 (Alfellanin et al. 2013) and these subtypes are rare overall in 
humans.  
Human to animal transmission of infection, in either direction, is likely 
(Noel et al. 2005; Wang et al. 2014c) but cannot be proven until more 
accurate / definitive molecular markers are used. 
 
1.5 Morphology of Blastocystis species 
1.5.1 Introduction 
Blastocystis exist in multiple morphological forms and these have been 
broadly categorised into six groups. In reality the protozoa may take many 
forms, even within the same culture, that are not easily categorised. This 
pleomorphism has led to confusion and misclassification in the literature. It is 
not clear how many of these different Blastocystis shapes are artefactual 
created by exposure to unsuitable environmental conditions. The size of the 
organism may vary 100 fold and the size, shape and type of form of the 
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parasite depends on the particular subtype, and the age and culture 
conditions (Tan 2008). 
The six most commonly categorised forms are the vacuolated form 
(VF), granular form (GF), multi-vacuolar form (MVF), amoeboid (AF), 
avacuolar (AVF) and cyst. The most easily recognised form is the central 
vacuolated form (VF) and generally without the presence of the VF in a wet 
faecal smear it is not possible to identify Blastocystis. Faecal specimens from 
symptomatic patients with diarrhoea have been reported to have 
predominantly AF (Tan & Suresh 2006b) and larger and slower growing 
parasites (Tan et al. 2008). 
 
1.5.2 Vacuolated, Granular, Multi-Vacuolar and Avacuolar forms 
The vacuolated form (VF) is the most distinctive form of Blastocystis found 
in faeces and culture (Figure 1.3.1)(Nimri 1993). It is a round or oval cell 
consisting of a large vacuole comprising 90% of the organism surrounded by 
a thin rim of cytoplasm. Compressed within the rim of cytoplasm are 
organelles consisting of 1-4 nuclei, multiple mitochondria-like organelles, 
Golgi apparatus and endosome-like vacuoles (Stenzel et al. 1991). The size 
of the VF averages 10 m but ranges from 2-200 m. Cells exposed to air 
quickly deform, collapse and burst looking like “empty balloons” (Zierdt 1991). 
The granular form (GF)  (Figure1.3.1) is similar to the VF with either 
stippled to dense central opacity or multiple distinct small granules within the 
central vacuole or the cytoplasm.  
The multi-vacuolar form (MVF) (Figure 1.3.2) is similar to a smaller VF (up 
to 8 m diameter), with only 1 or 2 nuclei and multiple small vacuoles present 
within the CV and cytoplasm.  
The avacuolated form (AVF) has been described as smaller (5 m 
diameter), with 1-2 nuclei, mitochondria with prominent cristae, Golgi 
apparatus, endoplasmic reticulum but no surface coat (Stenzel & Boreham 
1996). The central vacuole is not present. 
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                                   Figure 1.3 
Light microscopy of different morphological forms of Blastocystis 
 
 
 
1.3.1   
Multiple smaller vacuolar forms, some 
larger granular forms 
Light microscopy, x40,  
polarised light 
acridine orange (0.05%) stain 
(image (Nagel et al. 2015a)) 
 
 
 
 
 
 
1.3.2  
Large multi-vacuolar form with two 
smaller granular forms 
Light microscopy, x40 
polarised light, 
acridine orange (0.05%) stain 
(image: R Nagel) 
 
 
 
 
 
 
 
 
1.3.3   
Two amoeboid forms, one with a large 
central vacuole and the filled with 
granules. 
Light microscopy, x40 
polarised light, 
acridine orange (0.05%) stain 
(image(Nagel et al. 2015a) 
 
 
1.3.4  
Cysts  
(image: (Zaman 1996)) 
 
 
Bar 10uM 
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There is no precise definition of each of these forms. It is likely that they 
represent a   continuum of each other although the direction of development is 
not clear. MVF reportedly become VF after short term culture (Stenzel et al. 
1991) and VF become GF under adverse culture conditions. VF cultures can 
be induced to become GF predominant specifically by increasing the serum 
concentration, changing the culture medium, axenising the culture, or adding 
antibiotics (Dunn 1992). In the absence of definitive cell markers it may be 
prudent, when using light microscopy, to describe only VF or GF. 
 
1.5.3 Amoebic form  
There are conflicting reports in the literature regarding the existence 
and morphology of the amoebic form (AF). They are reported to be smaller in 
size and occur more frequently in the stools of patients with diarrhoea (Tan & 
Suresh 2006b) and range from 8-200 m diameter. The AF is irregular in 
shape with pseudopodia, but no apparent motility, with a surface coat and a 
plasma membrane reported to be devoid of coated pits (Stenzel et al. 1989). 
Two forms of AF have been described (Tan & Suresh 2006a)(Figure 1.3.3 ) a 
dense granular sort (CV filled with dense granules) and another lucent form 
(no CV, cytoplasm with vacuoles and minimal organelles). The organelles 
(nuclei 1-2), mitochondria, lipid inclusions, ribosomal strands) appeared to 
concentrate in pseudopodia that often encircle bacteria (Figure 1.4) and 
phagosomes containing bacteria were present in the cytoplasm. 
 
1.5.4 Cysts 
The small cystic stage (2-5 m diameter) was not described until more 
recently (Mehlhorn 1988; Stenzel et al. 1991). It is round or oval, with a 
characteristic highly refractive, thick cell wall with or without a loose, fibrillar 
coat. The cell wall contains some chitin (Stenzel 1995). Multiple nuclei (1-4), 
mitochondria, endoplasmic reticulum, vesicles are seen within the cell wall 
that has a distinctive notch (Figure 1.3.4). Although rarely present in in vitro 
cultures, Blastocystis can be induced to encyst with the addition of 
conditioned bacterial products or trypicase (Suresh et al. 2009). This form is 
robust and can remain viable for 2 months at 4C (Yoshikawa et al. 2004b) 
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but is susceptible to drying, high temperatures and freezing (Table 1.4). 
Faecal cysts have been reported in only 21% of infected patients (Sun 1989) 
and it is likely they are shed intermittently and/or difficult to identify. 
 
Table 1.4 Properties of Blastocystis cysts 
Condition 
 
 
40-50C 
Survival Time 
(Moe et al. 1996) 
 
12 hours 
Survival Time 
(Yoshikawa et al. 
2004b) 
 
Survival Time 
(Zaki et al. 
1996) 
 
25 water  1-2 months  
4C water 14-28 days 1-2 months  
-20C 24 hours   
Room temperature 
air 
3 days 
 
 
 
 
 
4C air 3 days   
37C air <12 hours   
2.5% potassium 
dichromate solution 
2 weeks   
Chlorine ( sodium 
hypochlorite) 
2.2ppm 
  survived 
 
 
1.5.5 Functional components 
This slimy coated organism contains multiple nuclei, mitochondria like 
organelles, Golgi apparatus, lysosomes, and endoplasmic reticulum 
compressed into a thin rim of cytoplasm surrounding the large central vacuole 
that often contains many granules (Figure 1.4).  
The surface coat of the Blastocystis parasite is a dramatic structure; this 
carbohydrate-rich, slimy coat has fibrils that may extend 10 m from the 
surface, although these shorten after prolonged culture (Stenzel et al. 1991) 
and may be lost off cysts and AVF’s altogether (figure 1.4.1). Bacteria and 
other parasites are often seen adhering to the coat, particularly in fresh faecal 
specimens, suggesting that entrapment may aid nutrition (Zaman et al. 1999). 
The coat appears to be continuously synthesised and may offer other 
mechanical or chemical protective functions (Cassidy et al. 1994) and binds 
Blastocystis organisms in culture together (Zhang et al. 2011). 
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Figure 1.4 Electron microscopy of Blastocystis functional components  
 
1.4.1 Blastocystis hominis showing the outer surface coat with adherent bacteria (Zaman et 
al. 1999) 
1.4.2 Vacuolar form of fresh monkey vacuolated from of Blastocystis showing puckered outer 
membrane of parasite (Cassidy et al. 1994) 
1.4.3 Multiple large, elongated mitochondria-like organelles displaying internal cristae (Dunn 
1992) 
1.4.4.Plasma membrane of Blastocystis showing surface pits and fuzzy outer coat (Dunn 
1992) 
1.4.5 Amoebic form apparently phagocytosing a bacterium with pseudopod (Dunn 1992) 
1.4.6 Different morphological forms of Blastocystis in the same culture (vacuolated and 
granular) (Dunn 1992) 
1.4.7 Granular form of Blastocystis showing typical cap of chromatin on large nucleus, 
multiple granules and vacuoles and internalised bacteria (Dunn 1992) 
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The role of the central vacuole is not known. It has been proposed to 
have a storage or metabolic role, and stains positively with periodic acid Schiff 
or Alcian blue for glycogen/ carbohydrates (Yoshikawa et al. 1995b) and 
Sudan black B or Nile blue for lipids respectively(Yoshikawa et al. 1995e). 
Neither 4’,6’-diamindino-2-phenylindole (DAPI) nor acridine orange staining 
detected DNA (Suresh et al. 1994b). Nutrients may accumulate in the central 
vacuole transferred in small vesicles in the cytoplasm that are transferred 
from the surface of the organism by clathrin-based endocytosis (Stenzel et al. 
1989). The central vacuole may also be a repository for the storage of 
apoptotic bodies (Nasirudenn et al. 2004). 
The heterogenous granules seen in the vacuole have been described as 
myelin-like inclusions, crystalline granules and lipid droplets (Dunn 1992).  A 
suggested reproductive role for these granules (Zierdt 1991) has never been 
proven. Cytoplasmic contents, often containing organelles, may invaginate 
and deposit filament or vesicle-like membrane bound structures into the 
central vacuole (Tan 2008). 
The plasma membrane of VF and GF (but not the AF) contains large 
coated pits (50 nm diameter) with clathrin present on the internal cytoplasmic 
surface (Stenzel et al. 1989)(Figure 1.4.2). These pits have a clear role in 
endocytosis. Ferritin particles (known to bind electrostatically to coated pits) 
are internalised almost immediately via coated vesicles. In VF ferritin was 
distributed to the CV, cytoplasmic vacuoles and tubules(Dunn 1992). The 
ferritin accumulation in GF was markedly different with loose accumulation 
only in the CV and no accumulation in the granules. The texture of the surface 
structure of Blastocystis (a function of the size of the coated pits), varies 
between different animal hosts and also becomes smoother in in vitro culture 
(Cassidy et al. 1994). 
Multiple nuclei are present in cells, usually at opposite ends of the cell, 
giving the VF a typical signet ring appearance. The nuclei are approximately 
1m diameter, surrounded by a nuclear envelope with nuclear pores, and 
topped by a characteristic eccentric electron-opaque spot of dense chromatin 
material (Stenzel & Boreham 1996) (Figure 1.4.7). 
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Although Blastocystis is a strict anaerobe, the parasite contains multiple 
(sometimes hundreds) mitochondrial-like organelles (MLO’s) that are 
spherical or oval in shape, 1-3 m diameter with cristae (tubuar or sacculate) 
(Dunn 1992), contain DNA and have a measurable trans-membrane potential 
(Figure 1.4.3). This organelle is presumed to be an ancient remnant of an 
oxidative proteobacteria that adapted its enzyme profile to the anaerobic 
environment. As well as a role in energy production it has been proposed as a 
site of lipid synthesis (Zierdt 1991). Analysis of the mitochondrial genome 
shows that it lacks cytochrome C complex genes predicting that this organelle 
has an incomplete oxidative phosphorylation chain, a partial Kreb’s cycle, 
amino acid and fatty acid metabolisms and an iron-sulphur cluster (Denoeud 
et al. 2011). These MLO’s, unlike classic mitochondria, have enzymes 
capable of converting pyruvate into CO2 and H2. 
Golgi apparatus (usually adherent to the nucleus), endoplasmic reticulum 
and lysosomes are also seen in cytoplasm. 
 
1.5.6 Life cycle 
It is generally agreed in the literature that the cyst is the robust infective 
form but there is no other consensus of the relationship of the particular 
morphological forms to each other. A number of different life cycles for this 
organism have been proposed but there is no general agreement (Figure 
1.5)(Zierdt 1991; Tan 2008). Infection may persist for longer than 10 years. 
 
1.5.7 Modes of reproduction 
Simple binary fission is the only widely accepted form of replication. 
The VF, GF or AF cell appears to divide in two and the organelles are divided 
between the two parts. Other modes of replication have been proposed, such 
as plasmotomy, endodyogeny, schizogeny, sporulation and invagination 
(Zierdt 1991; Singh 1995; Zhang et al. 2007). Binary fission of the VF and GF 
is relatively commonly seen. Division of nuclei within an intact outer 
membrane is also seen (schizogeny) suggesting this may be the first step into 
formation of two separate organisms. 
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                                  Figure 1.5 Proposed lifecycle (Tan 2008)                                          
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1.6 Laboratory Diagnosis 
1.6.1 Stool samples and microscopy 
The formol-ether concentration technique (FECT), commonly used for 
detecting parasite ova and cysts, is ineffective in detecting Blastocystis 
(Suresh & Smith 2004), even if this technique is optimised using faecal 
specimens preserved in formalin. Concentration and use of distilled water 
often lyse fragile Blastocystis cells. Microscopy of fresh faecal smears 
(unstained or stained with Lugol’s iodine or trichrome) is the tool commonly 
used by commercial pathology laboratories (polymerase chain reaction (PCR) 
testing of DNA has been combined with microscopy since 2013 in Australia). 
Detection rates of simple microscopy of wet faecal smears are modest (30-
50%). Some reports suggest that greater numbers of Blastocystis organisms 
(>5 organisms per high power field) seen in the faeces correlate with 
presentation with acute diarrhoea (Kain et al. 1987) whilst others report no 
correlation (Doyle et al. 1990). Multiple faecal specimens may be required as 
the parasite sheds intermittently (Suresh et al. 2009). Microscopy of faecal 
smears has been reported to be improved using a fluorescent Blastocystis 
specific antibody (Blastofluor)(Dogruman-Al et al. 2010).  
 
1.6.2 Stool samples and culture 
Xenic in vitro culture (XIVC) of faeces is relatively cheap and increases 
the diagnostic yield by 50% (Dogruman-Al et al. 2010).  Culture of 
Blastocystis in association with bacteria is possible in a number of mediums 
including Jones, Iscove’s modified Dulbecco, minimal essential medium, 
Robinson’s medium, or biphasic inspissated egg slant overlaid with Locke’s 
solution (Tan 2008). The organism appears tolerant of different osmotic 
conditions. Anaerobic culture is required at 37C (except for ST7 that prefers 
40C). Although the presence of bacteria aids Blastocystis growth, bacterial or 
fungal overgrowth will kill the organisms (Barret 1921). Some XIVC may need 
longer incubation as particular subtypes are slow growing (Ho et al. 1993). 
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Axenic (without contaminating microorganisms) cultures (AXC) are 
useful for research into aspects of Blastocsytis including sensitivity to 
antimicrobial agents but are not used routinely for diagnosis. 
PCR analysis of the Blastocystis 18S ribosomal RNA gene (18S rDNA) 
(Stensvold et al. 2007a) in faecal specimens is commonly used in research 
and may be considered the “gold standard”. XIVC sensitivity and specificity 
closely approaches that of PCR techniques. If subtype analysis is required 
DNA is preferably extracted from the faecal sample rather than XIVC to avoid 
fast growing subtypes dominating in mixed subtype infections (Tan et al. 
2010). PCR testing has been reported to be more sensitive with particular 
diagnostic kits (Yoshikawa et al. 2011) and false negative results may be due 
to the presence of faecal PCR inhibitors such as bile and complex 
polysaccharides.  
Differences between the subtypes have been described. Subtype 7 
parasites prefer to grow at a higher temperature and have much longer 
doubling times in cultures (50-80 hours) compared to ST4 parasites that 
double every 20-30 hours (Tan 2008). XIVC will favour organisms with faster 
growth. Axenic cultures have shorter doubling times of 7-12 hours (Lanuza et 
al. 1997) compared to XIVC. Subtype 1 parasites are approximately 30% 
smaller in size in culture than subtype 4. Differences in sensitivity to 
metronidazole and emetine have been demonstrated between axenically 
cultured ST4 and ST7 organisms (Mirza et al. 2010). 
Detection rates of Blastocystis vary widely between commercial 
laboratories (Utzinger et al. 2010) and Blastocystis is often undiagnosed. 
Some pathology laboratories do not report the presence of Blastocystis, even 
if seen, considering it not to be pathogenic or relevant.  
 
1.6.3 Immunological techniques 
Immunological techniques are not used currently for diagnosis of 
Blastocystis infection. Different studies have reported variously that different 
Blastocystis subtypes have characteristic electrophoretic protein banding 
patterns (Chen et al. 1999) or similar banding patterns (Init et al. 2003). 
Antibodies specific for Blastocystis have been reported in human sera (IgM 
and IgG) (Zierdt & Nagy 1993; Garavelli et al. 1995) and faeces (IgA) 
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(Mahmoud & Saleh 2003) that are significantly higher in symptomatic patients. 
Antibody titres have been reported to be higher with length and severity of 
infection (Zierdt & Nagy 1993). The characteristics of antibody demonstrating 
a significantly raised titre in symptomatic patients has been variously reported 
as of the IgG2 class (Hussain et al. 1997), and detecting 12kD (Kaneda et al. 
2000), 29kD (Gamra et al. 2011) 30 kD, 50kD and 118kD molecular weight 
proteins ((Hegazy et al. 2008). A cytopathic antibody, specific for a 30kD MW 
protein in Blastocystis, has been identified as reacting to the legumain (a 
cysteine proteinase) (Petersen AM 2012) present on the Blastocystis surface 
(Tan et al. 2001). 
 
1.7 Molecular Techniques and Subtyping 
1.7.1 Subtyping the organism using the ribosomal RNA gene 
Analyses of the Blastocystis ribosomal RNA gene began in 1993 (Clark 
1997a) and proved useful to establish its taxonomic classification as a 
Stramenopile (Silberman et al. 1996). Analysis of the 18S rDNA using mainly 
PCR and restriction-fragment-length-polymorphism (RFLP) has revealed wide 
genetic variation. A collaborative effort in 2007 produced a consensus for the 
organisation and definition of Blastocystis 18S rDNA subtypes (ST’s) 
(Stensvold et al. 2007b).  
Scicluna primers (Scicluna et al. 2006) identify a 500bp length of the 
SSU rRNA gene and the PCR products are not as reliable for sequencing as 
the nested Wong primers (Wong et al. 2008) that produce a 1100bp nucleic 
acid sequence more distally towards the 3” end of this gene. Examination of 
the SSU-rRNA gene has identified a specific region that may allow separation 
of Blastocystis organisms into particular allelles/clades that allow more 
accurate genetic identification, within particular subtypes (Figure 1.6).  
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Figure 1.6 
Barcode region of Blastocystis 18S ribosomal RNA gene identifed by 
different primers (Clark et al. 2013) 
 
 
1.7.2 Epidemiology of Blastocystis subtypes 
Subtype-specific sequence-tagged-site primers have currently defined 
up to 17 subtypes (Figure 1.2) each displaying more than 5% divergence from 
each other. Subtypes 1-9 are found in man, the most commonly found 
subtypes being ST3 (42-92%), 1 (8-25%), 4 (10-23%) (Tan 2008). Within 
countries there is marked regional variation in ST prevalence patterns (Li et 
al. 2007a) and mixed ST infections are common. 
ST3 is almost universally the most common in humans in different 
countries (Tan 2008) (Table 1.5 ) and is thought to be the subtype of human 
origin. ST 1,2,3,4 and 6 are common in humans. ST8 is commonly seen in 
non-human primates and in contrast ST4 is rarely seen in this group of 
animals. Subtype 9 appears exclusive to humans. There is moderate species 
specificity and in general avian subtypes 5, 6, 7 and subtypes 11-13 
(elephants, giraffes) do not infect humans. Subtypes found commonly in 
rodents (ST4), pigs (ST1, 5) and non-human primates (ST1,8) infect man. 
Interestingly ST4 is commonly detected in European and Australasian human 
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and rodent populations but almost absent in Egypt, Libya, Iran and Nepal 
(Clark et al. 2013). 
 
 
 
Table 1.5 
Distribution of Blastocystis subtypes infecting humans in different 
geographic regions (Tan 2008) 
 
 
 
 
1.7.3 Multilocus sequence tagging (MLST) and clades 
Molecular techniques to define Blastocystis organisms more uniquely 
are required for epidemiological purposes. MLST sequencing of the 
mitochondrial DNA is used mainly in haploid genomes, usually in bacteria, but 
is possible in Blastocystis mitochondria and has now been developed for ST1, 
3 and 4 organisms (Stensvold et al. 2012; Clark et al. 2013). Large intra-
subtype genetic diversity has been confirmed, particularly in ST3, and in 
contrast ST4 has very little genetic diversity. Human ST3 organisms mostly 
fall within one clade but with significant sequence variation, with multiple 
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clades seen in non-human ST3 hosts. Human ST4 organisms fall within one 
clade as well but with little sequence variation suggesting that ST4 entered 
the human population relatively recently (Clark et al. 2013). 
 
1.7.4 Whole genome sequencing 
Whole genome sequencing has been achieved for ST7 and ST4 
(Denoeud et al 2011; Wawrzyniak et al, 2015). The ST7 genome is small 
(19Mb in size) containing 6000 genes, and this has allowed prediction of the 
Blastocystis metabolic and secretory proteins. These predictions may need to 
be interpreted with some caution as a recent study has reported that the 
parasite has another unique feature for a eukaryote, namely it uses 
polyadenylation-mediated termination codons in the nuclear DNA (Klimes et 
al. 2014) thereby requiring re-annotation of genome sequences deposited on 
GenBank1. 
 
1.8 Clinical Association in Humans 
1.8.1 Introduction 
The pathogenicity of Blastocystis in humans is hotly debated. Currently 
there is no reliable animal model to test Koch’s postulates developed in 1884, 
and even with the many modifications to these “rules” since the recognition of 
viruses, healthy carrier states and the advent of molecular biological 
techniques (Fredricks & Relman 1996), proof of pathogenicity remains 
challenging. Indisputably many healthy people carry Blastocystis but over the 
last 100 years increasingly frequent reports of diarrhoeal illness associated 
with the parasite have emerged. The number of Blastocystis organisms 
observed in some patients has been reported as high as several billion per 
stool and up to 200 fluid bowel actions per day (Mehlhorn 1988). Co-infection 
with other enteric parasites is common (Markell & Udkow 1986). Case 
controlled studies of symptomatic and asymptomatic individuals have reported 
conflicting results (Kain et al. 1987; Nigro 2003; El-Shazly et al. 2005b; 
Graczyk et al. 2005; Leder et al. 2005; Kuo et al. 2008). Symptoms that have 
                                                        
1 www.ncbi.nlm.nih.gov/genbank/ 
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been attributed to Blastocystis include diarrhoea, abdominal discomfort, 
anorexia and bloating (Stenzel & Boreham 1996). In children it has been 
reported to be associated with diarrhoea (Graczyk et al. 2005), poor growth 
and presentation with “acute abdomen” (Andiran et al. 2006). Blastocystis has 
been detected frequently in traveller’s diarrhoea (Jelinek et al. 1997; Paschke 
et al. 2010). Isolated case reports have described bloody diarrhoea (al-Tawil 
et al. 1994), but generally the organism is only invasive opportunistically 
(Horiki et al. 1999). Chronic urticaria (Valsecchi et al. 2004; Gupta & Parsi 
2006; Vogelberg et al. 2010; Zuel-Fakkar et al. 2011), and reactive arthritis 
(Lee et al. 1990) have also been reported to be associated with Blastocystis 
infection.  
 
1.8.2 Blastocystis and Irritable Bowel Syndrome 
Case controlled studies of patients with IBS have shown positive 
(Giacometti et al. 1999; Yakoob et al. 2004; Stensvold et al. 2009c) and 
negative association with Blastocystis infection (Sun et al. 1989; 
Tungtrongchitr et al. 2004; Surangsrirat et al. 2010; Krogsgaard et al. 2014). 
Carriage of Blastocystis is reported to be as high as 49% in patients with IBS 
compared to 24% in control patients (Yakoob et al. 2004). Carriage in patients 
with IBS-D is even higher (73%) compared to healthy controls in a later study 
(Yakoob et al. 2010). A recent meta-analysis of eleven trials, consisting of 
1,728 patients with IBS and 1,292 control subjects showed that IBS patients 
were 2.3 times more likely to be infected with Blastocystis spp. than healthy 
controls (Nourrisson et al. 2014).  
Levels of immunoglobulin G2 (IgG2) class antibodies directed against 
Blastocystis were reportedly higher in patients with IBS carrying Blastocystis 
compared to asymptomatic control subjects positive or negative for 
Blastocystis carriage (Hussain et al. 1997). 
 
1.8.3 Immune-compromised patients 
Parasite infections and symptomatic diarrhoea are more common in 
immune-compromised patients, including those with human immunodeficiency 
virus (HIV), malignancy, renal failure or immunosuppressant therapy (Stark et 
al. 2007; Poirier et al. 2011). Blastocystis carriage is reported in over 50% of 
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immune-compromised patients (Idris et al. 2010) and rates are also higher in 
men who have sex with men (Stark et al. 2007). Case controlled studies in 
immunocompromised patients have shown conflicting results (Tasova et al. 
2000; Poirier et al. 2011), and although the prevalence of Blastocystis is 
accepted to be higher in immunocompromised patients gastrointestinal 
symptoms are common in Blastocystis-positive and negative patients. 
 
1.8.4 Cancer patients 
In vivo studies have suggested that Blastocystis hominis may facilitate 
the growth of human colorectal cancer cells (Chandramathi et al. 2010). 
Blastocystis antigen derived from infected patients with gastrointestinal 
symptoms also caused an up-regulation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-) and protein coding gene CTSB in 
colorectal cancer cell HCT116 culture (Chan et al. 2012). No up-regulation 
was seen with antigen from non-symptomatic carriers. Subtype 3 was shown 
to cause more proliferation of the HCT116 cells than subtypes 1,2,4 and 5 
(Kumarasamy et al. 2013). 
Blastocystis is found commonly in cancer patients (Tasova et al. 2000) 
and survives despite concurrent chemotherapy (Chandramathi et al. 2012)  
and it may be an opportunistic infection that contributes to chemotherapy 
diarrhoea.  
 
1.8.5 Inflammatory Bowel Disease (IBD) 
Blastocystis carriage has been reported to be uncommon in patients 
with active ulcerative colitis (Petersen 2012) and rare in patients with Crohn’s 
disease in Denmark but equivalent rates of carriage (around 6%) were seen in 
Turkey in IBD patients and healthy controls (Cekin et al. 2012). Blastocystis 
has also been reported in association with active colitis with resolution of 
colitis with metronidazole therapy (Tai 2011). 
 
1.9 Animal studies 
Despite the wide prevalence of Blastocystis carriage in animals 
Blastocystis infection with diarrhoea has only been reported to occur in pig 
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herds (Burden et al. 1978), a pig-tailed macaque (McClure et al. 1980) and a 
dog (Chapman et al. 2009).  
 Animal models have been used to investigate Blastocystis infection 
and experimental infections in rats, mice, guinea pigs and chickens have been 
described (Tan 2008). Diarrhoea with caecal and colonic mucosal ulceration 
has been shown to occur in germ free guinea pigs (Phillips & Zierdt 1976), 
albino (Elwakil & Hewedi 2010) and BALB/c mice (Moe et al. 1997) infected 
with Blastocystis. Mucosal damage was more severe in rats infected from 
symptomatic human patients, particularly ST1 compared to asymptomatic 
patients (Hussein et al. 2008). These animal models have been useful to 
confirm the infectivity of the cystic form (Yoshikawa et al. 2004b; Tanizaki et 
al. 2005). Rats and chickens have been favoured as animal models as they 
have high rates of carriage (95%)(Lee & Stenzel 1999). Blastocystis ST 2,4,7 
derived from humans could infect both rats and chickens but ST3 was not 
able to infect these animals (Iguchi et al. 2007), again suggesting moderate 
species subtype specificity.  
A major issue with these animal models is that the range of 
Blastocystis subtypes described in chickens and rats are not the most 
commonly seen in humans (Scanlan 2012a) and mice rarely carry 
Blastocystis naturally (Chen et al. 1997). Pigs may provide a useful animal 
model to study Blastocystis infection as they commonly carry the parasite, 
(although they predominantly carry ST5 organisms that rarely infect humans) 
(Wang et al. 2014a). 
 
1.10 Possible Mechanisms of Pathogenicity 
1.10.1 Introduction 
Although many Blastocystis carriers are asymptomatic this does not 
exclude pathogenicity, as we know that most infections with the known 
pathogens Giardia and Entamoebae histolytica are asymptomatic (Tan 2008). 
It is not clear if Blastocystis pathogenicity, if it exists at all, is related to an 
intrinsic property of the organism or to host factors or both.  
 
1.10.2 Intrinsic factors 
 36 
It is difficult to quantitate the number of Blastocystis organisms 
infecting a patient for a number of reasons. It is difficult to identify any form 
but the VF of Blastocystis in the stool, the number of parasites in the stool 
may not necessarily represent the number in the caecum, the quality of the 
faecal specimen may be important as the parasites lyse easily when exposed 
to fresh air and we know that the parasite is shed intermittently. However, 
using simple microscopy of faecal smears large numbers of Blastocystis 
organisms can be seen in symptomatic and asymptomatic individuals 
suggesting that parasite load does not determine symptoms (Sun 1989). It 
has been suggested that longitudinal quantitative PCR studies may allow 
better assessment of the relative importance of parasite load (Stensvold 
2013a).  
A number of studies have explored whether the subtype of the 
Blastocystis has any association with symptoms, IBS or urticaria. ST1 
(Kaneda et al. 2001; Tan et al. 2006; Yan et al. 2006; Hussein et al. 2008; 
Eroglu et al. 2009; Stensvold et al. 2009b), ST3 (Tan et al. 2008) and ST4 
(Poirier et al. 2011) have variously been reported to occur more frequently in 
symptomatic patients. Other studies have not shown any significant difference 
in the ST pattern between patients and the control population (Yoshikawa et 
al. 2004a; Dogruman-Al et al. 2009; Elwakil & Talaat 2009; Rene et al. 2009; 
Souppart et al. 2010) or other asymptomatic household members (Nagel et al. 
2012) (Table 1.6). The large genetic diversity within each 18S rDNA subtype 
makes it possible that this form of molecular characterisation is not sufficient 
to discriminate different organisms. 
 
Table 1.6 Blastocystis subtype variation in irritable bowel syndrome 
(Scanlan 2012b) 
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 Virulence factors intrinsic to the parasite have been explored in a 
number of ways. Axenic cultures of Blastocystis (ST4) have been shown to 
cause cytopathic effects on Chinese hamster ovary cells (Walderich et al. 
1998). Cultured cells and lysates of the culture induced apoptosis, disrupted 
epithelial barrier function in a contact independent manner, rearranged F-actin 
distribution and increased the permeability across rat colonic epithelial 
monolayers (Puthia et al. 2006).  
If Blastocystis causes pathogenic effects without adhering to the gut 
mucosa it suggests that the parasite may be secreting a virulence factor. 
Blastocystis proteases, particularly cysteine proteases, have been shown to 
cleave human secretory immunoglobulin A (Puthia et al. 2005) and induce 
pro-inflammatory cytokine IL-8 production (Puthia et al. 2008) from host cells 
via NF-B activation. Cysteine protease activity has been demonstrated to 
vary between different Blastocystis subtypes (Mirza & Tan 2009). Analysis of 
the genome of Blastocystis ST7 organism has predicted that the parasite 
would be able to produce all major classes of proteases, and particularly 
cysteine proteases (20/22 predicted to be cysteine proteases) (Denoeud et al. 
2011). Cysteine proteases are known to degrade luminal immunoglobulin A 
(IgA) and disrupt the epithelial mucosal barrier (Figure 1.7). Cysteine protease 
legumain is secreted by Blastocystis and this legumain has been shown to be 
(unusually) located on the cell surface and important for the survival of the 
parasite (Wu 2010). 
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Figure 1.7 
Cysteine proteases and possible virulence mechanisms  
(Denoeud et al. 2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.10.3 Host factors 
Host factors that might influence the effect of Blastocystis carriage, 
apart from studies in immune-compromised patients, are relatively 
unexplored. A study that assessed differences in cytokine expression 
between symptomatic and asymptomatic carriers of Blastocystis found that 
symptomatic patients were more likely to have polymorphisms in IL-8 and 10 
(Olivo-Diaz A 2012) but not IL-6 and TNF-α (Jimenez-Gonzalez et al. 2012).  
Host antibody responses to infection may vary between individuals. 
Faecal (Mahmoud & Saleh 2003) and serum (Zierdt & Nagy 1993) antibody 
titres to Blastocystis antigens have been reported to be higher in symptomatic 
patients. A serum antibody reacting to a 30kDa MW protein in Blastocystis 
has been reported to be more common in symptomatic patients (Gamra et al. 
2011). This antibody may correlate with the antigen that has been identified 
as a cysteine protease present on the cell surface of Blastocystis organism 
(Wu et al. 2010). 
 
1.10.4 Pathogenic passengers 
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The term endosymbiosis has no implication regarding pathogenicity for the 
host but simply means that one organism is able to live and replicate within 
another host organism. Some endosymbiont bacteria have evolved 
mechanisms to avoid phagosomal lysis by their host and this increases their 
survival time in chlorinated water and decreases their susceptibility to 
antibiotics (Winiecka-Krusnell & Linder 2001). Endosymbiosis is not 
uncommon and almost 30% of free living amoebae Acanthamoebae 
polyphaga had some type of endosymbiont (Lau & Ashbolt 2009). Bacteria 
pathogenic to humans that have been reported to replicate in other free living 
amoebae include Chlamydia pneumonia, Helicobacter pylori, Mycobacterium 
leprae & avium, Rickettsia-like organisms, Legionella, Franscisella tularensis, 
coliforms, Yersinia enterocolitica, Burkholderia spp., Listeria, Vibrio and 
Wolbachia spp.(Winiecka-Krusnell & Linder 2001).  
Endosymbionts in Blastocystis have been reported previously (Zierdt & 
Tan 1976a; Dunn 1992; Stenzel & Boreham 1994). Intracellular replicating 
gram negative rods/cocci were first noted in 1976 (Zierdt & Tan 1976a; 
Stenzel & Boreham 1997) and the endosymbiotic condition was found to be 
more prevalent in axenised cells, unaffected by many antibiotic therapies and 
more likely to occur in association with giant Blastocystis cells. Zierdt (Zierdt & 
Tan 1976a) was unsuccessful in culturing or identifying the endosymbiont. He 
reported that the endosymbiont had no cell wall, was not flagellated and there 
was no evidence of a bacteriophage. Endosymbiosis of axenically cultivated 
cells was stable and permanent. Blastocystis cells died when high dose 
chloramphenicol or tetracycline appeared to eradicate the bacteria. Stenzel 
(Stenzel & Boreham 1994) reported two instances only of endosymbiosis in 
Blastocystis derived from a duck (Figure 1.4) and a monkey faecal samples. 
No endosymbionts were seen in the central vacuole; the duck samples had 
organisms within the nucleus of the Blastocystis and the monkey sample 
showed the bacteria in the cytoplasm. The number of organisms per cell 
varied from 2 to 40. The size of the bacteria (a Gram-negative rod/cocci), 
differed in duck and monkey samples suggesting they were different 
organisms. Almost all Blastocystis organisms in those samples contained the 
endosymbionts, although overall this was a rare finding.  
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Viruses may also be endosymbionts. Virus-like particles have also been 
reported in the cytoplasm of a small number of Blastocystis forms, in parasites 
derived from Macaca monkeys (Stenzel & Boreham 1997) and seasnakes 
(Teow et al. 1992). 
Endosymbiosis can alter the virulence of the host or the endosymbiont in 
either direction. The endosymbiotic bacteria in the free-living amoebae 
described above often developed increased virulence after passage through 
the amoebae. In contrast, the host Filaria sp. parasites become more 
pathogenic if the endosymbiont Wolbachia remains viable. Although 
endosymbionts were only seen in a small number of Blastocystis cultures 
(<10%) they may be difficult to detect. It is possible that Blastocystis is an 
innocent bystander and pathogenicity derives from carriage of unidentified 
endosymbionts. 
 
1.11 Antimicrobial Therapy 
1.11.1 Current therapeutic guidelines for Blastocystis 
The Center for Disease Control and Prevention in the United States 
stated in the latest update in 2012 2 that although the clinical significance of 
Blastocystis infection is controversial the following three antibiotics are 
suggested as first line therapies, namely metronidazole, 
trimethoprim/sulfamethoxazole and nitazoxanide.  
 
1.11.2   In vitro antibiotic sensitivity 
In vitro studies have systematically assessed Blastocystis antibiotic 
sensitivity. Only a small number of organisms were tested, subtype data is 
only available on the most recent ones and practical application may be 
limited by restricted availability of amoebicides. 
  Axenic strains from three symptomatic patients and one monkey tested 
for antibiotic sensitivity were classified in three groups namely inhibitory  
“reducing cell counts 50-100 fold” , (emetine, metronidazole, firazolidone, 
trimethoprim-sulfamethoxazole, Entero-Vioform and pantamidine), 
                                                        
2 http://www.cdc.gov/parasites/Blastocystis. 
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moderately inhibitory “reducing cell counts 5-50 fold” (floraquin and 
chloroquine) and not inhibitory, “reduced cell counts less than five fold” 
(diloxanide furoate and paromycin, other common antibacterial or antifungal 
drugs)(Zierdt et al. 1983). 
The sensitivity of various drugs against Blastocystis (axenic strain 
Netsky) was measured using incorporation of 3H-hypoxanthine to assess cell 
viability (Dunn & Boreham 1991). The most effective drugs in descending 
order were furazolidone, emetine, EnteroVioform, satranidazole, secnidazole, 
chloroquine and trimethoprim (Table 1.7).  
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Table 1.7 Activity of drugs against Blastocystis axenic stock cultures  
 (Dunn & Boreham 1991) 
 
 
The most recent study (Mirza et al. 2010) used a resazurin assay to 
measure intrinsic cellular activity in different subtypes of Blastocystis exposed 
to antimicrobial microassays. Variation in drug sensitivities between subtypes 
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were found, namely resistance to metronidazole and tindazole was observed 
in ST7 (but not another similar imidazole, ornidazole). Blastocystis was found 
to be sensitive to the antimalarial drug mefloquine and increased sensitivity 
was noted with a trimethoprim-sulfamethoxazole combination ratio of 1:2 
(rather than the conventional ratio of 1:5). Herbs including ginger, black 
pepper, white cumin and garlic have also been tested recently in vivo and 
garlic has been found to be as effective as metronidazole in inhibiting growth 
in cell culture (Yakoob et al. 2011). The effects of garlic were ascribed to the 
presence of thiosulfinates that inhibit RNA and DNA synthesis and the other 
herbs contain alkaloids with antibacterial activity. 
 
1.11.3 In vivo antibiotic sensitivity 
Clearance of Blastocystis infection is often unsuccessful (Stensvold et 
al. 2010). Many different drugs (metronidazole, tinidazole, iodoquinol, 
trimethoprim/sulfamethoxazole, nitazonanide, paromomycin, ketoconazole, 
ornidazole) have been reported to be useful in eradicating Blastocystis 
clinically (Table 1.8).  
 
 
 
 
 44 
 
Table 1.8   In vivo efficacy of antimicrobials against Blastocystis (Stensvold et al. 2010) 
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The most commonly used drug has been metronidazole and 
eradication rates reported in the literature vary widely from 0-100% (Stensvold 
et al. 2010). Eradication rates in children treated with 10 days of probiotic 
Saccharomyces boulardii, 10 days of metronidazole therapy and 10 days with 
no therapy (evaluated using only faecal smears for diagnosis) were 77%, 66% 
and 40% respectively (Dinleyici 2011).  
A recent retrospective study has reported Blastocystis clearance rates 
of 77% using paromomycin sulphate (500 mg tds for 5-10 days) and much 
higher than comparable clearance with metronidazole (38%) or no therapy 
(22%) (van Hellemond et al. 2013). This high clearance rate is at odds with 
the finding that paromomycin has no in vivo inhibition against ST 4 and 7 
isolates of Blastocystis (Mirza et al. 2010) and perhaps the broad spectrum 
antibacterial actions of paromomycin are more relevant for clearance (Mirza et 
al. 2010). A single transcolonic infusion of furazolidone, nitazoxanide and 
secnidazole followed by ten days of oral nitazoxanide was also reported to 
clear 100% of eighteen Blastocystis positive patients (Borody 2012).  
Comparison of eradication in different studies is difficult. False negative 
results may be due to the low sensitivity of different diagnostic tests and 
irregular shedding of the parasite. Perceived failure to clear the parasite may 
be due to drug resistance (Mirza et al. 2010), suboptimal dosing schedule, 
poor compliance or rapid re-infection from the environment. Eradication may 
be due to the effect of the drug on Blastocystis, an indirect effect on bacterial 
enteric flora or even occur spontaneously. The age of the patient and clinical 
presentation are other factors that may change response to therapy.  
 
1.11.4 Therapeutic challenges 
We need to be able to identify the patients, if any, who warrant therapy 
for Blastocystis. Knowledge of the life cycle of Blastocystis is needed to 
understand how long therapy will be required for and perhaps what 
morphological forms should be targeted. Effective drugs for the particular 
organism and subtype need to be identified and a means developed to deliver 
them to the site of infection in the right colon. Reservoirs of infection in the 
community need to be identified and strategies designed to limit spread of 
infection. 
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1.12. Aims and objectives of this thesis 
1.12.1 The hypothesis 
 
Blastocystis carriage may cause irritable bowel syndrome 
symptoms in susceptible people. 
 
Blastocystis carriage is common in the community and most carriers 
are healthy. Irritable bowel syndrome, diagnosed according to subjective 
clinical criteria, is also commonly diagnosed in the community.  A multi-
pronged approach is required to identify individuals where these two 
conditions may be causatively linked. This thesis will investigate i) features of 
the parasite’s life cycle through observation of live parasites in xenic cultures, 
ii) the association between prevalence of particular Blastocystis ST’s and 
symptomatology iii) antibiotic therapy efficacy and if possible, clinical 
outcomes following parasite eradication iv) host immune responses to 
infection and v) whether significant differences exist between the gut 
microbiome of clinical groups of Blastocystis- positive and negative IBS 
patients and healthy controls. 
 
1.12.2 Investigative approaches and objectives 
Microscopy of the Blastocystis organism in cultures may offer insights into its 
life cycle.  
(i) I will use deconvolutional microscopy to examine xenic cultures of 
Blastocystis organisms. Using fluorescent spectroscopy and specific 
fluorescent-tagged antibodies I will examine the different morphological 
forms of Blastocystis. Time-lapse sequences will be used to monitor 
the cultures and examine possible morphological or physiological 
changes in the organisms over time. 
 
Clinical studies of symptomatic patients and their household contacts will 
provide information about the ease and mode of transmission within human 
and animal household contacts. It will also provide information about the 
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subtypes encountered in these groups and whether subtypes are clinically 
relevant.  
(ii) I will study symptomatic Blastocystis-positive IBS patients and their 
household contacts, both human and animal, to assess rates of 
transmission within households and identify the subtypes found within 
these groups. 
 
Assessment of different antimicrobial regimens will guide us to the most 
effective therapeutic regimen for eradication. Giardia duodenalis was only 
recognised to be pathogenic when it was possible to effectively eradicate it in 
symptomatic patients (Gardner & Hill 2001). We may be able to better assess 
whether Blastocystis is the cause of symptoms if we have a therapeutic 
regimen with a high success rate (>90%) for eradication.  
(iii) I will conduct two clinical studies using different antimicrobial 
regimens, namely monotherapy with either metronidazole or 
trimethoprim/sulfamethoxazole, and triple antibiotic therapy with 
secnidazole, diloxanide furoate and trimethoprim/sulfamethoxazole, to 
assess eradication rates. 
 
Subtyping may not be able to discriminate Blastocystis organisms with regard 
to pathogenicity. Instead, assessment of host antibody responses to the 
parasite might establish whether significant differences exist between 
symptomatic and asymptomatic carriers and this may support the hypothesis 
that Blastocystis is pathogenic in some people and not in others. It might 
enable Identification of specific Blastocystis antigens associated with 
symptoms and may also provide insights into the mechanism of pathogenicity 
of Blastocystis spp.  
(iv) I will evaluate serum immunoglobulin reponses in IBS patients and 
healthy controls using Western blotting. Further analysis of subgroups 
based on Blastocystis carriage status will be carried out to identify any 
Blastocystis proteins of interest. I will attempt to identify any reacting 
proteins by probing with protease antibodies, including antibody 
specific for legumain (MAb1D5), which has already been identified as a 
protein of interest in symptomatic patients (Wawrzyniak et al. 2012). 
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We know that the faecal microbiome has a distinctive pattern in patients with 
IBS. IBS is likely a heterogenous clinical condition. If Blastocystis patients are 
not a distinct clinical subset of IBS patients the FM pattern should be similar in 
IBS patients positive and negative for Blastocystis carriage. If the FM pattern 
is different in these two groups it suggests Blastocystis carriage status defines 
a different clinical group within IBS patients, and would support the hypothesis 
that Blastocystis spp. cause IBS symptoms.  
(v) The FM in IBS and healthy controls will be assessed using 
metagenomic analysis. The bacterial profiles in these groups will be 
evauluted from phyla to genus and further subgroup analysis will 
assess any relationship with the Blastocystis carrier status
 49 
 50 
 
 
 
 
 
 
2 Blastocystis subtypes in symptomatic and asymptomatic 
family members and pets and response to therapy 
 
 
Nagel, R., Cuttell, L., Stensvold C.R., Mills, P., Bielefeldt-Ohmann, H., Traub, R., 2012. 
Blastocystis subtypes in symptomatic and asymptomatic family members and pets 
and response to therapy. Internal Medicine Journal 42: 1187-1195 
 
 
-presented as published 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
Blastocystis subtypes in symptomatic and asymptomatic family 
members and pets and response to therapy 
 
Robyn Nagel*1, Leigh Cuttell1, C.R. Stensvold2, Paul C. Mills1, Helle Bielefeldt-
Ohmann1 and Rebecca J. Traub1 
 
1 School of Veterinary Science, The University of Queensland, Gatton 4343, Queensland, 
Australia.2 Department of Microbiological Diagnostics, Statens Serum Institut, 2300 
Copenhagen S, Denmark and Department of Infectious and Tropical Diseases, London 
School of Hygiene and Tropical Medicine, London WC1E 7HT, UK 
 
2.1 Abstract 
 Background: Blastocystis is a common, enteric parasite. The pathogenicity of the 
organism is uncertain but subtypes (ST) 1,3 have been reported more likely to cause 
Irritable Bowel-like symptoms. Aims: We treated symptomatic patients positive for 
Blastocystis (BSP) with conventional therapy and analysed 16SSU3 rDNA to assess 
clearance and carriage rates and subtype prevalence of the parasite in the asymptomatic 
household members. Methods: In a longitudinal, prospective case study 11 symptomatic 
patients positive for Blastocystis (SBPs) underwent outpatient clinical assessment to 
exclude other diagnoses before 14 days of either metronidazole 400 mg three times daily 
or trimethoprim/sulfamethoxazole 160/800 mg twice-daily therapy. Faecal specimens were 
collected from patients at baseline, Day 15, 28 and 56 after therapy and from 17 family 
members and 8 pets at Day 15. Specimens were analysed by faecal smear, culture and 
PCR analysis of 16SSU rDNA. Results: No patient cleared the organism following 
therapy.  Subtypes 1 (45%), 3 (36%), 4 (36%), and 6 (9%) were found in the SBPs and 
subtypes identified before and after therapy were identical in each individual. All 
household contacts were positive for Blastocystis and 16/17 (94%) contacts showed 
identical Blastocystis subtypes to the symptomatic family member. All pets were positive 
for Blastocystis with PCR testing, 7/8 (88%) demonstrating ST concordance with the SBP. 
Conclusions: Conventional therapy is ineffective for symptomatic Blastocystis infection. 
The high prevalence of Blastocystis infection within households suggested transmission 
                                                        
3 This chapter is reproduced as published but should read 18SSU (16SSU used for bacteria, 
18SSU used for detecting eukaryotes) 
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between humans and their pets. Sub-typing analysis of SSU rDNA alone in Blastocystis 
does not appear to predict pathogenicity.  
Key Words: Blastocystis; Irritable Bowel Syndrome; Endoscopy; Metronidazole; 
Transmission 
 
2.2 Introduction 
Blastocystis are ubiquitous, anaerobic parasites commonly identified in human and 
animal stool (Tan 2004). Reports suggest Blastocystis causes disease in humans (Tan 
2008). Symptoms attributed to the organism are abdominal pain, bloating and diarrhoea 
(Zierdt 1991; Yakoob et al. 2004). The genus of Blastocystis comprises at least 13 
subtypes (ST) that demonstrate moderate animal species-specificity (Stensvold et al. 
2009a). There is regional variation in the prevalence of different Blastocystis subtypes 
found in humans, although ST3 is universally the most common.  Recent studies have 
suggested ST1 (Tan et al. 2006; Yan et al. 2007; Hussein et al. 2008; Eroglu et al. 2009; 
Stensvold et al. 2009c) and/or ST3 (Tan et al. 2008) may be more likely to be pathogenic 
in humans. The parasite cyst is transmitted by the faecal-oral route (Leelayoova et al. 
2004) and close contact with animals may  be a risk factor for  acquisiton of infection (Li et 
al. 2007b; Parkar et al. 2010).  
Metronidazole, the most commonly prescribed drug for Blastocystis, is reported to 
have widely varying rates of efficacy (Stensvold et al. 2010). These inconsistencies may 
be attributed to insensitive diagnostic methods, variability of Blastocystis subtype-response 
to drugs, rapid re-infection or drug resistance.  
In this pilot study we examined the Blastocystis STs of symptomatic patients and 
their respective human and animal household contacts and recorded the efficacy of 
conventional therapy in the patients. We aimed to evaluate antimicrobial efficacy, the rate 
of environmental re-infection, and explore ST variations in clinical presentation or 
response to therapy. 
 
2.3 Methods 
2.3.1 Study Outline 
This prospective longitudinal study was conducted in a rural specialist outpatient 
clinic (Toowoomba Gastroenterology Clinic). Patients who presented complaining of 
chronic gastrointestinal symptoms and were positive for Blastocystis carriage were 
screened to exclude other causes for symptoms. Faecal samples were collected from 
eligible patients before and after a course of antimicrobial therapy for Blastocystis, and at 
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completion of the antimicrobials faecal samples were collected from all the human and 
animal household contacts.  
2.3.2 Inclusion protocol 
Thirteen adult patients presenting consecutively to the clinic from 09/04/2008 to 
31/08/2009 positive for Blastocystis carriage and complaining of gastrointestinal symptoms 
of more than 6 weeks duration were assessed clinically. Blood tests, full blood count, 
serum calcium, thyroid function tests and tissue transglutaminase antibody, were checked. 
Faecal microscopy, culture and toxin assay for Clostridium difficile was performed to check 
for ova, cysts, oocysts and bacterial pathogens. In addition a faecal ELISA kit 
(“ProsSpecT, Remel Xpect” by Oxoid, UK) tested for Giardia and Cryptosporidium.  A 
validated, in-house real-time faecal PCR analyses carried out by Statens Serum Institute 
laboratory excluded occult Dientamoeba fragilis, Giardia duodenalis, Cryptosporidium 
spp., Entamoeba histolytica and E. dispar infection. A 3-day culture for hookworm was 
performed. Helicobacter pylori infection was evaluated by gastric biopsy at endoscopy. 
One patient with ulcerative colitis and another patient unable to undergo endoscopy were 
excluded from the study.  
The remaining 11 symptomatic Blastocystis patients (SBP’s) proceeded to upper, 
lower endoscopy and capsule enteroscopy, performed by the same endoscopist. Mucosal 
biopsies were taken from the gastric antrum and duodenum for histology and estimation of 
disaccharidase levels. Biopsy specimens were taken from the ileum, right and left sides of 
the colon. 
 
2.3.3 Study Protocol 
Three baseline faecal specimens were taken from 11 eligible SBP prior to starting 
14 days of metronidazole 400 mg three times daily or trimethoprim-sulfamethoxazole 
160mg/800 mg twice daily. Further faecal samples were taken within 48 hours of ceasing 
antibiotics and 2 and 6 weeks after cessation of therapy.  
Trimethoprim-sulfamethoxazole 160mg/800 mg twice daily for 14 days was given to 
patients who had previously failed one course of the identical dose of metronidazole or 
who were intolerant of the medication. Patients were reviewed clinically initially 2 weeks 
prior to therapy, at the completion of the antibiotic therapy and 6 weeks later at the 
completion of the study. All patients kept a diary recording the number of daily bowel 
movements and general well being (scored 1-10; poor-excellent). They also recorded 
whether any household contact or animal was experiencing any change in gastrointestinal 
health. 
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All the household contacts (HC) of these patients were asked to provide fresh stool 
specimens within 48 hours of the symptomatic patient finishing the course of therapy. 
Stool specimens were also collected on this date from all the household animal contacts 
(AHC).  All SBP stool specimens were subjected to routine pathology faecal specimen 
microscopy and culture throughout the study. All stool specimens (SBP, HC and AHC) 
were subject to smear, culture and PCR for detection of Blastocystis and sub-typing.  
 
2.3.4 Diagnostic methods 
All samples were run in parallel for the presence of Blastocystis using a simple 
fresh unstained wet faecal smear, in vitro culture and PCR (confirmed as Blastocystis 
using DNA sequencing). An individual human or animal was considered positive for 
Blastocystis if any one of the tests were positive. 
Parasitological Methods 
Fresh unpreserved faecal samples from patients were divided into two samples 
upon receipt. One sample was screened using a faecal smear by a commercial diagnostic 
laboratory in Brisbane while the other was transported to the School of Veterinary Science, 
University of Queensland (SVS-UQ). Unstained fresh faecal smears were examined under 
40x magnification by light microscopy. The load of Blastocystis organisms was classified 
as light, medium or heavy (<5, 5-10, >10 organisms per high power field). 
Additionally, 100 mg of stool was inoculated in Jones’ culture medium (Jones 1946) 
and incubated at 37 ºC for 48-72 hours. Cultures were examined for the presence of 
Blastocystis by light microscopy. 
Molecular methods 
DNA was extracted from unpreserved faecal samples and pelleted cultures of 
Blastocystis using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions, except that following the addition of lysis buffer, the faecal 
suspension was subjected to three freeze-thaw cycles in liquid nitrogen and a 95 ºC water 
bath, respectively. 
The genomic DNA from stool and cultured Blastocystis specimens from all patients, 
household members and animals were subjected to PCR analyses. Three different 
published PCRs capable of amplifying the small subunit (SSU) rRNA gene of STs 1-13 of 
Blastocystis (Bohm-Gloning et al. 1997; Clark 1997b; Stensvold et al. 2006; Wong et al. 
2008) were utilised in order to maximize the likelihood of detecting mixed ST infections.  
All PCR products positive for Blastocystis were subjected to DNA sequencing and 
phylogenetic analysis to identify the subtype. PCR products were run on gels of 1.5% 
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agarose in 1×TAE buffer at 150V in a Biorad electrophoresis system and were purified 
using Purelink PCR Purification Kit (Invitrogen) prior to sequencing.  Sequencing was done 
using an ABI 3130xl Genetic Analyzer (Applied Biosystems) using a Ready Reaction Kit 
Version 3.1 (PE Applied Biosystems, California, USA) and sequences edited and 
assembled using Finch TV v 1.4.0. DNA. Sequences were deemed as ‘mixed’ when 
sequence profiles were characterized by a clean sequence with multiple peaks at sites of 
nucleotide polymorphism. 
DNA sequences were aligned with 15 previously sequenced Blastocystis SSU 
rRNA genes sourced from GeneBank (NCBI4) representing the 13 established subtypes 
described from mammals and birds. Distance-based analyses were conducted on 
readable sequences using Kimura 2-parameter distance estimates and trees were 
constructed using the Neighbor Joining algorithm using Mega 3.1 (Kumar et al. 2001) 
software. Proteromonas lacerate (U37108) was used as an out-group. Bootstrap analyses 
were conducted using 1000 replicates. 
 
2.3.5 Ethics Approval 
The study was approved by The University of Queensland Medical Research Ethics 
Committee and Animal Ethics Committee and registered with the Australian New Zealand 
Clinical Trials registry (www.ANZCTR.org.au) ACTRN12610001066077 
 
2.4 Results 
2.4.1 Clinical characteristics of patients and household members 
Male (n=3) and female (n=8) patients with an age range of 23-71 years participated 
in the study.  The shortest symptom duration was 3 months in one patient, six patients had 
exhibited symptoms for 2 years and the other five patients had complained of symptoms 
for more than 10 years. Presenting clinical symptoms were bloating (7/11; 64%), diarrhoea 
(5/11; 45%), nausea (5/11; 45%), flatulence (4/11; 36%), variable bowel habit (4/11; 36%) 
abdominal pain (3/11; 27%) and fatigue (2/11; 18%) (Table 2.1) 
 
 
 
                                                        
4 www.ncbi.nlm.nih.gov/ 
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Table 2.1 Clinical profile of symptomatic Blastocystis patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BO= Bowel actions per day   WB=general wellbeing, 10/10 excellent TI=terminal ileum BH= bowel habit 
 
 
Five patients had previously received therapy for Blastocystis, which did not clear 
either the infection or their symptoms. The remaining patients were naïve to therapy. 
During the period of the study no SBP had any organism other than the Blastocystis noted 
in the faecal testing. No patient demonstrated eosinophilia on the peripheral full blood film.  
In total 17 HC submitted specimens; only one teenage HC was unable to donate a 
sample (three other HC specimens collected from that family). Eight AHC samples were 
collected, five dogs and three cats from seven households (one of two dogs in one 
household escaped submitting a specimen). Household water sources were varied. No HC 
or AHC was undergoing medical investigation or therapy for gastrointestinal symptoms. 
Patient 
 
Main 
symptoms 
Duration 
of 
symptoms 
Previous 
therapy 
Blastocystis? 
Reversible 
Causes 
Treated before 
Inclusion in 
Study 
Small 
bowel and 
colonic 
Endoscopy 
Baseline 
week 
median 
daily 
BO/WB 
Week 6 
Daily 
median 
BO/WB 
ST at 
Baseline 
1 Pain 
Bloating 
10 years Yes , x2 
2 years ago 
Giardia Prominent 
lymphoid 
follicles TI 
1/8 1/8 3 
2 Bloating 
Alternating 
BH 
11 years Yes, x2 
5 years ago 
Enterobius 
vermicularis 
Mild focal 
active colitis 
colonic 
biopsy 
3/8 4/8 3 
3 Alternating 
BH 
Nausea 
2 years No  N 1/10 1/9 3 
4 Diarrhea 
Bloating 
Pain 
2 years Yes, x3 
1 year ago 
Aeromonas 
Low Lactase 
N 3/8 3/8 3 
5 Diarrhea 2 years 
 
No  Colonic 
polyp 
2/9 2/8 4 
6 Nausea 
Fatigue 
3 months No  2mm 
nodule mid-
small bowel 
Colonic 
polyp 
1/7 1/7 1 
7 Nausea 
Pain 
Alternating 
BH 
2 years No  Prominent 
lymphoid 
follicles TI 
1/7 1/8 1 
8 Bloating 
Alternating 
BH 
10 years Yes, x3 
10 years ago 
 
 N 1/9 1/9 1 
9 Nausea 
Bloating 
Alternating 
BH 
2 years No  N 2/6 1/8 1 
10 Bloating 
Fatigue 
 
30 years No Ursodeoxycholic 
Acid for small 
bowel resection 
Colonic 
polyp 
1/7 1/8 1 
11 Bloating 
Alternating 
BH 
2 years No  N 2/7 1/7 4+6 
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2.4.2 Endoscopy 
All patients displayed normal stomach and duodenum and all were negative for 
Helicobacter pylori at gastric biopsy. Duodenal biopsy showed mild intra-epithelial 
lymphocytosis in 2/11 (SBP2, 4) patients (Table 2.1). Colonoscopy with ileoscopy was 
macroscopically normal in 8/11 patients. One patient (SBP1) displayed prominent 
lymphoid follicles in the terminal ileum, confirmed on ileal biopsy. All the other ileal 
mucosal biopsies were normal. Random colonic mucosal biopsies were normal in 10/11 
patients; SBP2 had mild focal active colitis noted at histology only. Capsule endoscopy 
looked normal in 9 patients; two patients (SBP1 and 7) displayed prominent distal ileal 
lymphoid follicles.  
 
2.4.3 Therapy 
Eight patients were prescribed metronidazole and one patient (SBP7) complained 
of severe nausea but completed the course. Three patients (SBP2, 4,9) were prescribed 
trimethoprim/sulfamethoxazole and one patient (SBP7) developed a rash and ceased the 
tablets on day 11 of the 14-day course. 
 
2.4.4 Faecal smears and culture in patients 
Faecal smear results prior to the commencement of treatment demonstrated a 
parasite load of <5 organisms per high-powered field (O/HPF) in five patients and > 5 
O/HPF in the remaining patients. All faecal smears or cultures performed at SVS-UQ were 
positive for Blastocystis at days 14, 28 and 56 (Table 2.2). 
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Table 2.2 Blastocystis faecal smear and culture results in patients 
 
 
 
MTZ= metronidazole TS=Trimethoprim/sulfamethoxazole c=culture   s=smear= number of Blastocystis 
organisms/high power field in wet faecal smear n/a=not  available: Time: 0 days =before antibiotic therapy 14 days = within 48 hours of 
finishing antibiotic therapy CL=commercial laboratory UQ=University of Queensland laboratory: Faecal smear results: organisms per 
high power field light microscopy x40magnification: <5, >5, >10  
 
  Faecal smears performed at the commercial laboratory (CL) showed negative 
results in 4/11 (36%), 2/11 (18%) and 3/9 (33%) at 14, 28 and 56 days, respectively. In 
3/33 specimens examined at SVS-UQ, the faecal smear result was negative and the 
culture positive (SBP6 at 28 days; SBP8 at 28 and 56 days). Change in parasite excretion 
load pre- and post- therapy was variable within the study group (Table 2.2). Four SBP’s 
(SBP6, 7,9,10) had “occasional leukocytes” noted in less than 50% of each individual’s 
faecal microscopy specimens, all other specimens were negative for faecal leukocytes. 
 
2.4.5 PCR and genetic sub-typing of Blastocystis in patients 
All patients were PCR positive for Blastocystis after antibiotic therapy. Sub-typing of 
Blastocystis showed that all patients retained the same subtype following therapy with 
antibiotics. Three patients (SBP 4, 9 and 11) were found to have mixed subtype infections 
and two of these patients appeared to acquire the second subtype after therapy. The STs 
Patient Day 0  Day 14 Day 28 Day 56 
         UQs 
              
Therapy CLs          UQs          UQc                  CLs       UQs         UQc               CLs          UQs        UQc 
 
1 >5 MTZ +               >5             + +              >5             + +                <5          + 
2 >5 TS -                >5             + +              >5             + +                 >5            + 
3 >5 MTZ +               <5             + +              <5             + n/a              >10          + 
4 >10 TS +               <5             + +             >10            + -                  -               - 
5 >10 MTZ +               <5             + +              <5             + +                 <5            + 
6 <5 MTZ +               <5             + -                  -             + -                  <5            + 
 
7 <5 MTZ +               <5             + n/a             <5           + +                 <5            + 
8 <5 MTZ -                <5             +  -                <5           - -                  <5             - 
9 <5 MTZ -                <5             +  +               <5           + -                  <5            + 
10 <5 MTZ +               <5             +  +               <5            + +                 <5            + 
11 <5 MTZ -                <5             +  +               >5             + +                 >5            + 
 59 
identified in the patients were ST1 (5/11, 45%), ST3 (4/11; 36%), ST4 (4/11; 36%) and 
ST6 (1/11; 9%)(Table 2.3). 
 
Table 2.3  Blastocystis subtype results in symptomatic patients pre- and post-
therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.6 Faecal smears, cultures and PCR sub-typing in household contacts  
Seventeen household contacts were tested and 10/17 (59%) contacts were positive 
for Blastocystis on faecal smear. Blastocystis organisms were low in number and only 1/10 
positive specimens contained >5 organisms per high power field. Cultures were positive in 
5/17 household contacts (29%). However PCR analysis of these specimens showed that 
17/17 (100%) of household contacts had evidence of Blastocystis carriage. Readable DNA 
sequences allowed subtype determination in all except one household member 
(SBP11/HC1). The patients and their household contacts had concordant Blastocystis 
subtypes in 10/11 cases. SBP8 was the only patient to have a different subtype to the 
household contact (Table 2.4). 
 
 
 
 
Patient 
 
Subtype 
before therapy 
Subtype 
after therapy 
1 3 3 
2 3 3 
3 3 3 
4 3 3+4 
5 4 4 
6 1 1 
7 1 1 
8 1 1 
9 1 1+4 
10 1 1 
11 4+6 4+6 
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   Table 2.4  Blastocystis subtype results in patients, household contacts and 
animals 
 
 
 
2.4.7 Faecal Smears, cultures and PCR sub typing in animal contacts 
Seven households had contact with eight household animals. Only 2/8 (25%) 
animals were positive for Blastocystis on faecal smear, and none were positive on culture. 
However, all eight animals had positive PCR tests. All of the animals harboured at least 
one subtype in common with each of the corresponding seven patients.  Most animals 
(7/8) also had subtypes in common with the corresponding household contacts (HC11 was 
the exception; Table 2.4) 
 
2.4.8 Clinical follow up at 6 weeks 
Only one patient reported any change in diary entry (SBP9 reported 2 point-rise in 
general well-being at 6 weeks post therapy; Table 2.1). No household contact or animal 
was reported to have any change in gastrointestinal health. 
 
 
 
Patient 
 
 
Patient  
Subtypes 
 
Household 
Contact 
 
Household 
Fecal 
Smear 
 
Household 
Fecal 
Culture 
 
Household 
PCR  
Subtypes 
 
Animal 
Contact 
 
Animal 
Fecal 
Smear 
 
Animal 
Fecal 
Culture 
 
Animal  
PCR 
Subtypes 
1 3 HC1 + + 3     
2 3 HC1 
HC2 
+ 
+ 
- 
+ 
3 
3 
Dog - - 3 
3 3 HC1 + - 3     
4 3+4 HC1 + - 3 Dog - + 3 
5 4 HC1 
HC2 
+ 
+ 
+ 
- 
1+6 
4 
Cat + - 1+4 
6 1 HC1 - - 1 Dog - - 1 
7 1 HC1 
HC2 
HC3 
+ 
+ 
+ 
+ 
- 
- 
7 
7 
1 
Dog + - 1 
8 1 HC1 - - 6     
9 1+4 HC1 - - 1     
10 1 HC1 - - 1 Cat1 
Cat2 
- 
- 
- 
- 
1 
1 
11 4+6 HC1 
HC2 
HC3 
- 
- 
- 
- 
+ 
- 
+ 
6 
6 
Dog - + 1+4 
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2.5 Discussion 
In this study, none of the eleven patients with symptomatic blastocystosis 
succeeded in clearing infection following a 14-day course of metronidazole or 
trimethoprim/sulfamethoxazole. Faecal Blastocystis organisms have been detected 2 days 
after oral ingestion of cysts in mice (Moe et al. 1997). Persistence of the parasite within 48 
hours of ceasing antibiotics in this study suggests failure to clear the parasite and not re-
infection. Reported rates of eradication of Blastocystis using these antibiotics vary widely 
in the literature from 22-100% (Ok et al. 1999; Moghaddam et al. 2005). High false-
negative rates of Blastocystis detection using routine faecal smears have previously been 
reported (Stensvold et al. 2007a) and false negative rates of 50% were confirmed in this 
study. Light microscopy is an unreliable tool for detecting this polymorphic parasite that 
exhibits highly variable daily faecal excretion rates (Suresh et al. 2009). The vacuolated 
form, which is the most readily identified form in the faecal smear, may have a 10-fold 
variation in size (Zierdt 1988) and small vacuolated forms, amoeboid or cystic forms (2-5 
m) with low excretion rates may not be readily identified (Suresh & Smith 2004). Large 
clinical trials using more sensitive diagnostic tests such as PCR in addition to conventional 
methods will be required to accurately evaluate the in vivo efficacy of the numerous agents 
(Stensvold et al. 2010) that have been reported to be useful in treating Blastocystis and to 
evaluate new antimicrobials. 
The possible causes of antimicrobial failure in clinical Blastocystis cases are 
numerous. Metronidazole and trimethoprim have been studied in vitro (Zierdt et al. 1983; 
Dunn & Boreham 1991; Vdovenko & Williams 2000) and, although both drugs inhibit 
growth of Blastocystis, higher doses are needed to be cytocidal. Delivery of a cytocidal 
dose of the antimicrobial to the organism in vivo may be problematic. Both antibiotics are 
rapidly absorbed systemically, primarily in the small bowel (70% of a single oral dose of 
both agents is excreted in urine), and little active drug reaches the colon. In animal studies 
Blastocystis has been found primarily in the caecum and proximal colon (Phillips & Zierdt 
1976; Moe et al. 1997). Endoscopic reports in humans demonstrate viable Blastocystis 
organisms in caecal fluid and in biopsy specimens of the large bowel mucosa but in 
humans generally the organism is not invasive (Zuckerman et al. 1994). Studies in humans 
do not report Blastocystis in the stomach or duodenum and no abnormality of the small 
bowel was noted in this study. It is likely that drugs effective against Blastocystis will need 
to be delivered in high concentration to the lumen of the caecum.  
Blastocystis subtypes may also vary in their susceptibility to various antimicrobial 
agents. Blastocystis STs have been shown to differ in their morphology and growth rates 
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(Cassidy et al. 1994; Tan et al. 2008) and a recent in vitro study has reported variation in 
metronidazole sensitivity between different subtypes in in vitro culture (Mirza et al. 2010). 
Studies assessing drug sensitivities may need to take account of the ST and regional 
origin of the organism. 
The pathogenicity of Blastocystis is uncertain. Blastocystis is commonly found in the 
stools of healthy people, which is in agreement with observations of healthy, yet positive 
household members in this study. The prevalence in an asymptomatic population in 
Australia has been reported to be 6% (Hellard et al. 2000) assessed with stained faecal 
smears, but is reported to be as high as 20-30% in other nations (Yaicharoen et al. 2005; 
Li et al. 2007b) when using faecal culture and DNA detection tools. However, the existence 
of healthy carriers does not necessarily exclude pathogenicity. Common parasitic 
pathogens, such as Giardia duodenalis and Entamoeba histolytica, are known to cause 
symptomatic disease in less than 50% of infected people (Pickering et al. 1984).  
Studies have found Blastocystis more commonly in the stools of patients with 
Irritable Bowel Syndrome (Yakoob et al. 2004; Yakoob et al. 2010), and Blastocystis has 
been linked to outbreaks of diarrhea in travellers and soldiers in camp (Jelinek et al. 1997; 
Leelayoova et al. 2004). Most large studies of symptomatic Blastocystis patients describe 
a non-inflammatory watery diarrhea with no mucosal ulceration or invasion (Zuckerman et 
al. 1994; Jelinek et al. 1997). This study is the first to examine the small bowel in 
Blastocystis infection, as previous studies have not reported inspecting the terminal ileum 
at lower endoscopy (Kain et al. 1987; Zuckerman et al. 1994; Chen et al. 2003). Prominent 
lymphoid tissue in the terminal ileum was the only mucosal abnormality seen in a minority 
of patients. 
One explanation for the apparent clinical paradox of symptomatic and 
asymptomatic infected household members may be that subtypes of Blastocystis vary in 
their pathogenicity, notably ST3 (Tan et al. 2008) and ST1 (Kaneda et al. 2001; Tan et al. 
2006; Yan et al. 2006; Hussein et al. 2008; Eroglu et al. 2009; Stensvold et al. 2009c) has 
been reported more frequently in symptomatic patients. Other studies have not confirmed 
any significant difference in the distribution of particular subtypes between symptomatic 
and asymptomatic Blastocystis carriers or specific diseases (Yoshikawa et al. 2004a; 
Dogruman-Al et al. 2009; Elwakil & Talaat 2009; Rene et al. 2009; Souppart et al. 2010). 
Although ST1, rather than ST3 was the most common in our small study we found no 
evidence that a particular 16SSU rDNA subtype of Blastocystis was more likely to be 
associated with symptoms. If particular Blastocystis strains are pathogenic, then the 
differences in the organism may not be apparent with our current sub-typing tools directed 
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at rDNA of the dominant faecal strain or it may be that individual host/parasite interaction 
determines pathogenicity.  
The parasite load may also be a significant factor in causing disease and no reliable 
guide to quantification exists. Although previous studies have suggested that Blastocystis 
infection is considered more severe if five or more organisms per HPF are recovered on 
faecal smear, this measure could be unreliable considering the wide variation in daily 
excretion of the parasite (Suresh et al. 2009). In this study, human and animal household 
contacts had fewer parasites positively documented on smear and a lower rate of 
successful culture of Blastocystis.  
Many aspects of the life cycle of Blastocystis are unknown. At present it seems 
likely that only the thick walled cyst, which survives water chlorination (El-Shazly et al. 
2005a), transmits infection (Moe et al. 1997). In this study the universal carriage of 
Blastocystis in household contacts and the concordance of subtypes suggest that 
Blastocystis is easily transmitted. A recent study has also reported concordance of STs 
between pets and their owners (Eroglu & Koltas 2010). Even if the primary infection is not 
acquired from the household animal these animals are likely to remain a reservoir for re-
infection. 
 
2.6 Conclusion 
The universal failure of single antimicrobials in this pilot study suggests that future 
studies may need to investigate efficacy of combinations of antimicrobial therapy as well 
as clearance rates in different patient subgroups (such as length of time of acquisition of 
infection or diarrhoea predominant illness). The high concordance of Blastocystis subtypes 
within households warrants further investigation in a larger study using more specific 
molecular tools to allow definitive comments on routes of transmission.  
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3 Axenic culture of Blastocystis spp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66 
Axenic cultures 
3.1 Abstract 
Although Blastocystis spp. are the most common enteric parasite found worldwide 
there is a dearth of basic information about the biology of the parasite. Axenic cultures 
provide a simple system to investigate molecular, biochemical processes and antimicrobial 
sensitivities of Blastocystis. Historically axenisation has been difficult to achieve, and there 
is limited quantity and diversity of axenic stock available worldwide. Three previously 
reported successful techniques to develop axenic cultures of Blastocystis were trialled, 
namely culture into solid agar, soft agar and preliminary partial elimination of 
contaminating bacteria using a Ficoll-metrozoic acid gradient. Although growth in agar was 
achieved, further propagation of the parasite was not successful.  
One major factor in this failure was likely the quantity of inoculum of the parasite. 
Future success would likely be improved if the cultures were attended daily, only stool with 
large numbers of Blastocystis was selected for culture and antimicrobial sensitivity on the 
enteric flora was determined and used to select antibiotics.  However, the most important 
step forward will be to understand the life cycle of this parasite and the parasite forms or 
priming factors necessary for reproduction. Despite documenting sufficient numbers for 
successful inoculation at six weeks of culture, it is well recognized that aging cultures will 
not succeed. Schizogony is a reported but not accepted mode of reproduction of 
Blastocystis. The apparent schizonts seen in this study cannot be confirmed without 
demonstrating genetic material within the daughter cells. 
 
3.2  Introduction to axenic culture 
3.2.1 Why attempt axenic culture? 
Blastocystis organisms living in a sterile, artificial environment are likely to differ in 
basic metabolic processes and possibly even life cycle from those living in and interacting 
with the luminal and microbial environment of the gut. Nevertheless, axenic cultures 
(homogenous culture devoid of any other contaminating microorganisms) provide a 
simpler model to investigate molecular and biochemical processes and the antimicrobial 
sensitivities of Blastocystis spp. However, reliable development of diverse axenic cultures 
of Blastocystis has been difficult to achieve and improving axenic culture protocols has 
been identified as one of the most important undertakings needed to improve our 
knowledge of this parasite (Poirier et al. 2012).  
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3.2.2. Early experience with axenic culture using antibiotics 
Axenic culture of Blastocystis sp. was first described in 1921 with the aim of proving 
that this parasite was a distinct species and not a degenerate faecal form of other 
parasites, yeasts or vegetable matter (Barret 1921). Twenty-five subcultures were 
successfully achieved in anaerobic conditions at the base of a test tube using a 10% 
human serum and 0.5% sodium chloride solution incubated at 37C. Bacterial overgrowth 
and subsequent culture death was commonly observed in the unsuccessful attempts of 
axenisation in this study. Subsequent studies cultured the parasite in small amounts with 
difficulty but could not isolate the parasite from bacteria (Ciferri & Redaelli 1938) or 
transfer to a solid media (Lynch 1922; Knowles & Das Gupta 1924).  
Finally in 1974 axenic culture of significant quantities was achieved in a strict 
anaerobic environment by the slow addition of antibiotics over months, with gradual 
reduction of the contaminating bacteria to three or four species and then final bacterial 
eradication (Zierdt & Williams 1974) using a bi-phasic medium consisting of egg medium 
slants overlayed by Locke’s solution (Boeck and Drbohlav (B-D) inspissated egg medium) 
(Boeck & Drbohlav 1925; Clark & Diamond 2002). Despite slow withdrawal of the antibiotic 
many cultures died when bacteria were finally eliminated. Later studies attained culture of 
significant quantity of parasite in a monophasic liquid medium (Molet et al. 1981). 
 
3.2.3 Physical separation of contaminating microorganisms 
Initial physical methods of differential centrifugation to separate out the 
contaminating bacteria damaged the fragile Blastocystis form that “bursts like a balloon” 
(Zierdt 1991). Attempts to improve culture yields and reduce contaminating organisms by 
layering culture sediments on a Ficoll-metrozoic acid gradient were reported to be partially 
successful (Upcroft et al. 1989). A later study combined this separation method with 
repeated exposure to antibiotics selected according to the bacterial contaminants 
antimicrobial susceptibility cultured in a B-D biphasic medium (Lanuza et al. 1997). This 
study developed 81 different cultures of Blastocystis and reported successful axenisation 
in 25 (31%). These axenic cultures had a mean generation time of 10.5 hours, took 3-5 
weeks to axenise and were observed for seven days to confirm no bacterial contamination. 
The final harvest was six tubes of axenic Blastocystis organisms with a concentration of 
Blastocystis organisms varying from 0.25-2.5 x 106 per tube. The broadspectrum 
antibiotics used included cephtazidine, ciproflacin, fosfomycin, imipenen and vancomycin. 
The authors reported that consecutive addition of antibiotics was more successful than 
adding a combination of antibiotics together.  
 68 
The authors had no explanation for the failure of 70% of the cultures to axenise, but 
suggested that this may support previous suggestions that some strains of Blastocystis are 
dependent on companion bacteria for growth (Zierdt 1991; Boreham & Stenzel 1993). 
 
3.2.4 Agar colonies 
To date the most successful axenic culture technique producing significant quantities of 
Blastocystis in a timely manner (three weeks) has used physical separation of colony 
growth on the surface of agar to complete the separation of the parasite from 
contaminating bacteria before expansion in liquid medium (Ng & Yan 1999). This method 
was further enhanced to increase clonal yield on the agar plates (Tan et al. 2000). These 
colonies grew to 3mm diameter in size by day eleven and were distinguishable from 
bacterial colonies by colour, domed shape and mucoid texture with maximum growth 
noted at day four or five. A later technique described successful growth after eight days in 
soft agar, but separation from the agar and transfer to liquid medium was more 
problematic (Valido & Rivera 2007).  
These agar colonies have been examined microscopically and appear to have an 
organised structure. Light microscopy showed large irregularly shaped amoeboid forms 
(AF) on the periphery of the colony with smaller (around 10m) mostly vacuolated forms 
(VF) at the centre (Valido & Rivera 2007). Scanning electron micrographs show two 
regions in the colonies, a central domed region and a flattened peripheral region (Tan et 
al. 2000) (Figure 3.1). A fine surface coat was present on most cells and this coat 
thickened as the colony aged.  
Figure 3.1 Scanning electromicrograph of Blastocystis colony grown on solid agar 
(Tan et al. 2000) 
 
D: dome  
P: periphery of colony 
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3.2.5 Requirements for successful axenisation 
Successfully culturing vigorous axenic cultures, which have been subcultured many 
times without requiring antibiotic supplementation to prevent subsequent bacterial 
contamination, is difficult. All studies have shown that strict anaerobic conditions are 
required, even to the extent of pre-reducing the medium for 48 hours. The size of the 
inoculum is important, requiring an initial inoculum of at least 1-1.5 x106 Blastocystis cells 
(Zierdt & Williams 1974; Ho et al. 1993), although surprisingly, further propagation was 
possible by transferring only a small number of cells (<100) from one established agar 
colony to another agar plate. The type of cell that is transferred is important, a mixture of 
VF and granular forms is preferred, VF alone usually fail (Zierdt & Williams 1974). Media 
with different osmolality have been used and indicate that Blastocystis is tolerant in this 
regard. The age of the seeding culture is also important, cultures 7 and 14 days propagate 
well but those after 20 days usually fail. There are also local factors that may be important 
including the type of culture containers (some glass and plastic tubes are not suitable) 
(personal communication, Dr K.W.S Tan, NUS, Singapore). 
Currently many laboratories around the world would like to have readily available 
axenic cultures of Blastocystis spp.. Subtype 4 (WR1), ST1 (Netski), and ST7 are currently 
subcultured successfully in Department of Microbiology, National University Singapore, 
Singapore (Dr K.W.S Tan). 
 
3.3 Methods 
3.3.1 Sample selection and management 
Fresh faecal specimens from patients positive for Blastocystis, as determined by 
light microscopy and later confirmed with PCR (sixty five patients with a range of subtypes 
1-8, 45 symptomatic for gastrointestinal symptoms), and from asymptomatic pigs were 
collected and subcultured within 2-6 hours of passage of stool. These specimens were 
subjected to preliminary subculture in high quality polypropylene test tubes (Sarstedt 10mL 
Cat no: 83.9923.929) and then transferred to agar for further culture. Two methods of 
axenic culture were used in our experiments, namely the solid agar (Ng & Yan 1999) and 
the semi-solid agar (Valido & Rivera 2007) method. Enrichment of Blastocystis passage 
was attempted using Ficoll-metrozoic acid (Histopaque, Sigma-Aldrich, cat no:10771) 
gradient to concentrate the organisms. 
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3.3.2 Preliminary subculture one   
A small amount of fresh faeces (approximately 10 gm) was cultured aerobically for 
48 hours in culture solution of Jones medium (Appendix 3.1) /10% heat inactivated horse 
serum (HS) (Gibco, Life technologies, Cat No: 26050-088). Sediment (0.5-1.0 ml) from the 
base of each test tube was subcultured anaerobically using pre-reduced Iscove’s Modified 
Dulbecco’s medium (IMDM)/10%HS medium supplemented with antibiotics every 2-3 
days. Anaerobic conditions were obtained using an anaerobic pouch GasPakTM (B-D, cat. 
No: 26001) system in a sealed jar. The sediment was examined microscopically and when 
a strong growth of Blastocystis was observed at the second, third or fourth subculture with 
relatively little bacterial contamination this was transferred to agar or subjected to 
Histopaque concentration.  
 
3.3.3 Preliminary subculture two 
The same method as above was employed except that following culture in Jones 
medium the sediment was transferred to B-D biphasic medium (Appendix 3.2), subcultured 
every three–four days and then subsequently transferred to agar. 
 
3.3.4 Antibiotic supplementation  
Antibiotics were added to the medium to give a final concentration of claforan 2,000 
g/ml, ampicillin 4,000 g/ml, streptomycin 1000 g/ml and benzylpenicillin 100 IU/ml. 
When fungal overgrowth was seen amphotericin 6 g/ml was added.  
 
3.3.5 Monitoring the subcultures 
Six symptomatic patients had their preliminary subcultures monitored for growth 
and morphological form over time. The pellet at the bottom of the tube was gently 
dispersed evenly in the whole test tube and cells were examined by light microscopy and 
counted using a haemocytometer. 
 
3.3.6 Solid agar culture  
BactoTM agar (Difco, Cat no. 214520) prepared as a 3.6% solution with 0.1% 
sodium thioglycollate (Sigma-Aldrich, cat no. T0632) was sterilised in an autoclave and 
then kept at 56C in a waterbath. Two mL of this agar was added to 18ml of warmed 
IMDM/10% inactivated HS combined with ampicillin (50,000 g) and streptomycin (1,000 
g) in a 50 mL centrifuge tube and gently mixed. Sediment from the preliminary subculture 
(0.5-1.0 mL) was added, the tube gently swirled and the mixture poured into a 100x15 mm 
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petri dish. A small amount of sediment (0.10 mL) was also sprayed onto the surface of the 
agar.  
The petri dish was placed in the freezer at -20C until the agar was set 
(approximately 3-5 minutes), then transferred to an anaerobic jar with GasPakTM and 
incubated undisturbed at 37C for ten days. At day ten the plate was observed for colony 
growth, if no growth was seen the plate was re-incubated for a further 4-7 days and then 
discarded if no growth was seen. A randomly selected sample of agar was examined with 
a light microscope to exclude unrecognised growth of Blastocystis colonies.   
If colony growth was observed the colonies were picked up separately with a sterile 
pipette and transferred gently to 2 mL microcentrifuge tubes containing pre-reduced 
IMDM/HS (with varying concentrations of HS from 10-30%), centrifuged at 11,000g for 
10sec in a microfuge to remove the agar and incubated at 37C in IMDM/HS 10% for 
further subculture and propagation at 3-7 days. 
 
3.3.7 Semi-solid agar culture 
BactoTM agar (Difco, Cat no. 214520) prepared as a 1.5% solution with 0.1% 
sodium thioglycollate (Sigma-Aldrich, cat no. T0632) was sterilised, and kept at 56C in a 
waterbath. The agar preparation and IMDM were added in equal proportion to a 50 ml 
centrifuge tube to a volume of 18 ml and two mL of inactivated HS and combined with 
ampicillin (50,000 g) and streptomycin (1,000 g) were added. Sediment from the 
preliminary subculture (0.5 mL) was gently pipetted onto a petri dish and 20 ml of agar 
mixture gently poured on top. The Petri dish was then treated as per the solid agar 
regimen. 
 
3.4 Results 
Preliminary cultures were attempted 210 times between 15/2/11 and 23/07/13. 
Bacterial and fungal overgrowth of cultures was common despite antibiotics. Growth of 
subcultures was more vigorous using the biphasic medium, but it appeared more difficult 
to reduce the numbers of contaminating bacteria in this medium. Subcultures with good 
growth of Blastocystis were placed into agar 32 times with two solid agar plates (Plate 1 
and Plate 2) derived from the same pig specimen growing small numbers of colonies (1-
3mm in diameter) (Figures 3.2, 3.3) and with two instances of poor growth in semi-solid 
agar from human and pig specimens (Figure 3.4).  
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Figure 3.2 Blastocystis colonies grown on solid agar 17/8/12 School of Veterinary 
Science, University of Queensland 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Light microscopy of Blastocystis colony grown on solid agar 17/8/12 
 
Arrows indicate cells possibly undergoing schizogeny   Black circle indicates the direction of the centre of colony   Bar: 10m 
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Figure 3.4 Light microscopy of Blastocystis colony grown in soft agar 17/7/12 
School of Veterinary Science, UQ 
Large numbers of amoeboid cells are seen in the centre and round clusters free at the edge. 
 
 
 
 
 
 
 
 
 
 
 
None of these partially successful cultures had had cells separated with HistopaqueTM.  
None of the Blastocystis organisms from Plate 1 could be further propagated in 
liquid media and the cultures died after 2-4 weeks. Plate 2 was placed back into the 
incubator for further colony growth, but examination a week later showed that all colonies 
had died (presumably the brief exposure to oxygen was detrimental to the organisms).  
Light microscopy showed mainly AF towards the centre of the colony or round VF 
free or very close to the periphery of the colony. Some of the cells had prominent granules 
at the edge of the vacuoles and one appeared to show round inclusions shaped like 
daughter cells inside the main cell suggesting reproduction via schizogony (Figure 3.3, 
arrow). 
Cell counts in the preliminary cultures fluctuated over time, showing peaks at 2-3 
weeks and again at 5-6 weeks before decreasing (Table 3.1, Figure 3.5). Our VF cell 
counts were never high but reduced with time over the life and demise of the culture. As 
the VF and AF counts fell the GF counts increased with the aging culture. 
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Table 3.1 Blastocystis cell counts in fresh faecal cultures derived from 6 patients 
with gastrointestinal symptoms, subcultured every 2-3 days, in Jones/Horse serum 
10% seven days, then IMDM/Horse serum 10% for following 11 weeks 
Patient 1 VF AF GF Patient 2 VF AF GF Patient 3 VF AF GF 
Baseline 1 5 277  8 16 72  1 7 83 
Week 1 0 8 271  2 17 188  0 4 275 
Week 2 0 0 344  0 1 178  0 10 109 
Week 3 0 2 656  0 5 524  1 4 202 
Week 4 7 3 273  0 7 276  1 0 453 
Week 5 1 10 858  0 8 742  2 3 412 
Week 6 0 6 111  0 1 294  0 0 336 
Week 7 0 0 50  0 0 199  0 0 157 
Week 8 0 0 200  0 0 377  0 0 276 
Week 9 8 1 277  2 0 226  1 0 231 
Week 10 0 0 121  0 0 199  0 0 129 
Week 11 0 0 15  0 0 27  0 0 49 
            
Patient 4 VF AF GF Patient 5 VF AF GF Patient 6 VF AF GF 
Baseline 0 7 193  1 14 162  0 13 333 
Week 1 0 18 399  0 5 335  0 3 337 
Week 2 3 5 305  1 3 249  2 4 487 
Week 3 0 14 580  0 1 468  1 7 379 
Week 4 0 8 690  0 4 436  1 5 403 
Week 5 1 4 640  0 3 777  1 3 784 
Week 6 0 6 463  2 7 459  0 1 118 
Week 7 0 0 218  0 0 400  0 0 212 
Week 8 0 0 286  0 0 446  0 0 211 
Week 9 1 0 265  0 0 216  1 1 127 
Week 10 0 0 88  0 0 100  0 0 47 
Week 11 0 0 51  0 0 16  0 0 25 
 
cell count x10
4
/mL VF: vacuolated form AF: amoebic form GF: granular 
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Figure 3.5 Blastocystis cell counts in fresh faecal cultures derived from six patient with gastrointestinal symptoms, subcultured 
every 2-3 days, in Jones/Horse serum 10% seven days, then IMDM/Horse serum 10% 
3.5.Patient 1      3.5.Patient 2      3.5.Patient 3 
3.5.Patient 4      3.5.Patient 5      3.5.Patient 6 
 y axis: cell count x104/mL  x axis: time in weeks  VF: vacuolated form AF: amoebic 
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3.5 Discussion 
I failed to develop an axenic culture of Blastocystis and it would be useful to 
understand why the cultures failed.  
The limited success that I had occurred using pig samples that generally had 
greater numbers of Blastocystis in the stool compared to humans. Only four of the total of 
65 patients had large numbers (3+ load of VF) of Blastocystis noted in their stool and only 
one of these patients was included in the six patients monitored with cell counts. Four of 
the six patients that had cell count monitoring all had baseline inoculum above the 1-1.5 
x106 (Zierdt & Williams 1974; Ho et al. 1993) suggested to be necessary for successful 
transfer. The remaining two patients were only slightly below this level. Nevertheless it is 
likely that the higher the number of organisms in the inoculum the greater the chance of 
success. 
The timing of subculture is also known to be important and working on the project 
part time prevented daily assessment of the subcultures. It is possible that some 
subcultures would have been more vigorous, if they had been transferred after 24 hours 
and this may have reduced bacterial overgrowth.  
Although we used antibiotics in a combination used in previous studies it is likely 
that during the last 10-20 years there has been significant changes in the enteric bacterial 
antimicrobial sensitivity spectrum. Future attempts could attempt to identify the 
contaminating organisms and their antimicrobial sensitivities. Sequential addition of 
antibiotics rather than a cocktail may be more successful. 
The HistopaqueTM gradient did separate out Blastocystis from the contaminating 
bacteria for further subculture, but it was apparent that much smaller numbers of 
organisms were obtained with this method. Failure may again relate to number of 
organisms available for inoculation into the culture. 
Although we did achieve one culture on the solid agar the number of colonies was 
small although the diameter of the colonies was similar to that reported previously. The 
failure to progress from there to further subculture may have been due to residual agar 
around the cells that prevents growth (Ng & Yan 1999). In the future it would be useful to 
use the agar colonies, as these require a much smaller inoculum, to seed another agar 
plate in order to obtain another agar plate with stronger growth. 
We are all constrained in this work by the lack of knowledge of the life cycle of the 
parasite. The fact that inoculating large numbers of VF into culture is not as useful as a 
mixture of forms (Zierdt & Williams 1974) suggests that the VF themselves either need 
priming to reproduce or are not the primary mechanism of cell reproduction. The VF is 
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characteristic of subcultures (particularly attenuated axenic cultures) but is not the 
predominant form seen in fresh faecal cultures, and was reported to be rarely seen in a 
patient with severe diarrhoea and profuse excretion of Blastocystis organisms (Zierdt & 
Tan 1976b). Transmission of infection is reported to occur via the cystic form of 
Blastocystis (Zierdt 1991). Transformation of VF to the cystic form can be achieved by 
culturing in excystation mediums (Suresh et al. 1994a). Future attempts at axenic culture 
could include early subculture in encystation mediums that may help to stimulate the VF to 
progress along the path towards encystment.  
There appeared to be at least a bi-modal distribution of cell growth over time in our 
monitored patients. Most patients had highest cell numbers at 2-3 weeks and then again, 
usually a smaller peak at 5-6 weeks before the culture waned. Peak growth at 10-15 days 
was a consistent finding in other uncounted cultures. Yet, even though the cell numbers 
are still high at 5-6 weeks some vital factor is lost as it is reported that it is not useful to 
subculture after 20 days (Zierdt & Williams 1974).  
The only mode of reproduction of Blastocystis that is currently generally accepted is 
binary fission although other modes of asexual transmission namely plasmotomy, 
endodyogony and schizogony have been described (Zierdt 1991; Zhang et al. 2007). Our 
axenic culture showed two cells with multiple round/crescentic inclusions that looked like 
daughter cells. A number of authors (Tan & Stenzel 2003; Windsor et al. 2003) have urged 
caution in interpreting these forms. It has been suggested that schizonts reported 
previously may be stressed cells undergoing degeneration, exuberant granular inclusions 
within the parasite or other unknown faecal forms. No definite confirmation of schizogony 
has been possible with electron microscopy to date. The cells we have imaged were in a 
pure uncontaminated culture and appeared to be thriving. Only two cells in the whole slide 
had this appearance, suggesting that if it does represent schizogony it may be uncommon. 
However Blastocystis is polymorphic and many forms have multiple granular inclusions. It 
will be necessary to document nuclear material in these daughter inclusions in order to 
prove schizogony. 
 
3.6 Conclusions 
Axenic culture of Blastocystis remains an important goal but is problematic. Understanding 
the life cycle of the parasite will aid progress with axenic culture methods. 
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4.1 Abstract 
Blastocystis organisms are a common human enteric parasite and have been 
reported to cause irritable bowel-like symptoms. Previous microscopy studies 
have described Blastocystis to possess complex morphology and 
ultrastructures. Cultured stool samples from patients with irritable bowel 
syndrome and asymptomatic healthy pigs were examined using time-lapse 
imaging and fluorescent spectroscopy on a deconvolutional microscope. 
Blastocystis organisms of the vacuolated, granular, amoebic and cystic forms 
were observed to autofluoresce in the 557/576 emission spectra. 
Autofluoresence could be distinguished from fluorescein-conjugated 
Blastocystis-specific antibody staining in vacuolated and granular forms. This 
antibody stained Blastocystis subtypes 1, 3 and 4 but not 5. Surface pores of 
1m diameter were observed cyclically opening and closing over 24 hours. 
Vacuolated forms extruded a viscous material from a single surface point with 
coincident deflation that may demonstrate osmoregulation. Tear-shaped 
granules were observed exiting from the surface of an amoebic form but their 
origin and identity remain unknown. 
Key words: Blastocystis; deconvolutional microscopy; autofluorescence 
 
4.2 Introduction 
Blastocystis spp. are common enteric, unicellular parasites found in 
almost every species of animal (Tan 2008). Seventeen different subtypes 
(ST’s) defined by the 18SSU of the ribosomal RNA gene are recognised and 
ST3 is almost universally the most common of the nine ST’s found in humans 
(Stensvold 2012). Blastocystis infection has been linked to irritable bowel 
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syndrome-like symptoms in humans but epidemiological studies are 
inconclusive (Scanlan 2012b). Many healthy people carry Blastocystis and it 
remains unclear if the parasite is pathogenic. Pathogenicity has been 
speculated to relate to parasite subtypes (Tan et al. 2006; Eroglu & Koltas 
2010) as well as to the host’s immune response (Olivo-Diaz et al. 2012).  
Analysis of the genome of two different ST’s of Blastocystis has 
allowed prediction of genes and proteins (Denoeud et al. 2011; Wawrzyniak et 
al. 2015) that may be associated with the organism’s pathogenic potential. 
Nevertheless, a lack of knowledge of the basic life cycle and metabolic 
function of the parasite remains a major limitation to exploiting the use of 
animal models and in vitro systems to further explore the clinical significance 
and therapeutic options for the control of this organism.  
Studies utilising light microscopy, transmission (TEM), scanning (SEM) 
and freeze-etch (FE-EM) electron microscopy have described multiple forms 
of Blastocystis, of variable sizes, including vacuolated (VF), granular (GF), 
amoebic (AF) and cystic (CF) forms (Figure 4.1).  
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Figure 4.1 
Morphological forms of Blastocystis sp. In xenic culture stained with 
acridine orange 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bar 10m    
solid arrow:granular forms   
dashed arrow:vacuolated form  Star: ameboid forms 
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The relationship of these different forms to each other is unclear (Tan 
2008), although it is certain that the robust cystic form transmits infection 
(Moe et al. 1997).  Microscopic images have often been obtained from 
attenuated or axenic cultures. These elegant studies have been useful in 
describing the intricate ultrastructure and surface morphology of the various 
forms of Blastocystis but their limitation is that they capture still images of a 
dead organism separated from the usual microbial environment.  
In this study, we employed deconvolutional microscopy of xenic 
cultures of live Blastocystis to obtain time lapse and 3-dimensional images of 
Blastocystis organisms. This microscope also has the capability to record 
fluorescence in various light spectra facilitating utilisation of Blastocystis-
specific fluorescent antibodies and fluorescent double stranded 
deoxyribonucleic acid (DNA) stain, DAPI (4’,6-diamidino-2-phenylindole) 
(Sigma-Aldrich, Australia). 
 
4.3 Materials and methods 
4.3.1 Sample preparation 
Fresh faecal specimens were obtained from irritable bowel syndrome 
patients positive for Blastocystis carriage and from pigs at the University of 
Queensland (UQ) Gatton Campus piggery, obtained in accordance with 
University of Queensland Medical and Animal Ethics Committee approvals 
numbers 2011000454 and 2012000069, respectively. Ten grams of faeces 
was subcultured anaerobically for 24-48 hours in Jones medium (Jones 1946) 
supplemented with 10% heat-inactivated horse serum. The sediment at the 
interface between the basal residue in the test-tube and the liquid medium 
was removed for microscopic analysis. 
 
4.3.2 Slide preparation 
15µL of fresh sediment was mixed gently with 10µL phosphate 
buffered saline and placed on a glass slide. The edges of the slide cover were 
sealed to prevent air entry to the specimen. An inverted slide was placed into 
a Deltavision Elite deconvolution microscope (Applied Precision, GE 
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Healthcare, Berthold Australia, Bundoora, Victoria, Australia) and examined 
with polarised light and with fluorescent filters.  
Four different filters that allowed excitation and emission ranges from 
350 nm to 700 nm, including DAPI, FITC (fluorescein isothiocyanate), TRITC 
(tetramethylrhodamine) and Cy5 (cyanine 5) spectroscopy ranges were used 
for examination. The images were magnified 20 times or 40-60 times with oil 
immersion and repeated images were taken at cross sections through the 
specimen or at different time intervals.  
Time-lapse microscopy was performed over 24 hours with images 
taken every 15 minutes. The environmental chamber was maintained at 37C 
throughout the microscopy session. 
 
4.3.3 Antibody staining 
Fluorescein (FITC)-conjugated Blastocystis specific polyclonal antibody 
raised against axenic ST3 (Blastofluor; Antibodies Inc, David, CA, USA) was 
also used to assess the specimens. Two hundred microliters of sediment was 
incubated with 5µL of Blastofluor for thirty minutes at 37C. Staining of 
double stranded deoxyribonucleic acid (DNA) with DAPI was performed by 
adding 2µL of stock solution of DAPI (0.5ug DAPI in 1mL PBS) to the 
prepared microscopy slide and gently mixed before incubating in the dark for 
10 minutes. 
 
4.4 Results and Discussion 
4.4.1 Auto and Immuno fluorescence 
Autofluorescence was observed in VF, GF and AF and the CF (Figure 
4. 2) of Blastocystis. The autofluorescence was greatest in the TRITC 
excitation/emission light spectra (557/576-nM) and appeared to be brightest in 
the central vacuole, with spots of light emission observed at the surface of the 
organism. The autofluorescence faded with time and appeared to be optimal 
in fresh VF forms, CF and least in AF. The autofluorescence was distracting 
but could be distinguished from the Blastofluor stain in the VF and GF. The 
Blastofluor stained the external cell membrane of VF, GF but not the AF 
(Figure 4.3) and was brightest using the FITC (495/515-nm) light spectrum. 
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Figure 4.2 Autofluoresence of different morphological forms of Blastocystis spp. 
 
           VF (ST4)            GF (ST4)          AF (ST 6)           Cyst (ST 6) 
  Polarised light  
 
 
 
 
 
TRITC 
fluorescence 
spectra 
 
 
 
 
 
 
 
 
 
 
 
  
 
TRITC: tetramethylrhodamine  VF: vacuolated form  GF: granular form AF: amoebic form CF cystic form      
Horizontal bar equals 20 m ST: subtype 
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Figure 4.3 Different morphological forms of Blastocystis spp. stained with Blastofluor 
 
VF VF GF cluster GF cluster 
 
 
 
 
 
 
 
 
 
 
 
Polarised light Polarised light Polarised light TRITC: No Blastofluor 
 
 
 
FITC/Blastofluor 
 
 
 
 
 
 
 
 
 
FITC/Blastofluor 
 
FITC/Blastofluor FITC/Blastofluor 
VF: Vacuolated form  GF: Granular form  FITC: fluorescein isothiocyanate spectra TRITC: tetramethylrhodamine spectra Bar: 20m
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The Blastofluor stain could not be reliably differentiated from the 
strong autofluorescence seen in the CF. The Blastofluor antibody stained 
the VF and GF of ST’s 1, 3 and 4 specimens but did not stain these forms in 
ST5 pig samples. DAPI staining of VF stained the nuclei on opposite poles of 
the central vacuole a dense bright blue. 
Non-specific green autofluorescence (GAF) was originally thought to 
be a rare occurrence in microalgae that might prove a useful taxonomic 
feature. However, over time GAF has been identified in many different 
organisms including algae, dinoflagellates, diatoms, cyanobacteria and 
raphidophytes (Tang & Dobbs 2007). The GAF occurs in the cytoplasm of 
these microalgae as well as in cysts that have little cytoplasm and is affected 
by various types of stress on the cell such as light, heat, drying and is caused 
by molecules other than chlorophyll. The chemical nature of GAF is unknown 
but is likely caused by multiple compounds or multiple derivatives of a single 
compound, such as flavin-like molecules, or luciferin compounds (Tang & 
Dobbs 2007).  
A variety of stains that fluoresce in the green light spectrum are used to 
assess morphology and physiological states of organisms and GAF has been 
reported to interfere with the interpretation of these stains (Tang & Dobbs 
2007). This is the first report of autofluoresence by Blastocystis organisms. 
Blastocystis diverged in evolution at the time of red algae and the genome 
suggests incorporation of cyanobacteria genes (Denoeud et al. 2011) so the 
presence of GAF is not unexpected. The GAF was seen strongly in the central 
vacuole of the VF. Little is known of the chemical constituents of this vacuole 
except that it stains positively for carbohydrates (Yoshikawa et al. 1995a) and 
lipids (Yoshikawa et al. 1995d).  
The GAF did not interfere with the ability to detect Blastofluor staining 
at the surface of the organism in the VF and GF’s but could not be 
differentiated from GAF in cysts. Blastocystis cysts are difficult to identify in 
stools but as GAF is a relatively non-specific finding in microalgae screening 
with fluorescent filters may not aid detection of the CF. Blastofluor did not 
stain the AF of Blastocystis suggesting that the surface antigens of this form 
differ from the VF and GF. Blastofluor is a polyclonal antibody raised in 
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rabbits to axenic cultures of ST3 and has been shown to react to Blastocystis 
organisms with no cross reactivity with Giardia duodenalis, Entamoebae 
histolytica or Cryptosporidium spp. (Dogruman-Al et al. 2010). Blastocystis 
immunolabeling with Blastofluor has previously been shown to stain faecal 
samples of steers, goats and humans, but not pigs after prolonged (up to a 
year) storage in formalin (Gould & Boorom 2013). This is consistent with our 
own observations in which no Blastofluor staining was detected in our ST5 
pig samples. ST5 organisms are commonly detected in pigs worldwide and 
locally 100% pigs have previously been shown to carry Blastocystis sp. ST5, 
and 7% harbour mixed infection with ST1 (Wang et al. 2014c). This suggests 
that the surface antigens display homology between some ST’s (ST 1,3,4) but 
that ST5 organisms differ in some respect to some surface antigens. 
 
4.4.2 Cell granules and time-lapse microscopy 
Detailed views of Blastocystis organisms were obtained but apart from 
observing binary fission developing in vacuolated and granular forms, we did 
not observe changes from one morphological form to another. It was difficult 
to keep the Blastocystis organisms in the field of view despite using the cell 
tracking facility of the microscope. The Blastocystis cells were fragile and 
would often either rupture (Figure 4.4) or drift away out of the field of view 
over the 24 hours of recording, preventing observation of progressive cell 
changes past a certain point (Figure 4.5). One GF, observed over 6 hours in 
total, that appeared stationary on the slide displayed a large central granule 
moving rapidly within the GF (Figure 4.6, Supplementary video file 4.1).  
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Figure 4.4 Vacuolated form of Blastocystis sp., 15 minute time-lapse sequence 
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Figure 4.5  Xenic culture of four Blastocystis granular forms, two showing development / rupture of cysts at cell surface 
 
      Bar 20m 
   Arrow shows cystic structures; three time lapse images taken over three hours 
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Figure 4.6 Blastocystis with moving central granule sequential images over 15 minute time intervals 
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Another time-lapse study of a granular AF showed the form enlarging 
and losing granularity on the surface with subsequent expulsion of small tear-
shaped granules. These granules appeared to arise from the surface of the 
organism or track along fissures to the surface (Figure 4.7). These granules 
varied in size from 1-3 µm and appeared to have a central dark spot 
surrounded by clear cytoplasm with a thick dark surface membrane. The 
release of the granules from the surface was best appreciated in the video 
images (Supplementary video file 4.2). Granules that appear to have tracked 
along fissures are identified as an area of interest in Figure 4.7. 
 
Figure 4.7 Granules exiting Blastocystis amoebic form in xenic culture 
Timelapse images taken over 24 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bar 15m  Circles indicate areas of interest 
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The life cycle of Blastocystis remains elusive and the function of the 
multiple inclusion granules present in the GF is still unknown. These granules 
have been proposed to have functions related to metabolism, storage or 
reproduction (Zierdt 1991). DAPI has been shown to stain VF double stranded 
DNA strongly in the nucleus and weakly in the mitochondria-like organelles 
(Stenzel & Boreham 1996) but did not stain the central vacuole or the 
granules of GF’s (Matsumoto et al. 1987). These granules have been 
classified into three different types based on TEM studies (Tan & Zierdt 1973), 
namely myelin-like inclusions, crystalline granules and lipid droplets (Dunn et 
al. 1989). None of these previous microscopy studies have supported the 
hypothesis that these central granules constitute a reproductive phase. The 
cause of the movement of the large central granule seen within the GF in this 
study (Figure 4.6) is not understood and simple Brownian motion cannot be 
excluded.  
The small granules that were expelled from the granular AF are 
intriguing (Figure 4.7) but DAPI stains were not performed on the AF to 
confirm a reproductive role. AF are reported to occur commonly in faeces 
(Stenzel & Boreham 1996), particularly in patients with symptomatic diarrhoea 
(Tan & Suresh 2006b), but only rarely in culture. Asexual binary fission of VF 
and GF occur commonly in culture but other routes of reproduction have not 
been proven (Tan & Stenzel 2003). It is possible that the gut microbiota is 
necessary for completion of the normal life cycle of Blastocystis and that 
sexual replication may occur only in primed AF in the gut. 
 
4.4.3 Other surface changes observed over time 
Surface pores, with an approximate diameter of 1µm, were seen on the 
external surface of the cell membrane of a partially ruptured ST3 Blastocystis 
organism (either a VF or a GF). The time-lapse recording of this event shows 
a total of 15 pores opening and closing (Supplementary video file 4.3). They 
appear to open and close fully over one hour during four 15 minutes interval 
observations. The regular movement of the pores continued for the length of 
the 24 hours study. A time interval sequence is shown with two pores in the 
foreground demonstrating fully open and closed pore positions in Figure 4.8. 
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Figure 4.8 Blastocystis form in xenic culture showing pores on surface 
 
 
   Open Pores     Closed Pores 
 
 
Bar: 20M   Arrows mark two pores of interest   
 
 
The presence of surface pores concurs with previous EM findings. 
Using TEM four morphological types of electron dense pits have been 
described on the surface membrane of the cell wall of Blastocystis, namely 
bars, cup-shaped pits, alveolate pits and tubular pits (Dunn et al. 1989). SEM 
studies have also confirmed the presence of small indentations on the 
external cell wall membrane, with fewer indentations noted on cells in 
prolonged culture (Cassidy et al. 1994). FE-EM has shown pores, 
approximately 0.5 µm in diameter, on the external surface of the outer 
cytoplasmic membrane that correspond to indentations on the inner surface of 
the outer cytoplasmic membrane (Tan et al. 1974), suggesting that pores may 
connect the outer and inner cytoplasmic membrane into the central vacuole. 
Unfortunately FE-EM damages the external layer of the outer cytoplasmic 
membrane so that FE-EM cannot confirm if these pores connect all the way 
through to the cell surface.  
Another time-lapse series of images showed extrusion of a viscous 
material apparently from one single point on the external cell membrane of 
two VFs of Blastocystis (Figure 4.9) (Supplementary video file 4.4).
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 Figure 4.9 Xenic culture of Blastocystis vacuolated form with extrusion; timelapse images                              .       
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The Blastocystis organisms were first seen to increase in size over 13 
hours then deflate, but without disintegrating, as this substance extruded. This 
extrusion process took 11.5 hours in total and the extruded material had an 
amoebic shape. A separate DAPI stained slide (with multiple images taken at 
cross sections through the slide, but not time-lapse) stained nuclei in adjacent 
VFs bright blue but there was no discrete nuclear material staining seen in the 
adjacent amoebic shape. This amoebic-shaped structure appeared very 
similar in shape to the extruded material observed in the previous slide 
(Figure 4.10). The centre of this amoebic structure stained a light diffuse blue 
and the surface is covered in granules that do not fluoresce with the DAPI 
stain.  
This curious extrusion of viscous material from the VF occurring over 
many hours was observed to occur with deflation but conservation of the VF 
(Figure 4.9). Typically VF’s have only a fine rim of cytoplasm surrounding a 
large central vacuole. The large amount of this viscous material extruded from 
a single point occurring simultaneously with deflation of the VF is consistent 
with a direct connection from the surface to the central vacuole. This fluid 
extrusion may be occurring through the surface pores although it was 
interesting to note that the fluid only appeared to exit from one place on the 
surface wall and not from multiple pores. 
The regular, repetitive movement of pores opening and closing in these 
time-lapse images suggests that the movement is active and requiring energy, 
even in this disrupted cell. Surface pores have been reported to be important 
for nutrition and osmoregulation in other protozoa (Bokhari et al. 2008). The 
possibility that this viscoid extrusion represented the formation of a different 
morphological form, namely the development of an AF from a VF was 
considered. The similar amoeboid shape recorded on a different day showed 
no evidence of nuclear material within it (Figure 4.10) and provided no support 
for this hypothesis.  
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Figure 4.10 
 
Fluorescent microscopy of Blastocytis forms stained with DAPI 
 
 
 
Bar: 20m 
Solid arrows: Vacuolated forms of Blastocystis with nuclei at tip of arrow 
Dashed arrow: Amoebic shape 
DAPI: 4’,6-diamidino-2-phenylindole 
 
Over the 24 hours of the study the material on the slide would have 
depleted nutrients and become progressively dehydrated, and it is possible 
this fluid extrusion is an osmoregulatory process occurring in a stressed VF. 
Blastocystis has been reported to survive in varying osmotic conditions (Ho et 
al. 1993) although only cysts survive immersion in fresh water.  
Osmosensing and osmoregulation have been reported in yeasts, 
microalgae and protozoa (Suescun-Bolivar & Thome 2015). Protozoans have 
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been reported to osmoregulate variously by changing the concentration of 
alanine, effluxing ions and water from either contractile vacuoles or 
intracellular compartments as well as inhibiting mitochondrial function during 
hyperosmolar conditions (Suescun-Bolivar & Thome 2015).  
 
4.5 Summary 
Deconvolutional microscopy of xenic cultures of Blastocystis spp. 
produced images of living organisms in their natural microbial environment but 
proved challenging due to the fragility of the organisms. Fluorescent 
spectrometry revealed that Blastocystis exhibits green autofluoresence in 
common with many other microalgae. GAF was able to be distinguished from 
fluorescein-specific Blastocystis antibody labeling in VF and GF but not cysts. 
Care will need to be taken in future studies to distinguish GAF from other 
stains fluorescing in the green light spectrum. Surface pores were observed 
and appeared to be opening and closing actively. Extrusion of a viscoid 
material from VF may be occurring via these pores. Coincident with the 
extrusion the VF appeared to deflate suggesting a direct connection from the 
surface to the central vacuole. This extrusion may be an osmoregulatory 
mechanism used by Blastocystis sp. to maintain cell homeostasis and 
integrity. Further studies could use time-lapse images to examine changes in 
organisms immersed in hypo-osmolar and hyperosmolar medium to further 
explore this hypothesis. The nature of the tear-shaped granules observed 
exiting from an amoebic form is unclear. Amoebic forms are common in 
diarrheal faeces and rarely observed in culture. It is possible these are 
reproductive granules occurring only in amoebic forms that have been primed 
by the gut faecal microbiota. Fluorescent nuclear stains to prove transmission 
of genetic material could be combined in future time-lapse studies of amoebic 
forms in xenic cultures. 
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5.1 Abstract 
Background: Blastocystis species are common human enteric parasites. 
Carriage has been linked to Irritable Bowel Syndrome (IBS). Treatment of 
Blastocystis spp. with antimicrobials is problematic and insensitive diagnostic 
methods and re-infection complicate assessment of eradication. We 
investigated whether triple antibiotic therapy comprising diloxanide furoate, 
trimethoprim/sulfamethoxazole and secnidazole (TAB) given to diarrhoea-
predominant IBS (D-IBS) patients positive for Blastocystis would achieve 
eradication. 
Methods: In a longitudinal, prospective case study 10 D-IBS Blastocystis-
positive patients took 14 days of diloxanide furoate 500mg thrice daily, 
trimethoprim/sulfamethoxazole 160/80mg twice daily and secnidazole 400 mg 
thrice daily. Faecal specimens were collected at baseline, day 15 and 4 
weeks after completion of TAB. Specimens were analysed using faecal 
smear, culture and polymerase chain reaction (PCR) of the 16 SSU rRNA. 
Patients kept a concurrent clinical diary. 
Results: Six (60%) patients cleared Blastocystis spp. after TAB, including 
three who had failed previous therapy. Subtypes detected were ST3 (60%), 
ST4 (40%), ST1 (20%) and ST7, 8 (10%); four patients had mixed ST 
infections. Serum immunoglobulin A (IgA) levels were low in 40% of patients. 
Higher rates of Blastocystis clearance were observed in patients symptomatic 
for less than a year (Mann-Whitney, p=0.032, 95% confidence) with no 
associations found with age, previous antibiotic therapy, faecal parasite load, 
ST, IgA level or clinical improvement. 
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Conclusions: Clearance of Blastocystis spp. was achieved with TAB in 60% 
of D-IBS patients, an improvement over conventional monotherapy. Higher 
clearance rates are needed to facilitate investigation of the relevance of this 
parasite in clinically heterogenous IBS.  
 
Keywords 
Blastocystis, Therapy, Irritable Bowel Syndrome, PCR 
 
5.2 Background 
Blastocystis spp.are unicellular, anaerobic enteric parasites found 
world wide in almost all species of animals (Tan 2008). The cystic form 
survives for days in the environment and likely transmits infection by the 
faecal-oral route either by direct contact or via contaminated water supplies. 
Blastocystis spp. are the most common parasite found in human faeces and 
carriage has been reported to be associated with Irritable Bowel Syndrome 
(IBS)–like symptoms (Tan 2008; Dogruman-Al et al. 2010; Jimenez-Gonzalez 
et al. 2012). IBS is a chronic heterogenous disorder present in up to 10% of 
the global population characterised by a symptom complex of abdominal pain 
and variable bowel habit in the absence of gross morphological, histological or 
inflammatory diagnostic markers (Drossman 2007). Although IBS does not 
increase mortality the disease impairs quality of life and costs billions of 
dollars annually in direct and indirect health care costs (Inadomi et al. 2003). 
Genetic, environmental, gender and psychological factors are known to be 
important in the development of the disease but the pathophysiology is 
unknown. As many as 10% of cases of IBS are recognised to develop after a 
bout of acute infectious gastroenteritis and this has focused research on 
microbial interactions with the luminal gut mucosa (Beatty et al. 2014).  
Faecal microbiota profiles are reported to be significantly different in 
IBS patients, most notably in the diarrhoea predominant IBS (D-IBS) 
subgroup (Collins 2014). IBS patients have diminished faecal bacterial 
diversity with temporal instability, fewer aerobic bacteria and decreased 
Bifidobacterium spp./ Enterobacter spp. ratio (Collins 2014; DuPont 2014). 
Altered intestinal motility and abdominal hypersensitivity are typically seen in 
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IBS, and many researchers have reported subtle alterations of the enteric 
immune and nervous system of IBS patients (de Salonen et al. 2010). 
Increased numbers of mast cells secreting serotonin that are closely aligned 
to mucosal dendritic cells are consistently observed in the gastrointestinal 
mucosa of patients with IBS (Matricon et al. 2012). Changes in cytokine 
secretion are reported not only with many luminal enteric microbial infections 
but increased levels of pro-inflammatory cytokines (interleukin (IL)-6, IL-8, and 
tumour necrosis factor- (TNF-)) have been reported in the plasma and 
peripheral blood mononuclear cells of IBS patients (Beatty et al. 2014). Many 
of these cytokines increase epithelial permeability by disrupting the mucosal 
tight junctions (Bruewer et al. 2003). Proteases are also reported to be 
elevated in the faeces of IBS patients (Gecse et al. 2008; Steck et al. 2014) 
although it is not clear if these proteases derive from enteric microorganisms, 
human intestinal cells or both.  Blastocystis organisms have been shown to 
activate IL-8 gene expression in human colonic epithelial cells in vitro (Puthia 
et al. 2008), increase epithelial permeability (Puthia et al. 2006) and degrade 
intestinal Immunoglobulin A (IgA) (Puthia et al. 2005), mediated possibly by 
action of cysteine proteases (Mirza & Tan 2009) reported to be present on the 
cell surface (Wu et al. 2010).  
The prevalence of Blastocystis carriage is increased in all IBS patients 
but highest in D-IBS patients (73% compared to 27% in healthy control 
patients) (Yakoob et al. 2010), suggesting that this subgroup may provide a 
more homogenous IBS patient group to study.  Seventeen different subtypes 
(ST) of Blastocystis spp. have been described to date (Stensvold 2013) 
revealing moderate host ST specificity and regional ST variation in humans. 
Early reports that particular subtypes of Blastocystis may be associated with 
clinical pathogenicity in humans have not been confirmed (Tan 2008). 
Treatment of Blastocystis spp. with antimicrobials is problematic and 
insensitive diagnostic methods and possible re-infection complicates 
assessment of successful eradication (Stensvold et al. 2010; Nagel et al. 
2012). Monotherapy with metronidazole is the most commonly recommended 
drug and published eradication rates vary from 0-100% (Stensvold et al. 
2010). If Blastocystis spp. could be predictably successfully eradicated in 
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symptomatic patients then it may be possible to more easily evaluate whether 
infection is associated with clinical symptoms. In this pilot study we treated ten 
patients with diarrhoea-predominant IBS (IBS-D) who were positive for 
Blastocystis carriage with triple antibiotic therapy (diloxanide furoate, 
trimethoprim-sulfamethoxazole, secnidazole) and assessed clinical status, ST 
and clearance rates. 
 
5.3 Materials and Methods 
5.3.1 Study Outline 
This prospective, longitudinal study was conducted in a rural specialist 
outpatient clinic (Toowoomba Gastroenterology Clinic). Patients presenting 
with chronic diarrhea were clinically assessed and patients who were 
subsequently diagnosed with diarrhoea-predominant IBS (IBS-D) (Drossman 
2007) and were positive for Blastocystis carriage were invited to participate in 
the study. Faecal specimens were collected from study participants at 
baseline, after two weeks of triple antibiotic therapy and six weeks after 
completion of antibiotics. 
 
5.3.2 Inclusion protocol 
Adult patients presenting to the clinic with chronic diarrhoea from 1/8/11 to 
20/02/14 were assessed clinically. Blood tests, including full blood count, 
serum calcium, thyroid function tests, serum immunoglobulin A (IgA) and 
coeliac antibody tests were performed. Serum IgA testing was performed 
using a nephelometry assay using a BNII device (Siemens, Germany). The 
reference range for a healthy population provided by the manufacturer was 
1.24-4.16 g/L. Selective IgA deficiency is defined as <50% of the lower range 
of normal (0.61 g/L). Faecal microscopy for ova, cysts and parasites 
(including Dientamoeba fragilis trophozoites), culture (for bacterial pathogens 
including Salmonella sp, Shigella sp, Vibrio cholerae, Campylobacter sp, 
Aeromonas sp) and PCR analysis for Giardia duodenalis, Clostridium difficile 
and Entamoebae histolytica (and a 3-day culture for hookworm) were 
performed by a commercial pathology laboratory to exclude known pathogens 
and initially detect the presence of Blastocystis spp.  All patients proceeded to 
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an upper and lower endoscopy that included gastric antral, duodenal, ileal and 
colonic biopsies. Ten consecutive, eligible symptomatic patients positive for 
Blastocystis carriage who had no other cause for symptoms identified and 
who fulfilled the Rome criteria (Drossman 2007) for D-IBS, namely symptoms 
of chronic abdominal pain, occurring frequently over the last 3 months, 
associated with defecation and the passage of predominantly loose stool, 
were enrolled in the study. All patients who were invited to participate 
consented to enrolment and completed the study. 
 
5.3.3 Exclusion protocol 
Only non-pregnant adults between 18 and 75 years of age were recruited for 
the study. Patients with a known allergy to sulphur drugs or patients with 
significant systemic diseases or co-morbidities were excluded. 
 
5.3.4 Study protocol 
One baseline faecal specimen was collected from patients prior to 14 days 
therapy with diloxanide furoate 500mg three times daily, 
trimethoprim/sulfamethoxazole 160/800mg twice daily and secnidazole 400 
mg three times daily. Two further faecal samples were taken, the first within 
48 hours of ceasing antibiotics and another 4 weeks after ceasing antibiotics. 
Patients were reviewed clinically at the start of the study, after completion of 
antibiotics and 6 weeks later. All patients kept a diary which recorded the 
number of daily bowel movements (number per day), consistency of the stool 
(scored: 1=very hard, 2=hard, 3=formed, 4=loose, 5=watery) and general well 
being (scored 1-10; from poor to excellent). Routine electrolytes, liver function 
tests and a full blood count were repeated 4 weeks after ceasing the 
antibiotics. 
 
5.3.5 Diagnostic methods 
All samples were run in parallel for the presence of Blastocystis spp. using a 
simple unstained wet faecal smear, xenic in vitro culture (XIVC) and PCR 
(confirmed as Blastocystis spp. using DNA sequencing). A patient was 
considered to be positive if any one of the tests was positive. 
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5.3.6 Parasitological methods 
Fresh unpreserved faecal specimens from patients were examined as a fresh 
faecal smear under 40x magnification by light microscopy. The load of 
Blastocystis organisms was classified as light, medium or heavy (<5, 5-10 and 
>10 organisms per high powered field (O/HPF). Additionally 100mg of fresh 
stool was inoculated in Jones’ culture medium (Jones 1946) and incubated at 
37C for 48 hours. Cultures were examined for the presence of Blastocystis 
spp. by light microscopy. 
 
5.3.7 Molecular methods 
DNA was extracted from the unpreserved faecal samples and pelleted 
cultures of Blastocystis using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturers instructions, except that following 
the addition of lysis buffer, the faecal suspension was subjected to three 
freeze-thaw cycles in liquid nitrogen and a 95C water bath respectively. 
The genomic DNA from stool and cultured Blastocystis specimens from all 
patients was subjected to PCR analyses. All samples were analysed using the 
Wong protocol (Wong et al. 2008) that amplified a 1000bp of the (SSU) rRNA 
gene of ST 1-17 of Blastocystis spp. All positive PCR products were subjected 
to DNA sequencing and phylogenetic analysis to identify the particular ST.  
All Blastocystis spp. positive samples were also analysed separately with 
three specific ST primers (ST1, 3, 4) in order to detect mixed infections. The 
ST1 specific protocol was developed by Dr CR Stensvold and the ST3 and 
ST4 protocols were developed in-house. These primers amplify highly ST-
specific smaller fragments of the (SSU) rRNA gene and obviate the need for 
PCR product sequencing. The ST specific primers 1 and 4 were specific for 
ST when tested against Netski (ST1) and WR1 (ST4) axenic cultures. The 
STS primer 3 demonstrated mild cross reactivity with ST1 and ST4 and if 
disparity was found between the Wong primer results and the STS primer 
result the PCR product was sequenced. The ST specific primers sequences 
are as follows:  
ST1:  Forward:TAATACATGAGAAAGTCCTCTGG 
Reverse: CTCAATCCAATTGCAAGAC 
Annealing temp: 57 C; amplicon size: 336 bp 
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ST3: Forward: GTAGTTGTGTAATGAATACATTCG 
Reverse: GTCCCTTTTAATCTTATTCTCATG 
Annealing temp: 62 C; amplicon size: 250 bp 
ST4:  Forward: GTGATCTTCGGATGACGTGAATC 
Reverse: CAGAATTTCACCTCTGACTATTG 
Annealing temp: 60C amplicon size 290bp 
PCR products were run on gels of 1% agarose in 1 x sodium borate 
(SB)(0.4gmNaOH/2.25g Boric acid/1L H2O) buffer at 200V in a Biorad 
electrophoresis system and were purified using a Purelink PCR Purification 
Kit (Invitrogen, Grand Island, NY, USA) prior to sequencing.  
Sequencing was done using an ABI 3130xl Genetic Analyzer (Applied 
Biosystems) using a Ready Reaction Kit Version 3.1 (PE Applied Biosystems, 
California, USA). Sequences were then edited and assembled using Finch TV 
v 1.4.0.  
DNA sequences were aligned with 15 reference sequences of Blastocystis 
SSU rRNA genes sourced from GeneBank (NCBI) representing the 
established subtypes described from mammals and birds. Distance-based 
analyses were conducted on readable sequences using Kimura 2-parameter 
distance estimates and trees were constructed using the Neighbour Joining 
algorithm using Mega 3.1(Kumar et al. 2001) software. Preoteromonas 
lacertae (U37108) was used as an out-group. Bootstrap analyses were 
conducted using 1000 replicates. 
 
5.3.8 Ethics approval, statistics 
The study was approved by the University of Queensland Medical Research 
Ethics Committee and registered with the Australian and New Zealand Clinical 
Trials registry (http://www.ANZCTR.org.au) ACTRN: 12611000918921. The 
results were analysed using the Mann-Whitney U test (Wizard statistical 
program). 
 
5.4 Results 
5.4.1 Clinical characteristics of the study group 
Male (1) and female (9) patients with an age range of 28-73 years (median 
age 49 years) participated in the study. The shortest symptom duration was 3 
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months and the longest 10 years and the presenting symptoms were chronic 
diarrhoea and abdominal pain (10/10). Six patients had received prior 
antibiotic therapy (including metronidazole, norfloxacillin, nitazoxanide) for 
Blastocystis infection that did not clear either the parasite in the faeces or their 
symptoms. The remaining patients were naïve to therapy. During the period of 
the study no patient had any organisms other than Blastocystis spp. noted on 
faecal testing. No patient demonstrated eosinophilia on the peripheral blood 
film. There were no abnormalities noted in the baseline electrolyte, liver 
function tests or full blood films blood tests. Five patients recorded a low 
baseline serum IgA level (<1.24 g/L).  
 
5.4.2 Antibiotic therapy and clinical follow up 
All patients completed 14 days of the triple antibiotic therapy (TAB). No 
serious adverse effects were noted; four patients complained of nausea, two 
patients of headache and one developed oral thrush and bloating during the 
antibiotic therapy course. At four weeks post antibiotic therapy repeat 
electrolytes, liver function tests and full blood count testing remained normal 
in all patients. 
 
5.4.3 Faecal smears, cultures and PCR results 
Faecal smear results prior to the commencement of treatment demonstrated a 
parasite load of <5 O/HPF in five patients, 5-10 O/HPF in four patients and 
>10 O/HPF in one patient. Five patients had cleared the Blastocystis parasite 
from faeces on testing with faecal smear, XIVC and PCR at Day 15 and six 
patients had similarly cleared the organism at 6 weeks. All baseline samples 
positive to either microscopy or culture were positive on PCR testing using the 
Wong primers. Four patients had mixed ST infections that were confirmed 
with the ST-specific primers and subsequent sequencing if indicated. The 
Blastocystis ST’s detected were ST3 (60%), ST 4 (40%), ST 1 (20%) and ST7 
and ST8 (10%). Day 15 and week six samples demonstrated good correlation 
between faecal smear/XIVC results and PCR testing (Table 5.1).
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Table 5.1 Blastocystis faecal microscopy, XIVC and PCR results before and after triple antibiotic therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XIVC: xenic invitro culture Polymerase chain reaction PCR *Sequenced
Patient 
Identity 
Time Faecal microscopy 
 
PCR-WONG* 
 
PCR-ST1 specific** PCR-ST3 specific*** PCR-ST4*** Clearance 
  Faeces XIVC Faeces XIVC Faeces XIVC Faeces XIVC Faeces XIVC  
1 Baseline + + ST4 ST6 Negative  Negative ST3* Negative ST4  
Day 15 Negative Negative ST4 Negative Negative Negative ST3 Negative Negative Negative Yes 
Week 6 Negative Negative Negative Negative       Yes 
2 Baseline + + ST7 Negative Negative  Negative  Negative   
Day 15 + + + Negative        No 
Week 6 + + ST7 Negative Negative  Negative  Negative  No 
3 Baseline +  ST1  ST1  Negative  Negative   
Day 15 + + +  Negative  Negative  Negative  No 
Week 6 + + Negative Negative       No 
4 Baseline + + Negative ST3 Negative Negative Negative ST3 Negative Negative  
Day 15 Negative Negative Negative Negative       Yes 
Week 6 Negative Negative Negative Negative       Yes 
5 Baseline + + ST4 Negative Negative  ST3*  ST4   
Day 15 Negative + Negative ST6 Negative  ST3*  Negative  No 
Week 6 Negative + ST4 Negative Negative  ST3*  ST4  No 
6 Baseline + + ST4 Negative Negative  Negative  ST4   
Day 15 Negative Negative ST1 Negative Negative  Negative  Negative  Yes 
Week 6 Negative Negative Negative Negative       Yes 
7 Baseline + Negative Negative ST4 Negative  ST3*  Negative   
Day 15 Negative Negative Negative Negative       Yes 
Week 6 Negative Negative Negative Negative       Yes 
8 Baseline + + ST8 ST8 Negative Negative Negative Negative Negative Negative  
Day 15 +  ST8  Negative  Negative  Negative  No 
Week 6 + + ST8 ST8 Negative Negative Negative Negative Negative Negative No 
9 Baseline + + Negative ST3  Negative  ST3  Negative  
Day 15 Negative  Negative        Yes 
Week 6 Negative Negative Negative Negative       Yes 
10 Baseline + + Negative ST3  Negative  ST3  Negative  
Day 15 + + ST3 Negative Negative  ST3  Negative  No 
Week 6 Negative Negative Negative Negative       Yes 
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5.4.4 Clearance and Clinical Follow up 
Overall 60% of patients cleared the organism from their faeces at 6 weeks. 
Three of these patients had had previous courses of antibiotics. The patient’s 
were reviewed clinically and their patient diary scored. The average score for 
the baseline week and week 4 following TAB therapy was calculated taking 
the weekly mean of the number of daily bowel actions, consistency of stool 
and general wellbeing. The final clinical score was calculated as the sum of 
improvement in frequency of bowel habit, consistency and wellbeing from 
baseline to week four after antibiotic therapy (Apppendix: Supplementary File 
5.1). Six patients reported that they felt clinically improved and this correlated 
with a positive change of greater than 1.0 diary score from baseline to six 
weeks. However, of these six clinically improved patients only three 
demonstrated faecal clearance of the organism. In contrast, four patients did 
not report clinical improvement and two of these patients demonstrated faecal 
clearance of Blastocystis spp. This data was analysed to assess whether 
clinical improvement or Blastocystis clearance had any relationship to age of 
patient, duration of symptoms, naïve therapy status, original Blastocystis 
faecal load, the particular Blastocystis subtype, serum IgA level or clinical 
outcome. Significantly higher rates of Blastocystis spp. clearance were 
observed if the patient had been symptomatic for less than a year (Mann-
Whitney, p=0.032, 95% confidence), but no other associations were found 
(Table 5.2). 
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Table 5.2 Clinical characteristics and outcome after triple antibiotic therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F=Flagyl O=other antibiotics (metronidazole, nitazoxanide, norfloxacillin) 
L=low, <1.24g/L, level defined by laboratory 
 
 
 
 
 
Patient 
 
Age 
yrs 
Duration 
of 
symptoms 
(years) 
Previous  
AB 
Therapy 
 
Blastocystis 
load in 
baseline 
faeces 
Blastocystis 
ST’s 
Serum
IgA 
g/L 
Diary 
score 
Clinical 
Score 
>=1 point 
Clearance 
at 
6 weeks 
1 35 4 Yes (F,O) 2+ 3,4,6 1.51 +4.1 Yes Yes 
2 59 5 No 2+ 7 1.12 (L) +2.4 Yes No 
3 28 1.5 Yes (F) 1+ 1 2.1 -0.3 No No 
4 35 0.25 Yes (F,O) 1+ 3 2.2 +0.2 No Yes 
5 51 1.5 Yes (F) 1+ 3,4,6 2.82 +2.0 Yes No 
6 58 0.5 No 2+ 1,4 1.03 (L) +1.1 Yes Yes 
7 73 0.75 No 1+ 3,4 1.22 +4.5 Yes Yes 
8 49 10 Yes (F,O) 3+ 8 1.94 +1.3 Yes No 
9 63 1 No 1+ 3 0.75 (L) -0.8 No Yes 
10 36 1 Yes (F) 2+ 3 0.98 (L) -0.6 No Yes 
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5.5 Discussion 
Successful faecal eradication of Blastocystis spp.occurred in 60% of 
patients at the end of this study following fourteen days of triple antibiotic 
therapy using diloxanide furoate, trimethoprim/sulfamethoxazole and 
secnidazole (TAB). Our previous study (Nagel et al. 2012) used 
metronidazole as a monotherapy and achieved 0% successful faecal 
eradication, suggesting that this TAB regimen may be useful to treat 
Blastocystis infection. Although six patients in our study had already received 
at least one course of metronidazole therapy previously, three of these 
patients proceeded to clear the organism after TAB therapy indicating that 
triple therapy is still a worthwhile alternative in this group. One recent study 
has reported 100% failure to clear in five patients with Blastocystis ST3 
infection treated with TAB combination (Roberts et al. 2014). However, these 
five patients had faecal specimens retested 12 months following the TAB 
therapy and it was not possible to exclude reinfection in this group. Triple 
antibiotic therapy has been shown to be useful in treating infecting organisms 
such as Helicobacter pylori and Mycobacterium spp. and it may be necessary 
to explore combinations of antibiotics and methods of delivery to further 
improve the clearance rate of Blastocystis infection.  
Widely varying rates of eradication (0-100%) of Blastocystis using a 
variety of antibiotics including ketoconazole, ornidazole, tinidazole, rifaximin 
and paromomycin have been reported (Stensvold et al. 2010) and some of 
this apparent inconsistency may be due to using insensitive faecal smears as 
a sole means of diagnosis. Diagnostic methods such as faecal XIVC or PCR 
have been reported to increase accuracy by 30-50% for detection of 
Blastocystis spp. (Matricon et al. 2012) . Metronidazole resistance has also 
been reported (Dunn et al. 2012) and differences in antimicrobial sensitivities 
to metronidazole and emetine demonstrated between axenic ST4 and ST7 
cultures (Mirza et al. 2010). Resistance may therefore contribute to regional 
variation in eradication rates. A number of antimicrobials have been tested for 
activity against Blastocystis spp. in vitro, in both axenic and xenic conditions 
(Zierdt et al. 1983; Dunn & Boreham 1991; Vdovenko & Williams 2000) and 
this data is a useful starting point for choice of antimicrobial. The Blastocystis 
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organism appears to establish in the anaerobic environment of the human 
ileum and caecum, thrives in the presence of bacteria, and only in extremely 
rare circumstances is invasive to the gastrointestinal mucosa(Tan 2008). An 
intrinsic difficulty in treating Blastocystis spp. may be delivering the 
appropriate drugs to the intraluminal site of infection or understanding how to 
alter the faecal microbiota to produce an environment that is unsupportive or 
hostile to the parasite.  
Secnidazole, similar to metronidazole, is a 5-imidazole drug substituted 
at position 1 and has been shown to have significant (although 50% less than 
metronidazole) inhibitory activity against Blastocystis spp. in vitro tested on 
axenic cultures (Dunn & Boreham 1991). All nitroimidazole drugs are rapidly 
absorbed from the small bowel, metabolised in the liver and excreted primarily 
in the urine. They exert their antimicrobial action in an anaerobic intracellular 
environment after reduction to a toxic metabolite that disrupts DNA linkage 
(Lamp et al. 1999). Metronidazole is the most common empiric therapy used 
against Blastocystis (Coyle et al. 2012) and as many patients that present for 
therapy have already failed metronidazole we felt it was useful to use a 
different imidazole particularly as resistance to metronidazole has been 
shown not to extend across the entire class of 1-sustituted 5-imidazoles 
(Mirza et al. 2010). The pharmacodynamics of secnidazole are not as well 
defined as those of metronidazole but it is known that secnidazole has 
reduced excretion of parent drug and metabolites in the urine (50% compared 
to 90% with metronidazole) and therefore may have increased faecal 
excretion. It also has more than double the excretion half-life of metronidazole 
at 29 hours (Mirza et al. 2010). These pharmacologic properties may be an 
advantage in treating Blastocystis infection. 
Trimethoprim/sulfamethoxazole duotherapy is often proposed as 
second line therapy for Blastocystis spp. infection and eradication rates of 22-
100% have been reported for this combination therapy (Stensvold et al. 
2010). These two drugs act synergistically to interfere with the production of 
dihydrofolate reductase that is required for purine and including DNA 
synthesis. Blastocystis ST7 does not take up Hthymidine (Dunn & Boreham 
1991; Wu et al. 2010), is likely to synthesize purines de novo, and 
consequently likely to have a dihydrofolate reductase that can be targeted. 
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Trimethoprim is rapidly absorbed from the small bowel (Menardi & J.P. 1984) 
is lipophilic with wide tissue distribution and 80% is excreted in the urine 
unchanged. Trimethoprim therapy alone has been shown to have inhibitory 
activity similar to secnidazole in vitro (Vdovenko & Williams 2000). 
Sulfamethoxazole similarly is rapidly absorbed in the small bowel (Menardi & 
J.P. 1984) metabolised in the liver, and over 90% excreted in the urine. They 
both have a half-life of around 10 hours. Although sulfamethoxazole alone 
was found to be non-inhibitory in vitro (Mirza et al. 2010) a combination of 
trimethoprim:sulfamethoxazole  (in the ratio of 1:5, Bactrim) was found to be 
much less effective at inhibiting Blastocystis growth in axenic cultures than a 
trimethoprim/sulfamethoxazole 1:2 ratio which may indicate that the 
synergistic effect of the sulfamethoxazole plays an important role in directly 
inhibiting Blastocystis spp. growth. Enteric coating this duotherapy 
compounded in a 1:2 ratio may be a useful therapeutic avenue to explore.  
An alternative therapeutic approach would be to use an antimicrobial 
drug that has already been described to have intraluminal amoebocidal 
properties. A number of these drugs tested in vitro such as emetine, 
furazolidone, nitazoxanide, mefloquine, quinicrine, quinine, iodoquinol, 
clioquinol (Entero-Vioform) and chloroquine showed moderate to high 
inhibition on Blastocystis cell growth (Zierdt et al. 1983; Dunn & Boreham 
1991; Vdovenko & Williams 2000; Mirza et al. 2010). Emetine and clioquinol 
therapy have serious adverse reactions reported and are not used currently in 
clinical practice. Other intraluminal drugs such as diloxanide furoate, 
paromomycin, doxycycline and pyrimethamine showed no inhibitory effect on 
Blastocystis (Zierdt et al. 1983; Vdovenko & Williams 2000). Paromomycin is 
a relatively safe, poorly absorbed aminoglycoside with activity against not only 
gram-negative but many gram-positive bacteria, including Mycobacterium 
tuberculosis, and protozoa such as Leishmania spp. (Davidson et al. 2009). 
Interestingly two recent studies have reported high Blastocystis clearance 
rates (77-100%) (van Hellemond et al. 2013; Roberts et al. 2014) using 
paromomycin and if confirmed this would suggest the broad spectrum 
aminoglycoside is achieving success by an indirect effect on the faecal 
microbiota. The largest study (van Hellemond et al. 2013) retrospectively 
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analysed faecal microscopy results on 52 symptomatic Blastocystis carriers 
treated with paromomycin alone and clearance rates were estimated to be 
77%. Rifaximin is an oral broad-spectrum antibiotic derived from rifamycin that 
is not absorbed systemically (97% excreted in the faeces) (Adachi & DuPont 
2006). It has been used successfully to treat, hepatic encephalopathy, 
travellers diarrhoea (Adachi & DuPont 2006) and non-constipated IBS 
patients (Pimental et al. 2011). Only one case report of its successful use in 
Blastocystis infection has been published (Amenta et al. 1999). Diloxanide 
furoate was chosen for our study as it had a good safety profile, the drug 
remains intraluminal until it is hydrolysed to diloxanide, absorbed and 
subsequently excreted in the urine. It is known to effectively clear intestinal 
amoebiasis although the mechanism of action is not known (Gadkariem et al. 
2004). It was not possible to assess whether the addition of diloxanide furoate 
increased the efficacy of the regimen in this study. The addition of an 
intraluminal antimicrobial to a therapeutic regimen seems logical and 
paromomycin may be the most appropriate choice to add to a regimen at the 
moment. Unfortunately monotherapy is usually a cheaper option (the cost of 
14 days of appropriate doses of metronidazole, 
trimethoprim/sulfamethoxazole, diloxanide furoate, paromomycin, secnidazole 
and rifaximin being AUS $24, $24, $55, $70, $80, $80 respectively) and the 
cost of TAB rising to AUS$159. If an effective drug combination could be 
identified it is likely the costs of a combination therapy would reduce.  
This small pilot study was not designed to interrogate specific variables 
that might be relevant to Blastocystis spp. symptoms, clearance or clinical 
outcome. The literature is inconsistent but some studies have suggested that 
particular subtypes, namely ST 1, 3 and 4 of Blastocystis may be pathogenic 
(Tan 2008). In contrast, and in accord with recent studies (Nagel et al. 2012; 
Roberts et al. 2014) our patients demonstrated a diverse range of subtypes 
and no association was seen between subtype and faecal clearance or 
resolution of symptoms. Although previous studies have reported mixed 
infection rates of 5-30% (Li et al. 2007a; Nagel et al. 2012) almost half of the 
patients (40%) in this study demonstrated mixed infections. The use of ST 
specific primers and XIVC techniques that allow ST’s present in small 
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numbers to grow to detectable numbers are factors likely to increase 
identification of mixed infections.  
It is well recognised that many Blastocystis carriers are healthy. Much 
research has been directed towards identifying genetic characteristics specific 
to the parasite, such as ST, that may indicate pathogenicity. Some studies 
have investigated host factors that may allow Blastocystis sp. to cause clinical 
symptoms. Epidemiological studies conducted in patients with compromised 
immune function (HIV carriage, chronic renal failure, haematological 
malignancies with immunosuppressant therapy (Tasova et al. 2000; Poirier et 
al. 2011) have shown increased rates of Blastocystis carriage but no clear 
consensus has emerged linking carriage to symptoms. IBS (Beatty et al. 
2014) and Blastocystis infection (Puthia et al. 2008) have both been linked to 
changes in inflammatory cytokine expression. The prevalence of single 
nucleotide gene polymorphisms present in IL-8 (pro-inflammatory) and IL-10 
(anti-inflammatory) cytokines is reported to be significantly increased not only 
in IBS patients but also in IBS patients positive for Blastocystis infection 
(Olivo-Diaz et al. 2012) suggesting that factors regulating the immune 
response in the host are important in expression of clinical disease.  
IgA is also an important part of host mucosal immunity. Blastocystis 
proteases have been reported to cleave human secretory IgA (Puthia et al. 
2005). Interestingly 40% of our group of IBS-D Blastocystis had low serum 
IgA and this was much higher than the 1.4% (1 in 19) recorded in our healthy 
adult volunteers negative for Blastocystis spp. (unpublished observations). 
The levels of serum IgA recorded in our patients are compatible with partial 
selective IgA deficiency but did not reach <50% of the lower limit of normal 
defined as selective IgA deficiency. Selective IgA deficiency (prevalence of 
0.17% in Australia) is usually asymptomatic, but may be associated with an 
increased risk of respiratory, urinary and gastrointestinal (including giardiasis) 
sepsis, and allergic and autoimmune diseases (Singh et al. 2014). There was 
no apparent association between IgA levels and subsequent clearance. 
Serum IgA levels recorded in children are generally lower than adults (Stoop 
et al. 1969) and if IgA levels influence the risk of carriage of Blastocystis then 
children may be more susceptible.  
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In this paper we describe successful clearance of the Blastocystis 
organism from faeces after testing at day 15 and week 4 after antibiotics. 
Blastocystis organisms may be excreted irregularly(Suresh et al. 2009) so it 
was useful to have had two clear faecal specimens 4 weeks apart to confirm 
faecal clearance.  We used three methods of detecting Blastocystis in the 
stool, taking care to include XIVC and PCR amplification of Blastocystis DNA 
as the latter two methods have approximately a 90% sensitivity detection rate 
compared with only around 50% for microscopy alone (Stensvold et al. 
2007a). Nevertheless false negative results may occur in a small percent of 
cases, where complete clearance of Blastocystis spp. in the ileum may not 
have occurred. It would be useful to be able to distinguish symptomatic and 
asymptomatic patients positive for Blastocystis faecal carriage. Although 
Blastocystis spp. are non-invasive organisms serum antibodies against 
Blastocystis spp. have been reported in humans infected with the parasite 
(Hussain et al. 1997). The presence of antibodies often only signifies 
exposure to that Blastocystis antigen some time in the past. However one 
study has reported that an antibody reacting to a 29kDa protein, thought to be 
a cysteine protease present on the plasma membrane of Blastocystis spp., is 
more commonly seen in symptomatic patients (Abou Gamra et al. 2011). If 
confirmed this finding and similar approaches may allow us to utilise the 
expression of host response to infection to determine need for therapy. 
The only variable that was found to be significant was duration of GIT 
symptoms and eventual clearance of the parasite. If we assume that the GIT 
symptoms were related to the Blastocystis carriage this finding may suggest 
that Blastocystis infection that persists in the host for years may be more 
difficult to eradicate, particularly as spontaneous clearance has been reported 
to occur in only 19% of symptomatic patients over 12 months (van Hellemond 
et al. 2013).  
The patients in this study were a careful selection of D-IBS patients with no 
other identifiable enteric pathogen or other cause for symptoms. Nevertheless 
only 50% of patients who reported clinical improvement had cleared the 
organism. Perhaps reducing parasite load was enough to achieve clinical 
improvement in these patients. The two patients who reported dramatic 
clinical improvement (>4 points) both cleared the organism. In contrast 50% of 
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the patients who did not report clinical improvement cleared the organism, 
suggesting that Blastocystis carriage was not the cause or not the only cause 
of their D-IBS. IBS is a heterogenous clinical condition and many diseases 
masquerade as IBS. Over time definitive specific diagnostic tests or therapies 
that allow us to discriminate other causes of IBS may become available. 
Although Giardia duodenalis was identified microscopically in the 1700’s 
acceptance of its pathogenicity only occurred in the last forty years when 
effective therapy with imidazoles (>90% successful eradication) demonstrated 
clinical improvement (Gardner & Hill 2001)[51]. Although 60% patients cleared 
in this study clinical cause and effect will be able to be more easily evaluated 
when we can more reliably and effectively eradicate Blastocystis spp. 
 
5.6 Conclusions 
Successful faecal eradication of Blastocystis spp. occurred in 60% of 
D-IBS patients at the end of this study following fourteen days of triple 
antibiotic therapy using diloxanide furoate, trimethoprim/sulfamethoxazole and 
secnidazole (TAB). Metronidazole monotherapy achieved 0% successful 
eradication in our previous study and as some isolates of Blastocystis spp. 
have also been shown to be resistant to metronidazole, this drug should no 
longer be recommended as first line therapy. Surprisingly paromomycin, a 
drug that exhibits little inhibitory activity in vitro, has been reported to have 
eradication rates above 75%. If these results are confirmed in future studies 
using sensitive diagnostic markers, paromomycin may prove to be a useful 
basis for a double or triple antibiotic regimen. Predictable successful 
eradication (>90%) of Blastocystis spp. will expedite investigation of the 
clinical significance of Blastocystis infection. No meaningful analysis of 
clearance and symptoms was possible in this trial but 40% Blastocystis 
patients demonstrated low serum IgA levels. It may be worth focusing future 
studies on investigating immune profiles in the host and including host IgA 
levels. 
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6.1 Abstract 
Background: Blastocystis species are common enteric human parasites and 
carriage has been linked to Irritable Bowel Syndrome (IBS), particularly 
diarrhoea-predominant IBS. The spectrum of immune reactivity to Blastocystis 
proteins has been reported previously in symptomatic patients. We 
investigated differences in serum immunoglobulin profiles between patients 
with IBS, both positive and negative for Blastocystis carriage, and healthy 
controls (HC).  
Methods:  
Forty diarrhoea-predominant IBS patients (26 patients positive for Blastocystis 
sp., 14 negative patients) and forty HC (24 positive, 16 Blastocystis-negative) 
were enrolled. Age, gender, ethnicity and serum immunoglobulin A (IgA) 
levels were recorded and faecal specimens were analysed using smear, 
culture and polymerase chain reaction amplification of ribosomal DNA. Sera 
were tested in Western blots and the reactivities compared to known targets 
using monoclonal antibodies Blastofluor (Blastocystis specific antibody), 
MAb1D5 (cytopathic to Blastocystis cells), anti-promatrix metalloprotease-9 
(anti-MMP-9) and SDS-PAGE zymograms. 
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Results: 
Levels of serum IgA were significantly lower in Blastocystis carriers (p<0.001) 
but had no relationship to symptoms. Western blots demonstrated serum IgG 
antibodies specific for Blastocystis proteins of 17, 27, 37, 50, 60-65, 75-90, 
95-105 and 150 kDa MW. Reactivity to the 27, 50 and 75-95 kDa proteins 
were found more frequently in the IBS group compared to the HC’s (p<0.001) 
and correlation was greater for Blastocystis-positive IBS patients (p<0.001) 
than for negative IBS patients (p<0.05).  MAb1D5 reacted with proteins of 27 
and 100 kDa, and anti-MMP-9 with 27, 50 and 75-100 kDa proteins. Bands 
were seen in zymograms around 100 kDa. 
Conclusions:  
Low serum IgA levels are associated with Blastocystis carriage. All IBS 
patients were more likely to demonstrate reactivity with Blastocystis proteins 
of 27 kDa (likely a cysteine protease), 50 and 75-95 kDa MW compared to 
HC. The presence of antibodies to these Blastocystis proteins in some 
Blastocystis-negative subjects suggests either prior exposure to Blastocystis 
organisms or antibody cross reactivities. The anti-proMMP-9 reaction at 50 
and 75-100 kDa and the zymogram result suggest that metalloproteases may 
be important Blastocystis antigens.  
Word Count: 322 
 
Trial registration 
Australian and New Zealand Clinical Trials registry ACTRN: 12611000918921 
Key Words 
Blastocystis; Irritable Bowel Syndrome; Immunoglobulin A; Western blotting, 
proteases 
 
6.2 Introduction  
 Irritable bowel syndrome (IBS) is a common clinical condition affecting 
up to 10% of the global population and characterised by abdominal pain, 
bloating and disturbance of bowel habit (Canavan et al. 2014a).The 
underlying cause of IBS is not known although differences in gut motility, the 
enteric immune and nervous system, intestinal permeability, systemic 
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cytokine production, faecal protease excretion, faecal microflora and 
psychological profiles have been reported in this condition (Whorwell 2014). 
The disease is defined by a clinical symptom complex description (Rome III) 
(Longstreth et al. 2006) that has a sensitivity of 70% and a specificity of 80% 
in differentiating IBS patients from patients with other gastrointestinal 
diseases (Corsetti et al. 2014). This clinical definition is the gold standard, but 
assessment can be subjective.  Reliable, clinically applicable IBS biomarkers, 
particularly if they enabled therapeutic choices, would be useful. Serum 
biomarkers for IBS have been investigated in two previous studies (Lembo et 
al. 2009; Jones et al. 2014) and both were less accurate than using the Rome 
III criteria. Post-infectious IBS is known to comprise 10% of the total cases of 
IBS and this has stimulated interest in the faecal microbiota as a possible 
contributing cause of IBS (Beatty et al. 2014). The carriage of the enteric 
organism Blastocystis has been reported to be three times higher in patients 
with diarrhoea predominant IBS (D-IBS) compared to healthy controls 
(Yakoob et al. 2010), making it an organism of interest in IBS.  
 Blastocystis sp. are the most common parasites found in human stool 
(Tan 2008). Sub-typing of the18S ribosomal DNA (rDNA) has identified 17 
different subtypes (ST’s) and nine have been identified in humans (Stensvold 
2013). Carriage of Blastocystis sp. is increased in patients with various types 
of immunosuppression (Tan 2008) and in patients with irritable bowel 
syndrome (Yakoob et al. 2010). Nevertheless, many carriers are healthy and 
a definite association between carriage and illness has not been proven in 
epidemiological studies (Poirier et al. 2012).  
Blastocystis sp. reside in the intestinal lumen, establishing in the ileum 
and caecum adherent to the outer layer of mucus (Phillips & Zierdt 1976; 
Wang et al. 2014a), with only rare reports of mucosal invasion. Antibodies 
specific for Blastocystis antigens have been demonstrated in the faeces and 
the serum of carriers (Zierdt & Nagy 1993; Kaneda et al. 2000; Hegazy et al. 
2008; Gamra et al. 2011; Wang et al. 2014b) and antibody titres have been 
reported to be higher with length and severity of infection (Zierdt & Nagy 
1993). These antibodies have been described in all immunoglobulin classes. 
IgA antibodies specific for Blastocystis sp. have been shown to be present in 
pig faeces (Wang et al. 2014b) and in both faeces and serum of infected 
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humans (Mahmoud & Saleh 2003). Our previous pilot study demonstrated 
lower serum IgA levels in IBS patients positive for Blastocystis carriage than 
in other patient groups or healthy controls (Nagel et al. 2014).  
Blastocystis specific immunoglobulin G (IgG) antibodies have also 
been detected in serum (Zierdt & Nagy 1993; Garavelli et al. 1995; Mahmoud 
& Saleh 2003) and faeces of Blastocystis infected humans (Mahmoud & 
Saleh 2003), with lower titres in the latter compartment. Using SDS-PAGE 
and Western blot analysis, serum IgG has been reported to react with 
Blastocystis-specific proteins of 12 kDa (Kaneda et al. 2000), 29 kDa, 50 kDa 
and 118 kDa molecular weights (MWs) (Hegazy et al. 2008).  Antibody 
reactivity to a 29 kDa MW Blastocystis protein has been reported to be more 
common in the serum of symptomatic patients compared to asymptomatic 
individuals (Gamra et al. 2011), and subsequent protein sequencing of a 30 
kDa protein showed it to possess 50% homology with known cysteine 
protease (legumain type) peptide sequences (Wu et al. 2010). A monoclonal 
IgM antibody 1D5 (MAb1D5), known to be cytopathic to Blastocystis 
organisms (Tan et al. 2001) as well as a human legumain antibody both bind 
to this 30 kDa Blastocystis antigen in Western blots. 
Protease secretion is a recognised virulence mechanism for parasites 
(McKerrow 1989)  facilitating tissue/cell invasion, protein activation and 
immunoevasion. These molecules are also highly immunogenic. Analysis of 
the genome of Blastocystis ST7 has led to the predictions that the parasite 
would be able to produce all major classes of proteases, including serine 
proteases, metalloproteases and perhaps as many as 20 different cysteine 
proteases (Denoeud et al. 2011; Wawrzyniak et al. 2012). Notably 
Blastocystis proteases have been shown to cleave human secretory IgA 
(Puthia et al. 2005) and induce production of the pro-inflammatory cytokine 
interleukin-8 (IL-8) by enterocytes in an in vitro model system (Puthia et al. 
2006).  
Our aim was to explore the clinical relevance of Blastocystis sp. in 
patients with diarrhoea predominant IBS by assessing serum antibody 
reactivities specific for Blastocystis. In this study we compared the serum IgA 
levels in IBS patients, either positive (IBS-P) or negative (IBS-N) for 
Blastocystis carriage, and healthy controls (positive (HC-P) and negative (HC-
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N) for Blastocystis). IgG serological responses to specific Blastocystis 
antigens were examined in all these subgroups using Western blotting 
techniques. Identification of specific Blastocystis antigens was attempted by 
probing the Western blots with Blastocystis specific antibody (Blastofluor, 
Antibodies Inc), MAb1D5 and pro-matrix metalloprotease 9 (anti-MMP-9) 
antibody. 
 
6.3 Methods 
6.3.1 Study outline 
Forty patients presenting with diarrhoea-predominant IBS to the 
Toowoomba Gastroenterology Clinic and forty healthy volunteers were 
enrolled in the study and signed written consent forms. The study was 
approved by the University of Queensland Medical Research Ethics 
Committee and was part of a clinical trial that is registered with the Australian 
and New Zealand Clinical Trials registry (http://www.ANZCTR.org.au) 
ACTRN: 12611000918921. Single baseline faecal and serum samples were 
collected from all participants. Total serum IgA levels were measured in all 
participants and faecal and serum specimens underwent further 
microbiological, molecular and Western blot analysis. 
Inclusion protocol 
Adult patients presenting with chronic diarrhoea and abdominal pain 
from 1/8/11 to 20/02/14 were assessed clinically. Baseline blood tests, 
including full blood count, serum calcium, thyroid function tests, serum IgA 
and coeliac antibody tests were performed. Other pathogens known to cause 
chronic diarrhoea such as Salmonella sp, Shigella sp, Vibrio sp., 
Campylobacter sp, Aeromonas sp),Giardia duodenalis, Clostridium difficule 
and Dientamoeba histolytica were excluded with faecal microscopy , culture 
and PCR testing performed by a commercial pathology laboratory. All patients 
proceeded to an upper and lower endoscopy that included gastric antral, 
duodenal, ileal and colonic biopsies. Forty eligible symptomatic patients who 
had no other cause for symptoms and who fulfilled the Rome criteria 
(Drossman 2007) for diarrhoea predominant IBS were enrolled in the study. 
Of these, 26 patients were positive for Blastocystis (IBS-P) and 14 were 
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negative (IBS-N). Forty healthy volunteers working at the University of 
Queensland and with no gastrointestinal symptoms in the preceding 12 
months were tested for Blastocystis sp. infection, 24 were positive (HC-P) and 
16 were negative (HC-N). Details of age, gender and ethnicity of participants 
were recorded.  
Exclusion protocol 
Only non-pregnant adults between 18 and 75 years of age were 
recruited for the study. Patients with significant systemic diseases or co-
morbidities were excluded. 
 
6.3.2 Diagnosis of Blastocytis infection 
All samples were run in parallel for the presence of Blastocystis sp. 
using a simple unstained wet faecal smear, xenic in vitro culture (XIVC) and 
PCR (confirmed as Blastocystis sp. using DNA sequencing). A study 
participant was considered to be positive if any one of the tests was positive 
as described previously (Nagel et al. 2014). 
 
6.3.3 Serum Immunoglobulin A  
Serum samples were stored at -20C prior to analysis at Sullivan and 
Nicolaides Pathology Service, Brisbane, Queensland using a Siemens BNII 
Nephelometer (Siemens, Munich, Germany) and Siemens reagents.  
 
6.3.4 Western Blotting 
Antigen preparation 
An axenic strain of Blastocystis sp. ST4 (WR1) was cultured 
anaerobically in pre-reduced Iscove’s Modified Dulbecco’s medium (IMDM) 
(Sigma-Aldrich, St Louis, USA: 13390) enriched with 10% heat-inactivated 
horse serum (Gibco: 26050088). WR1 was originally obtained from the stool 
of Wistar rats in Singapore but has been in continuous axenic culture for more 
than seventeen years. Blastocystis antigen was prepared using the proteinase 
inhibitor Complete Lysis-B (2x), EDTA-free kit (Roche, Mannheim, Germany: 
04719948001) and stored at -20C until required. 
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SDS-PAGE protocol 
Approximately 300 ng of Blastocystis antigen was mixed with equal 
volumes of loading buffer (Laemmli sample buffer mixed with 2M 2-
mercaptoethanol in a ratio of 19:1 vol:vol (Bio- Rad, California, USA)) and 
loaded into the large well of a preparative 4-15% Tris-HCl Ready Gel (Bio-
Rad: 161-1140). A separate single protein standard ladder well in the gel was 
loaded with 15 uL of Precision Plus Protein Western C Standard (Bio-Rad: 
161-0385). The gel was electrophoresed in M Tris/Glycine/SDS buffer (Bio-
Rad: 161-0732) at 100V for 40-60 minutes at room temperature and then 
rinsed three times with deionised water. The proteins were transferred to a 
nitrocellulose membrane using 1M Tris/Glycine/20% methanol buffer 
electrophoresed at 100V for 60 minutes at 4C. The membrane was rinsed 
three times with 0.1% 1M phosphate buffered saline (PBS)/Tween 20 (PBST) 
(Sigma Aldrich, St Louis, USA: P5927) solution and then blocked in 100 ml of 
blocking solution (0.1% PBST, 4gm skim milk and 1gm bovine serum albumin 
per 100 ml (Sigma Aldrich: A2153) for 60 minutes at room temperature. The 
membrane was cut into strips and stored at -20C till required. 
Immunolabeling protocol 
Membrane strips were incubated with primary antibody (patient sera or 
MAbs) diluted in 1 mL of Signal BoostTM Immunoreaction Enhancer Kit  
(Calbiochem, Darstadt, Germany: 407207) Solution One for 24 hours on a 
rocker platform at 4C before washing consecutively three times for 15 
minutes in PBST. The strips were then incubated with secondary antibody 
diluted in Signal Boost Solution Two at room temperature for 1 hour on a 
rocker platform and the washing steps repeated.  
The patient sera were diluted 1:10 and the secondary antibody was a 1: 2000 
dilution of horseradish peroxidase (HRP)-conjugated goat anti-human IgG Ab 
(Sigma Aldrich: A8786). 
An additional four antibodies were tested for reactivity with the 
Blastocystis antigens: (i) a mouse derived Blastocystis-cytopathic monoclonal 
IgM antibody, MAb1D5 (purified Mab against surface legumain of Blastocystis 
ST7, IgM, 16 g/L) (Tan et al. 1996; Tan et al. 1997; Wawrzyniak et al. 
2012), (ii) a control unrelated mouse derived monoclonal IgM antibody, MAb5, 
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(iii) a rabbit polyclonal anti-Blastocystis ST3 antibody (Blastofluor)(Gould & 
Boorom 2013), and (iv) a rabbit polyclonal anti-human matrix 
metalloproteinase 9 (Anti-MMP-9) (Calbiochem: 444236). These primary 
antibodies were diluted 1:100, and the secondary antibodies 1:1000, using 
HRP-conjugated-goat anti-mouse IgM (Sigma, St Louis, USA: Cat no: A8786) 
and HRP-conjugated anti-rabbit polyclonal Ab, respectively.  
All blots were run with a protein standard ladder and a negative control. 
Negative controls were prepared according to the protocol above except 
exclusion of serum/primary antibody in step one followed by incubation with 
the secondary antibody.  
The antibody binding was visualized using Clarity Western ECL 
Substrate (Bio Rad, California USA) and a Bio Rad Chemi-DocTM XRS Gel 
Documentation system. The brightness and contrast was adjusted over entire 
images to optimise the image but no differential image manipulation was used 
on separate lanes. 
 
6.3.5 Zymograms  
The Blastocystis antigen was prepared as per the Western blotting 
protocol and combined with Zymogen buffer (Bio-Rad: 161-0764) in a vol:vol 
ratio of 1:1. Approximately 50 ng of buffered Blastocystis antigen was loaded 
into each well of a 10 % gelatin Ready Gel Zymogram Gel (Bio-Rad: 161-
1167) and the gel was electrophoresed in 1M Tris/Glycine/SDS buffer (Bio-
Rad: 161-0732) at 90V for 40-60 minutes at room temperature. The gel was 
cut in half and both gels subjected to renaturation and development steps. 
The gels were incubated in 100mL of Zymogen Renaturation buffer (Bio-Rad: 
161-0765) for 1 hour at room temperature on a rocker platform and then 
incubated in 100mL of Zymogen Development buffer (Bio-Rad: 161-0766) for 
24 hours at 37C without or with protease inhibitor, 1mM EDTA 
(ethylenediaminetetraacetic acid), added to the two solutions for one gel. The 
buffer was decanted and the gels were stained with 100 mL Aqua stain 
(Bulldog Bio, Portsmouth, UK) for 15 minutes on a rocker platform and rinsed 
with deionised water. 
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6.3.6 Statistical Analysis 
Statistical analysis was carried out using SPSS v.22 (IBM SPPS 2013).  
The level of IgA was transformed using natural logarithm to get a normal 
distribution. A one-way Analysis of Covariance (ANCOVA) was used to 
compare the level of IgA between the four groups, adjusting for potential 
confounders, such as seasonality (Weber-Mzell et al. 2004). Pearson’s chi-
square/ Fisher exact test were used to assess the significance of association 
between subjects with IBS and healthy controls with the presence of serum 
IgG antibodies detected against Blastocystis proteins of various sizes. 
 
6.4 Results 
6.4.1 Study subjects 
The eighty study participants comprised forty symptomatic IBS patients 
(26 positive and 14 negative for Blastocystis carriage) and forty asymptomatic 
healthy controls (24 positive and 16 negative for Blastocystis). The average 
participants’ age was 45.2 ± 14.4 years (range 16 - 75 years). There were no 
significant between-group differences in terms of age (F (3,76)=0.81, p=0.49) 
and gender distribution (λ2=4.37, p=0.22). However, there were significantly 
more Caucasians compared to non-Caucasians in the IBS-P, IBS-N and HC-
P groups (λ2= 16.83, p=0.001). The Blastocystis sp. subtypes detected were 
ST3 (34%), ST4 (26%), ST1 (16%), ST2 and ST7 (8%), ST8 (6%) and ST5 
(2%). Characteristics of the 80 subjects and their Blastocystis subtypes are 
given in Table 6.1 and 6.2. 
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Table 6.1 Demographic and epidemiological characteristic of subgroups 
 
SD: standard deviation  ST: subtype IgA: Immunoglobulin A 
IBS-P/N: Irritable bowel syndrome subjects positive/negative for Blastocystis  
HC-P/N: Healthy control subjects positive/negative for Blastocystis 
*unadjusted mean; results IgA of different subtypes in IBS-P & HC-P groups were pooled for 
analysis purposes 
 
Table 6.2 Serum antibody reactions to Blastocystis antigens detected by 
Western immunoblotting in all subjects infected with different subtypes 
of Blastocystis 
 
  ST: subtype kDa: kiloDalton 
Absence of bands
 IBS-P 
(n= 26) 
IBS-N (n=14) HC-P 
(n=24) 
HC-N 
(n=16) 
Age (years; 
mean±SD) 
44.5±15.2 44.5±14.2 48.7 ±13.2 41.7±15.0 
Female (n, %) 19 11 12 11 
     
Caucasian (n, %) 26 (100) 13 (93) 21 (88) 9 (56) 
     
Season recruited (n)     
Spring  2 3 19 0 
Summer  8 5 4 1 
Autumn  11 4 0 7 
Winter  5 2 1 8 
     
Blastocystis ST distribution     
ST1 2  6  
ST2 1  3  
ST3 9  8  
ST4 9  4  
ST5 0  1  
ST6 0  0  
ST7 3  1  
ST8 2  1  
     
Serum IgA* (g/L; 
mean±SD) 
1.63±0.95 2.19±1.01 1.54±0.76 3.06±1.61 
Protein band 
at molecular 
weight 
Number of subjects infected with particular subtype of 
Blastocystis 
ST1            ST2          ST3          ST4         ST5          ST7          
ST8 
(n=8)         (n=4)        (n=17)     (n=13)       (n=1)      (n=4)        
(n=3) 
17kDa 2  3 1    
27 kDa 7 3 16 10 1 2 3 
37 kDa 1 2 2 1    
50 kDa 7 2 14 11 1 4 3 
60-65 kDa 7 4 16 11 1 3 3 
75-90 kDa 8 4 12 9 1 3 2 
95-105 kDa 5 1 10 7 1 2 2 
150 kDa 5 3 8 2 1 2  
 
 133 
6.4.2 Serum IgA levels 
Serum IgA levels were higher in male (2.36±1.36 g/L) compared to 
female participants (1.79±1.09 g/L) (t=4.15, p<0.05). Levels of IgA were not 
found to be different between Caucasian and Asian participants, nor across 
the different Blastocystis subtypes (both p>0.05). 
The average level of serum IgA was lowest in the HC-P group, followed by 
IBS-P, IBS-N and HC-N (Table 6.1). Participants who tested Blastocystis-
positive (combined IBS-P and HC-P subgroups) had a significantly lower 
serum IgA level (1.59±0.54 g/L) than their Blastocystis- negative counterpart 
(combined IBS-N and HC-N) subgroups (2.65±1.41 g/L) (t(78)=4.06, 
p<0.001). Planned contrasts revealed that participants in the HC-N group had 
significantly higher serum IgA levels compared to those in the IBS-P group, 
t(75)= -3.31, p=0.001, and HC-P group, t(75)= -4.30, p<0.001. Pairwise 
comparisons showed that IgA levels in IBS-N participants were higher than 
those in the HC-P group (p<0.01).  
There was a significant difference in IgA levels between the four 
groups after controlling for the potential confounding effect of seasonality and 
gender, F(3,73)=9.05, p<0.001. The gender covariate was significantly related 
to the level of IgA, (F(1,73)=7.93, p<0.01), whereas seasonality, was not 
(F(1,75) = 3.42, p= 0.07).  
 
6.4.3 Blastocystis-specific serum IgG antibody bands 
Western blots were employed to assess the serum IgG response to 
Blastocystis proteins in the four clinical groups and the analysis of these 
results is shown in Tables 6. 2, 6.3 and 6.4. Reactivity was seen to 
Blastocystis proteins of approximately 27, 50, 60-65, 75-90, 95-105 and 150 
kDa MW (Yakoob et al.) in all groups of patients (Figures 6.1-6.3). These 
results were examined to assess whether serum reactivity to Blastocystis 
proteins of different sizes was associated with carriage of a particular subtype 
of Blastocystis sp., or either the presence of Blastocystis sp. or IBS 
symptoms.  If Blastocystis spp. were to prove to be a cause of IBS then it is 
possible that IBS-N patients may have had Blastocystis infection in the 
relatively recent past and the subgroups with IBS were analysed separately in 
order to reduce any contribution from pre-existing antibodies (Table 6.4).  
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Table 6.3 Serum antibody reactions to Blastocystis antigens detected by Western immunoblotting in different groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IBS-P/N: Irritable bowel syndrome subjects positive/negative for Blastocystis     
HC-P/N: Healthy control subjects positive/negative for Blastocystis 
n: number    kDa: kiloDa 
 
 
 
 
 
 
 
 
Protein band 
at molecular 
weight 
Number of subjects with presence of protein bands 
(n, %) 
IBS-P (n=26) IBS-N (n=14) HC-P (n=24) HC-N (n=16) 
17kDa  1 (4) 0 (0) 5 (21) 0 (0) 
27kDa 25 (96) 12 (86) 17 (71) 7 (44) 
37kDa 3 (12) 0 (0) 3 (13) 0 (0) 
50kDa 26 (100) 13 (93) 16 (67) 8 (50) 
60-65kDa 26 (100) 12 (86) 19 (80) 13 (81) 
75-90kDa 25 (96) 13 (93) 14 (58) 9 (56) 
95-105kDa 14 (54) 3 (21) 14 (58) 2 (13) 
150kDa 5 (19) 1 (7) 16 (67) 1 (6) 
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Table 6.4 Comparison of presence of Blastocystis and/or gastrointestinal symptoms to specific sized antibody bands 
directed against Blastocystis proteins using Western immunoblotting 
 
  Presence of antibody to Blastocystis protein at band MW (n, %) 
Gp1 Gp2 17kDa 27kDa 37kDa 50kDa 60-65kDa 75-90kDa 95-105kDa 150kDa 
  Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 
Blastocystis 
presence 
                
IBS-P 
& 
HC-P 
(n=50) 
IBS-N 
& 
HC-N 
(n=30) 
6 (12) 0 (0)* 42 
(84) 
19 
(63)* 
6 (12) 0 (0)* 42 
(84) 
21 
(70) 
45 
(90) 
25 
(83) 
39 
(78) 
22 
(73) 
28 
(56) 
5 
(17)*** 
21 
(42) 
2 
(7)*** 
IBS-P 
& 
HC-P 
(n=50) 
HC-N 
(n=16) 
6 (12) 0 (0) 42 
(84) 
7 
(44)*** 
6 (12) 0 (0) 42 
(84) 
8 
(50)** 
45 
(90) 
13 
(81) 
39 
(78) 
9 (56) 28 
(56) 
2 
(13)** 
21 
(42) 
1 (6)** 
IBS-P 
(n=26) 
 
 
IBS-N 
(n=14) 
1 (4) 0 (0) 25 
(96) 
12 
(86) 
3 (12) 0 (0) 26 
(100) 
13 
(93) 
26 
(100) 
12 
(86)* 
25 
(96) 
13 
(93) 
14 
(54) 
3 
(21)* 
5 (19) 1 (7) 
HC-P 
(n=24) 
 
HC-N 
(n=16) 
5 (21) 0 (0)^ 17 
(71) 
7 (44) 3 (13) 0 (0) 16 
(67) 
8 (50) 19 
(79) 
13 
(81) 
14 
(58) 
9 (56) 14 
(58) 
2 
(13)** 
16 
(67) 
1 
(6)*** 
GIT 
symptoms 
                
IBS-P 
& 
IBS-N 
(n=40) 
HC-P 
& 
HC-N 
(n=40) 
1 
(Bailar 
& 
Mostel
ler) 
5 (13) 37 
(93) 
24 
(60)*** 
3 (8) 3 (8) 39 
(98) 
24 
(60)*** 
38 
(95) 
32 
(80)* 
38 
(95) 
23 
(58)*** 
17 
(43) 
16 
(40) 
6 (15) 17 
(43)** 
IBS-P 
(n=26) 
HC-P 
&  
HC-N  
1 (4)  5 (13) 25 
(96) 
24 
(60)*** 
3 (12) 3 (8) 26 
(100) 
24 
(60)*** 
26 
(100) 
32 
(80)* 
25 
(96) 
23 
(58)*** 
14 
(54) 
16 
(40) 
5 (19) 17 
(43)* 
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(n=40) 
IBS-P 
(n=26) 
 
 
HC-P 
(n=24) 
1 (4) 5 (21) 25 
(96) 
17 
(71)* 
3 (12) 3 (13) 26 
(100) 
16 
(67)*** 
26 
(100) 
19 
(80)* 
25 
(96) 
14 
(58)*** 
14 
(54) 
14 
(58) 
5 (19) 16 
(67)*** 
IBS-P 
(n=26) 
 
HC-N 
(n=16) 
1 (4) 0 (0) 25 
(96) 
7 
(44)*** 
3 (12) 0 (0) 26 
(100) 
8 
(50)*** 
26 
(100) 
13 
(81)* 
25 
(96) 
9 
(56)*** 
14 
(54) 
2 
(13)** 
5 (19) 1 (6) 
IBS-N 
(n=14) 
HC-P 
& 
HC-N 
(n=40) 
0 (0) 5 (13) 12 
(86) 
24 
(60) 
0 (0) 3 (8) 13 
(93) 
24 
(60)* 
12 
(86) 
32 
(80) 
13 
(93) 
23 
(58)* 
3 (21) 16 
(40) 
1 (7) 17 
(43)* 
IBS-N 
(n=14) 
 
HC-N 
(n=16) 
0 (0) 0 (0) 12 
(86) 
7 
(44)* 
0 (0) 0 (0) 13 
(93) 
8 
(50)* 
12 
(86) 
13 
(81) 
13 
(93) 
9 
(56)* 
3 (21) 2 (13) 1 (7) 1 (6) 
 
Gp: group of study subjects n: number of subjects kDa: kiloDalton MW: molecular weight 
IBS-P/N: Irritable bowel syndrome subjects positive/negative for Blastocystis 
HC-P/N: healthy control subjects positive/negative for Blastocystis 
*p≤0.05  **p≤0.01 ***p≤0.001 
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Figure 6.1 Serum antibodies from Blastocystis positive clinical subgroups IBS-P and HC-P reacting with Blastocystis 
proteins in Western blot 
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IBS-P= Irritable bowel Syndrome patients positive for Blastocystis HC-P=Healthy controls positive for Blastocystis    
N=negative control  L=protein standard ladder  kDa=kiloDalton molecular weight 
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Figure 6.2 Serum antibodies from Blastocystis positive clinical subgroups IBS-P and HC-P and Blastofluor Ab reacting 
with Blastocystis proteins in Western blot 
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IBS-P=Irritable Bowel Syndrome patient positive for Blastocystis  
HC-P=Healthy controls positive for Blastocystis N=negative control   
Bf=Blastofluor antibody    
kDa=kiloDalton molecular weight 
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Figure 6.3 Serum antibodies from Blastocystis negative clinical subgroups IBS-N and HC-N reacting with 
Blastocystis proteins in Western blot 
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IBS-N=Irritable Bowel Syndrome patient negative for Blastocystis   
HCN=Healthy controls negative for Blastocystis   
N=negative control   
L=standard ladder 
 kDa=kiloDalton molecular weight
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The numbers of Blastocystis-positive subjects in each subtype group 
were small but serum reactivity to all the protein bands was present in every 
subtype with the exception of 17 kDa, 37 kDa and 150 kDa bands (Table 6.2).  
No significant associations were found between Blastocystis sp. subtypes and 
reactivity to particular protein bands based on Fisher’s exact test results (all 
p>0.05). 
Reactivity with proteins of approximately 17 and 37 kDa MW were 
observed in 7.5% of total participants and these were only present in those 
subjects who tested positive for the presence of Blastocystis sp. Proportions 
of participants with reactivity for proteins of 95-105 kDa and 150 kDa MW, 
were significantly lower in the combined Blastocystis-negative group (λ2= 
11.97, p≤0.001 and λ2= 11.43, p≤0.001 respectively) (Table 6.3). The 
association of antibody-reactivity to the 95-105 kDa protein(s) with 
Blastocystis carriage was statistically significant in the intra-subgroup 
comparisons in both HC and IBS groups (p≤0.05) (Table 6.4). 
Reactivity to the 27, 50 and 75-90 kDa MW bands were detected in 
descending order of frequency in the IBS-P group (96%, 100%, 96%), the 
IBS-N group (86%, 93%, 93%), the HC-P (71%, 67%, 58%) and the HC-N 
(44%, 50%, 56%) groups (Table 6.3). Reactivity to each of these three 
proteins was found to be significantly associated with IBS symptoms, 
regardless of Blastocystis status (combined IBS-P + IBS-N (p≤0.001), IBS-P 
(p≤0.001) or IBS-N (p<0.05), respectively, versus HC (Table 6.4).  
 
6.4.4 Further Analysis of the Blastocystis Antigens 
The Blastofluor antibody was tested in parallel with IBS-P and HC-P 
sera on a Western blot and showed reactivity with all the protein bands noted 
in the study subgroups, namely 17, 27, 37, 50, 60-65, 75-90, 95-105, 150 and 
250 kDa MW (Table 6.2).  
The MAb1D5 and MAb5 monoclonal antibodies were tested in parallel 
with four sera derived from BSP patients on a Western blot. The MAb1D5 
reacted strongly with two protein bands of approximately 100 kDa MW and 
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less strongly with a 27 kDa protein. The MAb5 gave no reactivity on the blot 
(Figure 6.4).  
The anti-MMP-9 antibodies were tested in parallel with two BSP sera 
on a Western blot and the anti-MMP-9 antibodies reacted with proteins of 27, 
50 and 75-100 kDa MW (Figure 6.5). The MAb1D5, MAb5, anti-MMP-9 were 
tested in parallel on a Western blot, using a 7.5% gel in an attempt to 
separate out the bands around 75-100 kDa MW, and this demonstrated that 
the MAb1D5 antibody reacted with a protein closer to 100 kDa MW compared 
to the anti-MMP-9 that reacted with a protein of approximately 80 kDa 
(Supplementary data: Figure 6.1S). Both antibodies reacted with a protein of 
approximately 25 kDa MW. 
A zymogram was run with and without EDTA (metalloprotease 
inhibitor). In the absence of EDTA two distinct bands above and below the 
100kDa protein marker (approximately 95 and 105 kDa, respectively) were 
apparent. Addition of EDTA to the zymogram abolished these two bands 
(Supplementary data: Figure 6.2S).  
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Figure 6.4 Serum antibodies from IBS-P clinical subgroup and monoclonal antibodies MAb1D5 and MAb5 reacting with 
Blastocystis proteins in Western blot 
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Figure 6.5 Serum antibodies in IBS-P clinical subgroup and MAb anti-proMMP-9 reacting with Blastocystis proteins in 
Western blot 
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Figure: 6.S1 Anti-proMMP-9, MAb1D5, MAb5 reacting with Blastocystis proteins in a Western blot* 
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Figure: 6.S2 Zymogram of Blastocystis WR1 proteins without addition of EDTA 
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6.5 Discussion 
Serum IgA levels were found to be significantly lower in subjects that 
were positive for Blastocystis sp. even after adjusting for the confounding 
variables of gender, age, season and Asian ethnicity that have been reported 
to influence serum IgA levels (Stoop et al. 1969; Weber-Mzell et al. 2004). 
The level of IgA correlated with carriage but not symptoms suggesting that a 
low serum IgA may permit Blastocystis sp. to establish in the gut lumen but 
may not influence pathogenicity. The association of Blastocystis carriage and 
low serum IgA would be consistent with the fact that IgA is the major 
immunoglobulin class involved in mucosal defence (Aghamohammadi et al. 
2009) and is known to prevent adherence of pathogens to the gut luminal 
surface, bind toxins and inhibit antigen absorption. IgA production increases 
after three months of age in parallel with the change from a sterile gut to one 
with a complex commensal intestinal microbiota (Macpherson et al. 2008). 
Secretory IgA can be effective against pathogens as an innate non-specific 
local response or develop into an adaptive specific systemic response after 
presentation of luminal antigen to gut associated lymphoid tissue (GALT) and 
subsequent generation of IgA-producing plasma cells in the intestinal mucosa. 
The complex relationship of IgA to the regulation or monitoring of the intestinal 
microbiota is not understood. Proteases derived from Blastocystis cell lysates 
have been shown to be capable of degrading secretory IgA (Puthia et al. 
2005).  
Low serum levels of IgA may be due to a number of causes including 
partial or complete selective IgA deficiency (Latiff & Kerr 2007) and likely 
influence host and microbial interactions.  IgA deficiency is associated with an 
increased risk of giardiasis (caused by another non-invasive luminal parasite) 
as well as respiratory infections and allergic and autoimmune diseases 
(Aghamohammadi et al. 2009). Patients with autoimmune diseases and 
selective IgA deficiency more commonly exhibit the major histocompatibility 
complex (MHC) haplotype 8.1 and other non-MHC gene defects have been 
reported (Singh et al. 2014).  
IgG serum antibodies from many study participants in all subgroups 
reacted with proteins of approximately 27, 50, 60-65, 75-90, 95-105, and 
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150kDa MW in the Western blots using axenic WR1 (ST4) as antigen source. 
Although differences in the quantity or affinity of the antibodies were 
suggested by the intensity of the signals, no attempt was made to apply 
quantitation by densitometry. The rabbit-derived Blastofluor antibody, raised 
in rabbits primed with axenic ST3, showed a very similar reactivity pattern to 
proteins of 10, 17, 27, 37, 50, 75, 100 KDa MW when tested in parallel with 
human sera (Figure 6.2), suggesting that these particular Blastocystis 
antigens are common to both subtypes 3 and 4. Whilst some researchers 
have described different SDS-PAGE protein patterns in different Blastocystis 
organisms (Kukoschke & Muller 1991; Chen et al. 1999) others have found 
little difference in the protein sizes between different Blastocystis 
subtypes(Tan et al. 1996; Init et al. 2003). 
Over 40% of healthy asymptomatic patients negative for Blastocystis 
sp. reacted to Blastocystis antigens at 27, 50, 60-65 and 75-90 kDa, 
respectively (Table 6.3), suggesting that positive reactions with these proteins 
occurred either due to past exposure to Blastocystis sp. or as a result of a 
cross reactivity with the Blastocystis antigens. Only the antibody band sizes 
95-105 and 150 kDA were significantly more common in those with current 
carriage of Blastocystis sp., occurring in approximately 60% of these 
individuals. 
However IBS groups, either positive or negative for Blastocystis 
carriage, when compared to HC displayed a different pattern with significantly 
higher number of reactions to 27, 50 and 75-95 kDa MW proteins. Overall 
these proteins were present in approximately 86-100% of IBS patients 
compared to 44-71% of HC. Although presence of these proteins was 
greatest in the Blastocystis-positive IBS group, it was still present in the IBS 
group negative for current carriage of Blastocystis sp.. This finding again 
suggests the positive reactions in the IBS-N group were either due to non-
specific antibody cross- reactions or due to residual antibody from past 
exposure to Blastocystis organisms. The gut epithelial permeability is 
increased in IBS (Simren et al. 2013; Beatty et al. 2014) and it is probable that 
IBS patients have greater exposure to intraluminal antigens. Although the 
number of subjects in our clinical subgroups was relatively small our findings 
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suggest that exploration of the nature of these 27, 50, 75-95 kDa MW proteins 
may be useful in identifying biomarkers for IBS (current biomarkers are not 
able to reliably exclude organic disease (Corsetti et al. 2014)), identifying 
patients who are symptomatic due to Blastocystis infection and informing 
development of effective therapies. 
Several studies have reported that an antigenic protein with a MW of 
approximately 30 kDa is present in Blastocystis organisms (Lanuza et al. 
1999; Hegazy et al. 2008) and differences in reactivity to this protein(s) 
between symptomatic patients and healthy controls have been reported 
(Hegazy et al. 2008; Abou Gamra et al. 2011). No reactivity with proteins of 
this size was reported in sera from patients with other parasitic infections 
suggesting the 30 kDa protein might be specific for Blastocystis organisms. A 
cytopathic monoclonal antibody, MAb1D5, previously shown to bind to the 
external surface of Blastocystis sp.(Tan et al. 1997), reacts with a 30kDa 
protein from Blastocystis isolates derived from humans (ST’s unknown), but 
reportedly not with antigen derived from WR1 (Tan et al. 2001). Peptide 
sequences derived from material obtained by 2-dimensional electrophoresis 
and Western blotting suggest that this 30kDa protein is closely related to a 
cysteine protease of the legumain type. Although no reactivity of the MAb1D5 
was reported previously with subtype WR1 (Tan et al. 2001),and this was the 
subtype we used as an antigen source in our study, the 27 kDa protein-
reactivity that we observed more frequently in the symptomatic group may 
nevertheless correspond to this previously described 30 kDa protein.  The 
difference in reactivity may be accounted for by increased purity of MAb1D5 
used in our study and differences in antigen preparation technique, and the 
MW size difference accounted for by differences in Blastocystis antigen 
source and preparation (e.g., subtype, level of glycosylation). The MAb1D5 
tested in parallel with our human serum samples reacted strongly with a 
double band around 100 kDa MW and also with a 27 kDa protein in the 
Western blots (Figure 6.4). This pattern of reactivity (100 and ~30 kDa) 
against an antigen preparation using ST7 organisms was shown previously 
(Wawrzyniak et al. 2012) and suggests that the 30 kDa antigen may be a 
processed or degraded form of the 100kDa protein.  
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We also noted differences in IBS patients (IBS-P and IBS-N) with 
regard to reactivity to 50 and 75-95 kDa proteins. These proteins may 
correspond to the 50 and 118 kDa antigens (Hegazy et al. 2008), or the 60-
100 kDa sized proteases (Rajamanikam & Govind 2013) reported previously 
in symptomatic Blastocystis infected patients. Parasitic proteases are known 
to be highly immunogenic and may facilitate tissue invasion in the host. We 
searched for a protease that might be consistent with this role and sizes. 
Matrix metalloproteinase-9 (MMP-9) is one member of the zinc binding matrix 
metalloproteinases (MMP) that degrade components of the extracellular 
matrix including gelatin (gelatinase B), collagens, and elastin, thereby 
potentially aiding tissue invasion (Geurts et al. 2012), and has been shown to 
interact with the immune system including potentiation of  IL-8 (Geurts et al. 
2012). MMP-9’s are found in the cytosol, vesicles and cell membranes of cells 
(Vandooren et al. 2013). They exist as a pro-enzyme at around 92 kDa, an 
activated form around 84 kDa and truncated forms at lower sizes around 50 
kDa in humans (Shimokawa et al. 2002). The pro-MMP-9’s are activated by 
other proteases, detergents and heat. We tested an antibody specific for 
human pro-MMP-9 in parallel with human sera in our Western blots and found 
that it reacted with Blastocystis proteins of approximately 75-100, 50 and 27 
kDa MW, respectively, and that the pattern differed from the MAb1D5 
reactivity. MAb1D5 reacted with a different distinct protein of approximately 95 
kDa as well as a 27 kDa protein.  
A subsequent zymogram performed using antigen that had been pre-
treated with protease inhibitors minus EDTA showed a positive double band 
around 100 kDa that was abolished with EDTA. These findings suggest that a 
metalloproteinase around 100 kDa MW is present in Blastocystis sp.. Inherent 
differences in gel runs and species variation of enzymes make it difficult to 
assess if this 100 kDa zymogram band is related to the Western blot 75-95 
kDa bands we noted to be of significance in symptomatic patients. The 
findings nevertheless suggest that a MMP-9 isoform is present in Blastocystis 
organisms, and the pro-MMP-9 band may correspond to the 75-95 kDa 
protein, while the 50 kDa protein may possibly be the enzymatically active 
form and the 27 kDa form a truncated fragment. 
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The detection of a 27 kDa protein with both the anti-MMP-9 and the 
MAb1D5 suggest that this band may contain more than one protein, including 
a truncated fragment of a MMP-9 isoform. Previous studies investigating 
proteases present in Blastocystis sp. have suggested that cysteine proteases 
constitute the major class of proteases in this organism (80% protease activity 
shown to be inhibited by cysteine protease inhibitors) (Sio et al. 2006). 
However it may be difficult to account for proteases that are present as pro-
enzymes that require activation or that may be inhibited from converting to 
active forms by other proteases. Protease activity at 32 kDa was reported to 
be significantly increased in symptomatic patients (Abdel-Hameed & Hassanin 
2011; Abou Gamra et al. 2011) but may be due to a mixture of enzymes of 
that size. The genome of ST7 has been sequenced and this has allowed the 
prediction that all classes of proteases (cysteine, serine and 
metalloproteases) could be secreted by the parasite (Denoeud et al. 2011) . 
The majority (91%) are predicted to be of the cysteine protease and none 
were specifically predicted, at this level of genome testing sensitivity, to be a 
metalloprotease of the MMP-9 class. Preliminary analysis of the ST4 genome 
has shown the presence of up to 30% genes with no ortholog present in the 
ST7 genome (Wawryniak et al. 2015) emphasising the genetic diversity 
present in this organism. Additionally, a recent study has discovered that 15% 
of nuclear genes in Blastocystis sp. Subtype 7 uniquely use a 
polyadenylation-mediated creation of termination codons (Klimes et al. 2014) 
and predicted genes may need to be re-evaluated in the light of this new 
information.  
 
6.6 Conclusions 
Low serum IgA levels may facilitate Blastocystis carriage but are not 
associated with the development of IBS gastrointestinal symptoms. Antibodies 
to Blastocystis organisms are commonly found in the serum of many healthy 
individuals, but antibodies to 27, 50 and 75-95kDa MW proteins are 
significantly increased in IBS patients regardless of Blastocystis status. Some 
of these serum antibodies are likely to be reacting to a previously reported 
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cysteine protease, but others may be reacting with another class of proteases, 
the metalloproteases. 
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7.1 Abstract 
Background and aim: Characteristic differences in the faecal microbiota 
(FM) have been described in irritable bowel syndrome (IBS). Blastocystis 
carriage has also been associated with IBS although overall the organism 
constitutes less than 1% of the total FM. We investigated whether the carriage 
of Blastocystis in IBS patients affects the FM profile. Methods and results: 
Forty patients with diarrhoea-predominant IBS (26 Blastocystis-positive and 
14 Blastocystis–negative) and fifty-seven healthy controls (HC) (42 
Blastocystis-positive and 15 Blastocystis-negative) submitted faecal samples 
for high throughput culture-independent metagenomic analysis using 16S 
ribosomal RNA gene sequencing.  Differences in abundance of bacteria in 
these IBS and HC groups were evaluated from phylum to genus level. 
Significant changes were seen in the two dominant phyla, namely a rise in 
Firmicutes and a statistical significant reduction in relative abundance of 
Bacteroidetes (with a three fold increase in the Firmicutes: Bacteoridetes 
ratio) were observed in IBS patients, regardless of Blastocystis infection 
status. Further subgroup analysis showed Blastocystis-positive IBS patients 
had significant reductions in abundance at the phylum level of Actinobacteria 
(p= 0.015) and Firmicutes (p=0.013), and significant increases in 
Bacteroidetes (p= 0.05), “Other” (unidentified bacteria) (p=0.004) and 
Proteobacteria (p=0.018)  compared to Blastocystis-negative IBS patients. 
These changes were reflected in a lower average Firmicutes: Bacteroidetes 
ratio of 6.19 in Blastocystis-positive compared to 9.00 in Blastocystis-negative 
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IBS patients. Minor differences at genus level were also seen between the 
IBS groups in Anaerostipes, Blautia and Alistepes spp.  
Conclusion: Significant differences in the FM between Blastocystis-positive 
and Blastocystis-negative diarrhoea-predominant IBS patients were found 
suggesting that Blastocystis carriage either alters the FM directly, or changes 
in the FM allow Blastocystis spp. to flourish. These differences in FM profile 
may define a separate clinical subtype of IBS. 
Key Words: faecal microbiome, Blastocystis , Irritable Bowel Syndrome 
 
7.2 Background 
The human gut is sterile at birth and during early infancy is colonised 
by organisms originating from the mother, diet and environment. The adult 
human gut is host to 100 trillion commensal organisms that live in facilitative 
harmony with the 10 trillion cells in the body (Bonfrate et al. 2013). Over 90% 
of the faecal mass is comprised of microbes, the “faecal microbiome”  (FM), 
comprising bacteria (93%), viruses (5.8%), archaea (0.8%) and eukaryotes 
(0.5%)(Arumugam et al. 2011).  
This intestinal microbiota is estimated to contain 3.3 million gene 
copies (the microbiome) vastly outnumbering the estimated 20,000 human 
genes and is increasingly recognised as an additional “human organ” with 
important neuroendocrine, metabolic, nutritional and protective functions 
(Albenberg & Wu 2014). The FM produces micronutrients Vitamin B and K 
and short chain fatty acids (SCFA) that are a primary energy source for 
colonic mucosal cells. The bacteria facilitate fermentation of food for host 
metabolism, produce neurotransmitters that are absorbed systemically, 
conduct immune priming, including differentiation of T helper cells, in the host 
and protect against other luminal pathogens (Furusawa et al. 2014).  
Metagenomic analysis, using culture-independent high throughput 16S 
ribosomal ribonucleic acid  (rRNA) quantitative gene sequencing and 
microarrays, allows genetic insights into the FM with most attention given to 
the bacterial populations. This technique allows taxonomic classification of 
organisms from phylum to species. Of the fifty bacterial phyla humans host, 
fifteen are found in the gut and 90% of the colonic microbiota consists of two 
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dominant phyla, namely Firmicutes and Bacteroidetes, with great individual 
variability seen at species and strain level. Over 80% of bacterial species 
identified with these techniques remain uncultured (Shanahan 2012).  
Although eukaryotes comprise less than 1% of the total FM, 
metagenomic analysis has identified thirty-seven eukaryotic species in the 
faeces of a healthy adult including Blastocystis spp., eighteen plant species 
and eighteen fungal species (Gouba et al. 2013). A recent study of 105 
healthy adults in Ireland showed the prevalence of Blastocystis carriage to be 
as high as 56%, with diverse subtypes and with stable carriage seen over a 
duration of 6-10 years (Scanlan et al. 2014) and concluded that  Blastocystis 
carriage is likely one of the components of a healthy FM. 
In the newborn infant the gut microbiota is aerobic, but within days 
becomes anaerobic, and within two years is relatively stable till advanced age 
(Arrieta et al. 2014). Some of the factors that influence the human faecal 
microbiota include mode of delivery (vaginal versus Caesarean), feeding 
patterns in early infancy (breast feeding duration, time of introduction of 
foods), immunisation, antibiotic usage, sanitation (Arrieta et al. 2014), gender 
(Aguirre de Carcer et al. 2011) and long-term dietary choices. For example, 
Prevotella species (Bacteroidetes phylum) dominate in rural Africa, where the 
diet is high in vegetables, fruit and fibre compared to Europe (De Filippo et al. 
2010).  
Irritable bowel syndrome (IBS) is a chronic heterogeneous condition 
affecting approximately 10% of the population worldwide (Canavan et al. 
2014a). The disease is defined by a clinical symptom complex description 
(Rome III) and classified according to the predominant bowel habit, namely 
diarrhoea, constipation or “mixed” diarrhoea/constipation (Longstreth et al. 
2006). Although the disease is benign, there are high direct and indirect 
health costs associated with diagnosis and management of this condition 
(Canavan et al. 2014b). The cause of IBS is not known, although 10% of 
cases of IBS arise after an enteric infection (Beatty et al. 2014), and 
improvement has been reported after broad spectrum antibiotic therapy 
(Laterza et al. 2015). Blastocystis spp. are three times more likely to be found 
in the stools of patients with diarrhoea-predominant IBS compared to healthy 
controls making this an organism of particular interest in the FM of patients 
 157 
with IBS (Yakoob et al. 2010).  No definite association between pathogenicity 
and specific Blastocystis subtype has been found. 
The FM is altered in various gastrointestinal diseases including IBS, 
leading researchers to ask whether this disease is caused by particular 
organisms within this altered FM or whether the disease is the end result of an 
abnormal host immune response to certain FM (Shanahan 2012). In adults 
with IBS the FM has characteristically displayed decreased diversity of 
organisms, temporal instability, changes in the dominant phyla, namely an 
increased Firmicutes:Bacteroidetes ratio, and changes in the minor phyla 
(decreased Actinobacter and increased Proteobacteria) (Simren et al. 2013).  
Changes in the abundance of certain bacterial families/species are also 
reported including Bifidobacterium, Lactobacillus (phylum:Actinobacter), 
Bacteroides, Prevotella (phylum:Bacteroidetes), Blautia, Clostridium, 
Collinsella, Coprococcus, Staphylococcus, Ruminococcus, Veilonella 
(phylum:Firmicutes) and Enterobacteria (phylum:Proteobacteria) (Malinen et 
al. 2005; Lyra et al. 2009; Rajilić–Stojanović et al. 2011; Jeffery et al. 2012b; 
Bye et al. 2014). 
A previous study has suggested that irritable bowel subtypes may be 
able to be characterised by their FM profile and that these subtypes do not 
necessarily correspond to their clinical categorisation (Jeffery et al. 2012b). 
IBS symptoms may have multiple causes and we hypothesized that 
Blastocystis spp. are one specific cause of IBS symptoms, and therefore it 
may be possible to identify differences in the bacterial FM between 
Blastocystis-positive and Blastocystis-negative IBS patients. In this study we 
compared the FM in diarrhoea-predominant IBS patients, positive and 
negative for Blastocystis and healthy controls, positive and negative for 
Blastocystis carriage. 
 
7.3 Methods 
7.3.1 Study outline 
Forty patients presenting with diarrhoea-predominant IBS to the 
Toowoomba Gastroenterology Clinic and fifty-seven healthy volunteers (HC) 
were enrolled in the study. Single baseline faecal samples were collected 
 158 
from all participants and tested for the carriage of Blastocystis and subjected 
to metagenomic analysis. The faeces were frozen at -20C within 4 hours of 
collection. The faecal microbiome profile of all patients was examined and 
comparative analysis was made between subjects with IBS and HC, and 
between Blastocystis-positive and Blastocystis-negative IBS (IBS-P, IBS-N) 
and HC (HC-P, HC-N) subjects. The study was approved by the University of 
Queensland Medical Research Ethics Committee and was part of two clinical 
trials registered with the Australian and New Zealand Clinical Trials registry 
(http://www.ANZCTR.org.au) ACTRN: 12610001066077 and 
12611000918921. 
 
7.3.2 Inclusion protocol 
Patients presenting to the clinic with chronic diarrhoea from 09/04/2008 
to 20/2/14 were assessed clinically (Nagel et al. 2014). Forty consecutive, 
eligible symptomatic patients who had no other cause for symptoms identified 
and who fulfilled the Rome criteria for diarrhoea-predominant IBS (Longstreth 
et al. 2006), namely symptoms of chronic abdominal pain, occurring 
frequently over the last 3 months, associated with defecation and the passage 
of predominantly loose stool, were enrolled in the study. Healthy volunteers 
were recruited from the University of Queensland and from asymptomatic 
members of households containing a symptomatic Blastocystis-positive 
patient. All patients who were invited to participate consented to enrolment 
and completed the study. A full medical history was taken only from 
symptomatic patients. No record was taken in any subject of diet, pre- or pro-
biotic intake. 
 
7.3.3 Exclusion protocol 
Non-pregnant subjects between 15 and 75 years of age were recruited 
for the study. Patients with significant systemic diseases or co-morbidities 
were excluded. Subjects were excluded if they had had a course of any 
antibiotic in the preceding six weeks prior to stool collection.  
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7.3.4 Diagnostic methods  
All samples were run in parallel for the presence of Blastocystis spp. 
using a simple unstained wet faecal smear, xenic in vitro culture (XIVC) and 
PCR (confirmed as Blastocystis spp. using DNA sequencing to enable 
subtyping) as previously described (Nagel et al. 2014) . A patient was 
considered to be positive if any one of the tests was positive. 
 
7.3.4.1 Metagenomic analysis 16S rRNA PCR  
Extracted DNA was quantified using a Qubit fluorometer and 1ng 
samples were amplified using the 16S V4/5 primers (515F/806R). The primer 
sequences and protocol was based on Caporaso et al 2012, with local 
modifications. Specifically, we used a mixture of gene-specific primers and 
gene-specific primers tagged with ion torrent-specific sequencing adaptors 
and barcodes. The tagged and untagged primers were mixed at a ratio of 
90:10. Using this method, the approximately 10 cycle inhibition observed by 
using long tagged primers could be reversed and hence we achieved 
amplification of all samples using 18-20 cycles, thus minimising primer-dimer 
formation and allowing streamlined downstream purification. Amplification was 
confirmed by agarose gel electrophoresis and product formation was 
quantified by fluorometry. Up to 100 amplicons were diluted to equal 
concentrations and adjusted to a final concentration of 15pM. Templated Ion 
Shere Particles (ISP) were generated on an Ion One Touch 2 (Life 
Technologies) using 400bp templating kit and sequenced on a PGM 
(LifeTechnologies) for 800 cycles using 400bp sequencing kit yielding a modal 
read length of 309bp. Reads were trimmed for quality purposes using 
TorrentSuite 4.0.2(Caporaso et al. 2010).  
 
7.3.4.2 Analysis of sequences 
Metagenomic analysis using culture-independent high throughput 16S 
rRNA quantitative gene sequencing and microarrays was performed on the 
PCR derived sequences. The data was analysed using software analysis 
program Quantitative Insights into Microbial Ecology (QIIME, version 
1.7)(Caporaso et al. 2010). The following commands were applied to the 
derived 16S rRNA sequences (Cock et al. 2010) (i) the rRNA sequence 
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FASTq reads were separated into two separate libraries, one containing 
“sequences (FASTA files)” and the other “quality of DNA information (QUAL)” 
scores)  (ii) Each file in the sequence library was assigned a unique subject 
identity barcode, creating a “mapping” library (iii) PCR “mixed sequence” 
chimeras were removed using a reference file and identification of “de novo” 
chimeric sequences (iv) Operational taxonomic units based on 97% 
specific16S rRNA gene sequence identities were used to distinguish different 
species of microbe and these were grouped into their most likely 
phylum/class/order/family/genus using GreenGenes database, Version 
12_10) (McDonald et al. 2012). The reads were repeated to refine the dataset 
to a consistent number of reads and taxonomic identification. Genomic 
analysis was obtained from taxonomic Level 1-6, but not including Level 7 
species subtype identification (Caporaso et al. 2010). 
 
7.3.5 Statistical analysis 
Statistical analysis was carried out using IBM SPSS Statistics (IBM 
SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). 
Percentages of gut microbial flora at phylum (L2) and species level (L6) 
across the four clinical groups were analysed using Kruskal-Wallis test. Those 
species with a significant overall difference were further analysed for between 
group differences using the following equation(Siegel & Castellan 1988): 
RBari - RBarj | >= Z*Sqrt[ (N*(N+1)/12)*(1/ni + 1/nj) ] 
where RBari, RBarj, ni, nj are the mean of the ranks and the sample sizes 
associated with the i-th and j-th groups. N is the total sample size and Z is the 
critical value from the standard normal curve (Z = 2.638 for k=4 groups and 
where alpha=0.05/(k*(k -1)) = 0.0083333.). 
Firmicutes: Bacteiodetes ratio is calculated by dividing individual abundance 
of Firmicutes by individual abundance of Bacteroidetes. Mann-Whitney test 
was used to test any significance between total IBS and total HC groups.  
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7.4 Results 
7.4.1 Subjects 
Ninety-seven participants comprised of 40 symptomatic diarrhoea-
predominant irritable bowel syndrome (IBS) patients and 57 asymptomatic 
healthy controls (HC) were included in the study. Mean ages of IBS and 
control subjects were 45.2 (range, 23 – 77) and 42.0 (range, 15 - 74) years 
old, respectively. Subjects were further classified as to whether they tested 
positive or negative for the parasite Blastocystis. A significant difference 
amongst the four participant groups was found in terms of gender (λ2=15.25, 
p<0.05), but not age (F=1.11, p= 0.30).  
Blastocystis subtype 3 (ST-3) was most common in both IBS and HC groups, 
ST-4 was seen more commonly in the IBS group but this did not reach 
statistical significance. Characteristics of participants in clinical subgroups are 
shown in Table 7.1.  
 
Table 7.1 Characteristics of clinical subgroups 
 IBS-P 
(n=26) 
IBS-N  
(n=14) 
HC-P 
(n=42) 
HC-N 
(n=15) 
Age  
(mean±sd) 
45.6 ± 13.6 44.5 ± 14.3 41.8 ± 15.6 42.4 ± 15.2 
Female  
(n, %) 
20 (76.9) 11 (78.6) 18 (35.7) 10 (66.7) 
Blastocystis subtypes (n, %)    
ST1 5 (19.2)  12 (28.6)  
ST3 8 (30.8)  12 (28.6)  
ST4 7 (26.9)  6 (14.3)  
Other subtypes 
(including ST2,5-8) 
6 (23.1)  7(28.6)  
Medications (n, %)     
Subjects on PPI/H2Bl 7 (27%) 4 (29%)   
Nil or OCP only 14 (54%) 4 (29%)   
IBS-P: Patients with irritable bowel syndrome positive for Blastocystis 
IBS-N:  Patients with irritable bowel syndrome negative for Blastocystis 
HC-P: Healthy controls positive for Blastocystis 
HC-N: Healthy controls negative for Blastocystis 
PPI=proton pump inhibitor therapy H2Bl=Histamine 2 blocker therapy OCP=oral contraceptive pi
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 Twenty-eight symptomatic patients were taking prescribed medications 
(16 of the IBS-P, 12 of the IBS-N), including amitriptyline, oral contraceptive 
pill, proton pump inhibitors, histamine 2 blockers, thyroxine, cholesytramine, 
antihypertensives and non-steroidal agents (Table 7.1).  
 
7.4.2 Bacterial phyla seen in the study participants 
The major phyla seen in all subjects were Firmicutes (46.27% of all 
phyla) and Bacteroidetes (40.99%). The other most common phyla in 
descending order of abundance were Proteobacteria, Actinobacteria, 
Verrucomicrobia and Fusobacteria and this pattern was observed in the first 
two phyla and varied in the remaining phyla in all the subject subgroups (IBS, 
IBS-P, IBS-N, HC, HC-P, HC-N) (Table 7.2a). Eight phyla (including 
“Unclassified”) were present in only a few patients (<15% of total cohort) in 
one or more of the clinical groups (see Table 7.2a) and comprised less than 
0.05% abundance (of the clinical subgroup mean value). The OD1 phylum 
was not found in any participant. The Spirochaetes, TM7 and Tenericutes 
phyla were only found in three individuals in the HC-P group. The Unclassified 
“phylum” was found in five individuals in the IBS-P group. The phylum 
Elusimicrobia was not found in the IBS-N group. 
7.4.3 Comparison of bacterial profiles in subjects with and without IBS 
The FM was compared between IBS and HC from phylum to species 
level. The two major phyla in subjects in both IBS and HC groups were the 
Firmicutes (IBS vs HC: 51% vs 43% of total FM, p=0.12) and Bacteroidetes 
(IBS vs HC: 34% vs 46% of total FM, p<0.05) (7.2a; Figure 7.1). 
Bacteroidetes abundance was significantly reduced in the IBS group and the 
Firmicutes:Bacteroidetes ratio was three times higher in the IBS group 
compared to the HC (Table 7.2b) (p=0.02). Increased abundance of 
Proteobacteria and Actinobacter phyla in the IBS group was observed but did 
not reach statistical significance. 
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                             Table 7.2a Abundance of bacterial phyla seen in clinical subgroups (%) 
 
Phyla Total IBS 
(n=40) 
IBS-P 
(n=26) 
IBS-N 
(n=14) 
Total HC 
(n=57) 
HC-P 
(n=42) 
HC-N 
(n=15) 
Actinobacteria 3.565 2.906# 4.789 2.014 0.668 5.784 
Bacteroidetes 33.780* 39.171+ 23.769 46.045 48.467 39.263 
Cyanobacteria/ Chloroplast 0.031 0.045 0.006 0.022 0.025 0.013 
Elusimicrobia 0.02 0.025 0 0.002 0.0005 0.003 
Firmicutes 51.037 44.350# 63.456++ 42.924
 
41.970 45.593 
Fusobacteria 0.272 0.031 0.720 0.082 0.110 0.003 
Lentisphaerae 0.020 0.025 0.010 0.018 0.020 0.011 
Other 3.786 4.893 1.729 3.185 3.481 2.356 
Proteobacteria 6.857 8.032+ 4.676 5.286 4.758 6.764 
Spirochaetes 0 0 0 0.001 0.002 0 
Synergistetes 0.007 0.004 0.011 0.003 0.003 0.004 
TM7 0 0 0 0.0004 0.0005 0 
Tenericutes 0 0 0 0.004 0.005 0 
Verrucomicrobia 0.309 0.217 0.479 0.297 0.347 0.159 
Unclassified 0.004 0.006 0 0 0 0 
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Table 7.2b Firmicutes: Bacteroidetes Ratio in clinical subgroups 
(abundance of Firmicutes/abundance of Bacteroidetes) 
 
* significant difference in Total IBS cf Total HC  
#
 significant reduction in IBS-P cf IBS-N  +significant increase in IBS-P cf IBS-N    
++ significant increase in IBS-N cf HC-N  IBS-P: Patients with irritable bowel syndrome positive for Blastocystis IBS-N:  Patients with irritable bowel 
syndrome negative for Blastocystis HC-P: Healthy controls positive for Blastocystis HC-N: Healthy controls negative for Blastocystis  cf=compare 
 
 
 
 
 
 
 Total IBS IBS-P IBS-N Total HC HC-P HC-N 
Firmicutes:Bacteroidetes Ratio 
(mean  standard deviation) 
7.1313.40 6.1914.85 9.0010.16++ 2.287.19 1.421.179 5.0814.51 
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Figure 7.1 Comparison of bacerial phyla profiles in subjects with and without IBS 
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A number of genera of microbes showed differences in abundance 
between IBS and HC subjects, and many of these differences reached 
statistical significance (Table 7.3). At genus level the organisms that were 
statistically increased in IBS patients were Methanobrevibacter, Actinomyces, 
Gordonibacter, Enterococcus, Streptococcus, Blautia, 
Lachnospiacea_incertae_sedis, Papillobacter, Ruminococcus and 
Gemminger. The genera significantly decreased in IBS patients were 
Olsenella, Parabacteroides, Peptococcus, Cantenibacterium, Alisonella, 
Dialister, Megamonas and Megaspaera (Table 7.3). 
 
7.4.4 Comparison of bacterial phyla across the four clinical subgroups 
Differences were found between bacterial phyla profiles in IBS-P and 
IBS-N patients (Table 7.2a; 7. 2a,b). Comparison of IBS-P to IBS-N subjects 
showed significant reductions in abundance in Actinobacteria (p= 0.015) and 
Firmicutes (p=0.013), and significant increases seen in Bacteroidetes (p= 
0.05), Other (unidentified bacteria) (p=0.004) and Proteobacteria (p=0.018). 
The only other difference seen at phylum level between the clinical subgroups 
was an increased abundance of Firmicutes in IBS-N compared to HC-N 
(p=0.05) (Table 7.4). The mean FB ratio of the IBS-P patients (6.19) was 
lower than the ratio found in the IBS-N patients (9.00), and similarly the FB 
ratio in the HC-P (1.42) was lower than that seen in the HC-N (5.06) although 
these trends did not reach statistical significance (7. 2b). The minor phyla only 
have small numbers of subjects in each group making meaningful statistical 
interpretation difficult (7.2b). 
 
7.4.5 Comparison of bacterial genera across the four clinical subgroups 
Significant differences in bacterial profiles at genus level were found 
between the clinical subgroups (Table 7.4). When comparison was made 
between the IBS-P and the IBS-N group a reduction in bacterial abundance 
was found in Anaerostipes, Blautia (Firmicutes phyla) and Other spp and 
increased abundance was noted in Alistepes spp. (Bacteroidetes phyla) 
(p<0.05). 
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Table 7.3 Comparison of bacterial profiles in subjects with and without IBS 
Phylum (L2) Class (L3) Order (L4) Family (L5) Genus (L6) 
Euryarchaeota Methanobacteria  Methanobacteriales  Methanobacteriaceae  Methanobrevibacter  
 
Actinobacteria Actinobacteria Actinomycetales  Actinomycetaceae  Actinomyces  
  Bifidobacteriales Bifidobacteriaceae Other  
  Coriobacteriales Coriobacteriaceae Gordonibacter  
    Olsenella  
Bacteroidetes  Bacteroidia  Bacteroidales  Porphyromonadaceae Parabacteroides  
     
Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus  
   Streptococcaceae  Streptococcus  
 Clostridia  Clostridiales  Lachnospiraceae  Blautia  
    Lachnospiracea_incertae_sedis  
   Peptococcaceae 1  Peptococcus  
   Rumincoccaceae Papillibacter  
    Ruminococcus  
 Erysipelotricha Erysipelotrichales Erysipelotrichaceae Cantenibacterium  
    Other  
 Negativicutes  Selenomonadales  Veillonellaceae  Allisonella  
    Dialister  
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L=level 
Bold entries indicate significant difference between groups (p<0.05) 
 indicate significant (p<0.05) increase or decrease in IBS relative to healthy subjects, respectively 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Megamonas  
    Megaspaera  
     
Proteobacteria Alphaproteobacteria  Rhizobiales Hyphomicrobiaceae  Gemmiger  
(Unclassified)  Other  Other  Other  Other  
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Table 7.4 Comparison of abundance of selected** bacterial species across the four clinical subgroups 
Species Mean ± SD (%) 
 IBS-P (n=26) IBS-N (n=14) HC-P (n=42) HC-N (n=15) 
Actinomyces spp. ^ 0.019± 0.052 0.033± 0.042 0.014± 0.005 0.016± 0.022 
Bifidobacterium spp. ^ 2.440± 8.130 3.636± 5.267 0.408± 1.039 5.265± 9.671 
2.1.1.2.1.4 Other 0.039± 0.156 0.023± 0.031 0.003± 0.013 0.085± 0.237 
Eggerthella spp. ^ 0.018± 0.058 0.116± 0.182 0.003± 0.010 0.037± 0.112 
Gordonibacter spp. 0.005± 0.012 0.011± 0.028 0 0.003± 0.007 
Olsenella spp. 0 0 0.006± 0.023 0 
Butyricimonas spp. 0.188±0.267 0.127±0.413 0.351±0.521 0.481±0.133 
Prevotella spp.  ^ 2.336± 5.513 0.034± 0.112 4.344±8.583 3.917± 11.803 
Alistipes spp.  * 6.142± 5.326 1.843± 2.460 5.473±5.802 4.336± 5.389 
Lauconostoc spp. ^# 0.035± 0.058 0.001±0.005 0.063±0.101 0.004± 0.011 
Weissella spp.  # 0.038±0.066 0.003±0.011 0.090±0.172 0.001± 0.005 
Streptococcus spp. ^ 1.276±2.612 0.646±0.631 0.192±0.273 0.516± 0.587 
Eubacterium spp. 0.004± 0.013 0.043±0.101 0.004±0.013 0.013± 0.036 
Anaerostipes spp.*^ 0.248±0.498 2.067±2.149 0.123±0.157 0.586± 1.461 
Blautia spp. *^ 1.130±1.923 8.011±8.001 0.450± 0.366 4.943± 9.926 
Lachnospiracea_incertae_sedis spp. ^ 2.092±3.592 3.163±2.645 0.813±0.769 2.400± 4.333 
Clostridium XI spp. ^ 0.224±0.378 0.850±0.766 0.255±0.505 0.453± 0.602 
Clostridium IV spp. # 0.829±1.501 0.487±0.422 1.037±1.373 0.268± 0.376 
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Oscillibacter spp. 0.675± 1.052 0.354± 0.284 0.655±0.534 0.360± 0.334 
Papillibacter spp. 0 0.023± 0.065 0 0 
Canternibacter spp. 0.004± 0.016 0 0.154±0.546 0.040± 0.118 
Coprobacillus spp. 0.008± 0.032 0.070± 0.138 0.006±0.019 0.017± 0.051 
Allisonella spp. 0.008± 0.028 0 0.016±0.049 0.129± 0.414 
Dialister spp.  
%
 0.227± 0.727 2.009± 4.290 3.799± 11.633 3.761± 5.844 
2.9.1.1.1.1 Other spp. *
%
 4.893± 5.681 1.726± 2.834 3.481±3.747 2.356± 5.774 
2.10.2.1.4.3 Other spp. 0.049± 0.080 0.006± 0.017 0.050± 0.095 0.019± 0.067 
Acinetobacter spp. 0.017±0.036 0.001±0.005 0.031±0.106 0 
Bacteria, Other spp. 0.006±0.015 0 0 0 
** Selection based on overall statistical significance across all clinical groups, determined by Kruskal-Wallis test with p<0.05. * significant post-hoc difference IBS-P vs IBS-N ^ 
significant post-hoc difference IBS-N vs HC-P # significant post-hoc difference HC-P vs HC-N % significant post-hoc difference IBS-P vs HC-N 
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Figure 7.2a Comparison of major bacterial phyla across the four clinical subgroups 
 
 
 
 
 
 
 
 
Figure 7.2b Comparison of minor bacterial phyla across the four clinical subgroups 
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No significant differences were noted between the IBS-P and HC-P but 
significantly decreased abundance was found between IBS-P and HC-N in 
Dialister spp. (p<0.05). 
No significant differences were found between the IBS-N and HC-N 
groups but between IBS-N and HC-P groups significantly increased 
abundance of Actinomyces, Bifidobacterium, Eggerthella, Streptococcus, 
Anaerostipes, Blautia, Lachnospiracea_incertae_sedis, Clostridium spp. and 
decreased abundance of Prevotella and Lauconostoc spp. was seen 
(p<0.05).   
 
7.5 Discussion 
Previously reported changes in the FM of the two dominant phyla with 
a raised Firmicutes:Bacteroidetes ratio in IBS patients compared to HC were 
confirmed in this study comprising diarrhoea–predominant IBS patients. 
Similarly a trend of increased Proteobacteria abundance was consistent with 
previous reports in IBS patients but did not reach statistical significance. 
Accord with previous studies was also observed with significantly increased 
abundance in a number of species such as Ruminococcus, Papillobacter, 
Actinomyces, Lachnospiracaea_incertae_sedis, Blautia and Peptococcus spp. 
(Rajilić–Stojanović et al. 2011; Jeffery et al. 2012b; Simren et al. 2013; Bye et 
al. 2014). The L.incertae_sedis spp in particular have previously been 
reported to be enriched in diarrhoea-predominant IBS patients (De Filippo et 
al. 2010). Reductions in abundance were in accord for Parabacteroides spp., 
but results found in our study for Dialister, Veillonellaceae and 
Methanobrevibacter spp. contradicted previous results reported for 
(constipation-predominant) IBS (Bye et al. 2014). Veillonellaceae (and also 
Coprococcus spp.) have been reported to be more abundant in the 
constipation-predominant subgroup of IBS patients (Simren et al. 2013). 
Methanobrevibacter spp. were found to be increased in our study, whereas 
previously levels have been reported to be low, particularly in constipation-
predominant IBS patients (Rajilić–Stojanović et al. 2011), and this had been 
thought to explain the increased flatulence reported by IBS patients.  
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Although our findings were consistent with other FM/IBS studies there 
were some notable differences. Actinomyces, Bifidobacterium and 
Faecalibacterium spp. are often reported to be reduced in abundance in IBS 
but were not significantly different from HC in this study. Bifidobacterium spp. 
may be underrepresented with qPCR techniques due to amplification biases 
(Simren et al. 2013). Although we found Bacteroidetes were significantly 
reduced in IBS, the genus Prevotella, which is often reported to be decreased 
in IBS patients (Simren et al. 2013) and increased in subjects with a high fibre 
intake (De Filippo et al. 2010), displayed no significant difference in 
abundance in our study. Currently three human gut enterotypes are described 
with predominance of Bacteroides, Prevotella and Ruminococcus (Arumugam 
et al. 2011) genera. The Ruminoccocus enterotype is less clearly defined than 
the first two and has been linked to IBS (Simren et al. 2013) and would be 
consistent with findings in this study. However, although this enterotype 
categorisation has been a useful starting point for understanding changes in 
the FM it now seems more likely that enterotypes follow a continuous gradient 
(Jeffery et al. 2012a) of profiles in the community rather than these three 
discrete enterotypes.  
Many studies of the FM in IBS patients have not separated out clinical 
subtypes of IBS (diarrhoea, constipation, or mixed-predominant) and as these 
have been shown to have different FM patterns (Lyra et al. 2009) this may 
account for differences in results between studies. Other confounding factors 
in most FM studies are the variable influences of non-standardised diets, pre- 
and probiotic therapy and other potential FM altering medications. In our study 
almost half the IBS patients were taking either no medication or only the oral 
contraceptive pill (OCP) and numbers of patients on medication were high in 
both IBS-P and IBS-N groups. Universally IBS has a female predominance 
(Canavan et al. 2014a). Sex hormone modulation of the gut microbiota has 
been reported (Mulak et al. 2014) and it is likely OCP therapy has some 
impact on the FM. Approximately one third of subjects with IBS were taking 
acid suppression therapy that has been reported to change the gastric 
microbiome significantly but have much less effect on the FM (Tsuda et al. 
2015). 
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A multilayered mucosal barrier separates the luminal microbes from 
intestinal epithelial cells. The mucosa associated microbiota (MAM) has been 
shown to be different to the FM (Merga et al. 2014) and more abundant  in 
IBS subjects compared to controls (Swidsinski et al. 2005). Discordant results 
in the microbiota profile have been reported between MAM and the FM 
(Codling et al. 2010; Ng et al. 2013; Bye et al. 2014) The FM, utilised in this 
study, constitutes 80% of the luminal microbiota and is much easier to sample 
by obtaining a simple faecal specimen. Differences between studies can still 
arise depending on whether fresh or frozen (and if so how quickly after 
passage of stool) specimens are used. The majority of the MAM are found on 
the luminal surface layer of mucus and only a small number of micro-
organisms that possess suitable adhesion molecules can penetrate the 
mucus layer and directly interface with the epithelial cell (Hong & Rhee 2014). 
MAM, although low in abundance, may have more capacity to influence the 
intestinal epithelial barrier and immune system. Analysis of MAM requires an 
endoscopic procedure with a mucosal biopsy that by necessity, with the 
exception of distal colonic specimens, requires a cleansing bowel preparation 
that has been shown to disrupt the microbial/mucus niche environment (Hong 
& Rhee 2014). 
The main aim of this study was to determine whether particular 
subtypes of diarrhoea-predominant IBS, positive or negative for Blastocystis 
carriage, could be distinguished by their FM profile. Previous studies have 
investigated subgroups of IBS. Significant divergence in the FM between 
diarrhoea-predominant IBS and other IBS groups (constipation-predominant 
and mixed-symptom) has been reported (Lyra et al. 2009), highlighting the 
importance of categorising IBS patients clinically. In contrast another study 
has described three different FM profiles in IBS patients, one profile similar to 
HC, and with no correlation found between the FM profiles and the clinical 
categorisation (Jeffery et al. 2012b). In our study significant differences 
between the IBS-P and IBS-N groups were seen at the phyla and genus level 
although only small numbers of subjects were available for comparison at 
genus level. At the phylum level it was notable that the 
Firmicutes:Bacteroidetes ratio in IBS-P patients was lower than in the IBS-N 
group and this ratio mirrored the changes seen in abundance in these two 
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phyla. The minor phyla also showed differences in our study; the rise in 
Proteobacteria was significantly greater in the IBS-P compared to N and 
conversely the rise in Actinobacteria greater in the IBS-N group.  
Differences between IBS-P and IBS-N have been found in this study 
suggesting Blastocystis spp. are either directly or indirectly influencing the 
local gut microbiome or that the FM in some subgroups of IBS patients is 
more conducive to the carriage of Blastocystis. If IBS-P patients constitute a 
separate clinical subgroup to IBS-N patients, therapy may need to be 
different. There are many possible pathophysiological mechanisms that could 
account for differences in the FM in these two IBS groups. Although no 
definite biomarkers have been identified for IBS, an impaired intestinal 
mucosal barrier (IMB) and evidence of mild chronic immune activation are 
frequent findings. The IMB is a physical, biochemical and immune barrier that 
allows absorption of water and nutrients across the semipermeable barrier 
while providing defence against invasion of luminal microorganisms (Sanchez 
de Medina et al. 2014). The physical elements are the type and density of 
secreted mucin, secretory immunoglobulin A (sIgA), and the integrity of 
epithelial cells and the intervening tight junctions. Biochemical antimicrobial 
peptides are secreted from crypt cells and innate and adaptive immune 
responses defend the basal surface of the epithelial cell lining.  
We have previously reported that Blastocystis carriage, but not 
symptoms, is associated with lower levels of serum IgA (Nagel et al. 2015b). 
IgA is produced by plasma cells and 80% of these are located in the gut 
lamina propria. More IgA is produced than any other immunoglobulin type 
(Suzuki et al. 2010) and it is the predominant mucosal immunoglobulin. sIgA is 
transported into the gut lumen via epithelial cells and physically prevents 
bacterial translocation across the epithelium. However, more importantly sIgA 
has modulatory effects on the FM. Lack of sIgA causes an expansion of 
anaerobic bacteria in the bowel and conversely increased IgA presence is 
reported to induce “tolerance” in host-microbial relationships (Fagarasan 
2008). Blastocystis is strictly anaerobic and may prefer an expanded 
anaerobic microbiota environment. It is likely that the Blastocystis-positive 
subjects may have changes in the FM related to the differences in IgA levels. 
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However, this would not explain why only some Blastocystis positive subjects 
are symptomatic.  
Blastocystis spp. constitute only <1% of the FM. However, their 
presence in the lumen and close contact with the epithelial cells (Wang et al. 
2014a), possibly facilitated by low sIgA levels, may allow greater interaction 
with the intestinal epithelial barrier and host-microbial immune pathways. 
Although some Blastocystis organisms may have unique, as yet undefined, 
pathological attributes, the host immune response may be an important factor 
in determining clinical response to Blastocystis infection. IBS patients are 
more likely to have polymorphisms that are associated with increased 
production of pro-inflammatory cytokines interleukin (IL)-2, 6, 8 and tumour 
necrosis factors and reduced production of anti-inflammatory IL-10 (Hughes et 
al. 2013). Polymorphisms of cytokines have also been reported in Blastocystis 
carriers, but interestingly although changes causing high IL-8 and low IL-10 
levels were associated with IBS only the IL-8 polymorphisms were associated 
with Blastocystis carriage (Olivo-Diaz et al. 2012). We can speculate that 
Blastocystis organisms flourish in an anaerobic luminal microbial environment 
induced by low sIgA that also facilitates intimate contact of Blastocystis or 
other microbes with the IMB and reduces “immune tolerance”. The host-
microbial response is characterised by high IL-8 levels in the Blastocystis 
carrier, and combined with low levels of IL-10 in some susceptible subjects 
causes chronic immune system activation and IBS symptoms. 
 
7.6 Summary 
Differences in the FM in the dominant phyla and the Firmicutes: 
Bacteroidetes ratio are confirmed in diarrhoea-predominant IBS patients 
compared to HC subjects.  Significant differences in the Actinobacteria, 
Bacteroidetes, Firmicutes and Proteobacteria phyla abundance are seen 
between IBS patients positive and negative for Blastocystis carriage. These 
differences might indicate that IBS patients with Blastocystis may constitute a 
separate clinical IBS group. These changes in the FM in symptomatic patients 
may be facilitated by low levels of IgA and IL-10 combined with high IL-8 
levels in the host.  
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Discussions and Conclusions 
8.1 Re-visiting the aims of this thesis 
8.1.1 Aim of the thesis and interest in the organism 
 Blastocystis spp. are the most common enteric parasite found in faecal 
samples submitted for examination in symptomatic patients. My aim was to 
investigate if these parasites are clinically relevant to humans. 
 Blastocystis spp. were first described in 1911 (Zierdt 1991) and finally 
correctly classified taxonomically as a Stramenopile in 1996 (Silberman et al. 1996). 
Scientific interest in the organism over the first eight decades was limited. However, 
over the last twenty years citations in Pubmed45 have risen almost fourfold (from 24 
to 81 articles published per year identified using “Blastocystis” as a search term). 
Research studies in Blastocystis spp. have been facilitated by technical 
developments such as PCR-based sub-typing and culture independent metagenomic 
techniques. Increasing interest in the pathogenesis of functional bowel disorders and 
the persistent reports of association of Blastocystis with clinical disease, particularly 
irritable bowel syndrome (IBS), in humans and the further possibility that infection 
may be zoonotic in nature has further boosted research interest in this organism. 
 
 
8.1.2 Irritable bowel syndrome today 
 Although benign IBS is a chronic disorder affecting approximately 7-21% of 
the population worldwide, usually with female predominance (Chey et al. 2015),  
direct IBS healthcare costs are estimated to be approximately US$5,000 per patient 
per year and a further US$2000 per patient cost to industry for absenteeism and 
presenteeism (Canavan et al. 2014b).  These high costs do not include the financial 
cost of self-medication (up to 45% of affected individuals), the loss of productivity of 
carers or the non-financial costs of reduced quality of life. 
IBS is characterised by a symptom complex of abdominal pain and altered 
bowel habits (Longstreth et al. 2006) and as yet no reliable biomarkers have been 
identified (Corsetti et al. 2014).  IBS is not a single disease but has been described 
as a symptom cluster resulting from diverse pathologies (Chey et al. 2015). Therapy 
for IBS is currently problematic and symptoms often persist for years.  If different 
                                                        
5 http://www.ncbi.nlm.nih.gov/pubmed 
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causes of IBS could be identified, then it is possible that specific therapy could be 
targeted to that particular cause of IBS. 
Previous studies of IBS have identified quantifiable changes in intestinal 
permeability, gut immune activation status, gut motility, visceral sensitivity and 
enteric-brain communication (Chey et al. 2015). It is recognised that more than 10% 
of cases of IBS are reported to follow an infectious gastroenteritis (Schwille-Kiuntke 
et al. 2011) and broad-spectrum antibiotics may be useful therapy (Laterza et al. 
2015). Recent research has further investigated microbial relationships in IBS and 
characteristic changes in the faecal microbiome have been described (Hong & Rhee 
2014). Additionally, the carriage of Blastocystis is reported to be 2-3 times higher in 
IBS patients (Yakoob et al. 2004) suggesting that this organism may be a 
contributing cause of IBS. 
 
8.1.3 Investigating the clinical relevance of Blastocystis spp. 
 Investigation into any common clinically heterogeneous condition lacking 
reliable biomarkers, such as IBS, is challenging. Investigating the clinical effects of 
an organism that is difficult to eradicate and likely causing no adverse health 
outcomes in the majority of carriers is also problematic. Combining both 
investigations is fraught with difficulties, and thus, it was clear that a multi-pronged 
approach to the question of the clinical relevance of Blastocystis was required.  
 In the first instance it was important to define as clearly as possible the 
symptomatic group of patients under investigation. It was necessary to exclude other 
pathology and ensure that no other aetiology for their symptoms could be found. 
Three clinical subgroups of IBS are described, and in order to reduce variables, 
wherever possible, only the diarrhea-predominant IBS group was studied in this 
project. All patients were recruited after presenting with symptoms to the 
Toowoomba Gastroenterology Clinic and having had appropriate clinical 
investigation. This recruitment process allowed tight selection of the IBS group under 
study and was an advantage that many previous studies lacked. 
 In addition, many symptomatic patients actively seeking therapy and within an 
appropriate ethical framework, were offered specific antimicrobial therapy. Follow up 
of these patients enabled evaluation of eradication rates and to a lesser extent, 
clinical outcome.  
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 Specific investigation into Blastocystis was conducted using deconvolutional 
microscopy to investigate the life cycle and PCR sub-typing to investigate possible 
subtype –associated pathogenicity and transmission routes. In order to evaluate 
whether immune responses in the host, rather than specific organisms determined 
symptoms, immunoglobulin levels, specific antibody/antigen reactions and finally 
changes in the faecal microbiome of the host were investigated.  
 
 
8.2 Life cycle of Blastocystis spp. 
8.2.1 Axenic cultures (Chapter 3) 
 Although the interaction of Blastocystis spp. with the human gut was our 
primary interest, axenic cultures can provide a simpler model to investigate 
molecular and biochemical properties of the organism. Axenic culture was first 
described in1921 (Barret 1921) and although basic prerequisites such as neutral pH 
and strict anaerobic conditions have been defined, the culture technique remains 
difficult and unreliable. The main difficulties in separating the parasite from 
contaminating bacteria arise because Blastocystis is physically fragile, limiting 
methods of separation. More importantly, Blastocystis appears to require the 
presence of bacteria for sustained growth (Lanuza et al. 1997). Difficulty in 
developing axenic cultures of Blastocystis has been nominated, in 2012, as one of 
the significant barriers to Blastocystis research (Poirier et al. 2012). We attempted to 
develop axenic cultures of Blastocystis with the intended ultimate aim of investigating 
the intrinsic properties of specific organisms associated with symptomatic clinical 
presentation and also in order to derive pure Blastocystis protein for use in our 
Western blot antibody/antigen studies. Despite trialling three different culture 
methods, and culturing 210 times over 29 months, axenic Blastocystis grew in agar 
only four times and had no success in further continuous subculture in liquid 
medium. Albeit limited, the success we achieved was associated with the transfer of 
a large inoculum of Blastocystis organisms (>106) and transfer to agar in the first few 
days of the initial subculture from faeces.  Initial subcultures had a bi-modal rate of 
growth pattern, peaking at 2-3 weeks and then again at 5-6 weeks before culture 
death. Our findings suggest that there may be some priming factor present in the gut 
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environment that stimulates reproduction and this factor is lost over time in relatively 
sterile culture conditions. 
 
8.2.2 Features of Blastocystis spp. in xenic culture revealed by 
deconvolutional microscopy (Chapter 4) 
 The Blastocystis parasite displays a bewildering array of morphological forms 
with great variation in size (Tan 2008). These attributes not only make it difficult to 
reliably identify the organism in stool but have confounded attempts to identify the 
separate stages of its life cycle. The forms that have been described include the 
vacuolated (VF), granular (GF), amoebic (AF) and cystic form (CF). Although it is 
certain that the robust cystic form transmits infection (Moe et al. 1997), the 
relationship of the other forms to each other is unclear. The function of the large 
vacuole compressing the peripheral cytoplasm of the VF and the multiple different 
granules present in the GF are unknown. The organism contains organelles such as 
nuclei, nucleoli, Golgi apparatus, lysosomes, endoplasmic reticulum but also 
contains often hundreds of unique mitochondria-like organelles (MLO’s) despite 
being a strict anaerobe (Stechmann et al. 2008). The VF and GF display a slimy 
carbohydrate-rich coat that extends for up to 10 m from the pitted surface 
membrane and often contains entangled bacteria (Zaman et al. 1999). 
 These and other features have been described using light microscopy (LM) 
and transmission (TEM), scanning (SEM), freeze-etch electron (FEM) microscopy 
studies. These studies have often been conducted on dead organisms growing in 
axenic culture. We used deconvolutional microscopy (DM) with time-lapse imaging 
and fluorescent spectroscopy of xenic cultures of Blastocystis from stool samples of 
IBS patients and healthy pigs in order to observe these living organisms in their 
natural microbiological environment (Nagel et al. 2015a).  
 Autofluorescence was observed in the VF, GF, cysts and less well in the AF in 
the TRITC excitation/emission light spectra (557/576-nM). The fluorescence was 
greatest in the central area of the cell with spots of light emission observed at the 
surface. This is the first report of green autofluoresence (GAF) in Blastocystis 
organisms. GAF is not a rare finding in microalgae and is known to occur in 
cyanobacteria. The Blastocystis genome suggests incorporation of cyanobacteria 
genes (Denoeud et al. 2011) and consequently the finding of GAF is not unexpected. 
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The chemical nature of GAF is not known although contribution from flavin-like 
molecules or luciferin compounds are suspected (Tang & Dobbs 2007). GAF was 
seen strongly in the central vacuole of the VF. Little is currently known about the 
contents of this vacuole except that it stains positively for carbohydrates (Yoshikawa 
et al. 1995c) and lipids (Yoshikawa et al. 1995d). FITC-conjugated Blastocystis-
specific polyclonal antibody (Blastofluor) stained the surface of VF and GF and 
could be distinguished from GAF. Interestingly, Blastofuor did not stain the surface 
of AF suggesting different surface antigens are present in this form, and could not be 
distinguished from strong GAF in cysts. If “green spectrum” fluorescent-conjugated 
dyes are used in future studies care will need to be taken to differentiate the 
fluorescent dye from GAF.  
 Detailed views of Blastocystis organisms were obtained with DM, but apart 
from observing binary fission developing in VF and GF, we did not observe changes 
form one morphological form to another. The fragile VF and GF‘s often abruptly 
ruptured over the period of observation. One time-lapse study of a large granular AF 
showed the form enlarging, with loss of surface granularity, and then subsequent 
expulsion of tear shaped granules that tracked along fissures to the surface. 
Although AF’s have been reported to be more prevalent in diarrheal stool the nature 
of the granules present in AF has not been studied. We were therefore unable to 
make any conclusions as to the identity of these intriguing tear-drop granules.  
 Indentations on the surface of Blastocystis were previously well described 
using LM and EM, and channels apparently connecting the central vacuole to the 
subsurface have been described using FEM but not confirmed to reach the surface 
membrane. The use of DM allowed description of the existence of multiple surface 
pores of 1m diameter that actively opened and closed every 15 minutes over the 
24hour period of observation. This finding would be consistent with active control of 
channels connecting to the central vacuole although the purpose is not clear. 
Surface pores have important nutritive and osmoregulatory functions in other 
protozoa (Bokhari et al. 2008). The presence of centrally connecting pores would be 
consistent with previous findings that ferritin particles, known to bind electrostatically 
to the lining of deep tubular pits present on the surface of the parasite, are rapidly 
internalised to the central vacuole (Dunn 1992). 
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Another curious phenomenon was recorded using DM, namely the extrusion 
of a viscous material from one or two points only on the surface of a VF. The 
extrusion occurred slowly over 11 hours and the organisms appeared to deflate but 
not rupture during this process leaving an adjacent amoebic-looking form. Typically 
VF has only a fine rim of cytoplasm surrounding the large central vacuole and this 
material most likely exuded from the vacuole. Some of the odd shaped forms seen in 
Blastocystis culture may be these extruded shapes, but we were not able to identify 
nuclear material within these using DAPI staining. Blastocystis is known to survive in 
varying osmotic conditions. The purpose of the vacuole is not known but this 
extrusion may represent an osmoregulatory process. 
In summary, using DM did not shed further knowledge on the life cycle of the 
parasite, but did allow observations of physiological properties and activities in the 
organisms that may inform our knowledge of function.  
 
8.3 Subtyping and epidemiology 
8.3.1 Expectations of subtyping 
 Two years before I started this thesis standardisation of Blastocystis sub-
types (ST’s) (based on the 18S rRNA gene) was published (Stensvold et al. 2007b) 
and in addition to improving diagnosis of Blastocystis carriage, this allowed a much 
more comprehensive comparison of studies than had been possible before using 
ribosome sequences. Previously diagnosis of Blastocystis carriage relied on light 
microscopy or culture and PCR techniques improved the diagnostic yield by 50% 
(Tan et al. 2010).  Using these techniques, carriage of Blastocystis in healthy 
individuals has recently been reported to be 20-53% (Scanlan et al. 2014; O'Brien 
Andersen et al. 2015) and over 60% in some developing countries (Tan 2004).  Most 
workers in the field expected that knowledge of the ST would allow markers for 
pathogenicity to be identified, in addition to giving insights into epidemiology and 
understanding of the zoonotic potential of this parasite. The latter two expectations 
have been realised but not the first.  
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8.3.2 Epidemiology advances 
Advances in our understanding of the molecular epidemiology of Blastocystis 
spp. have revealed subtype variation to occur in different countries and even 
different counties. Currently 17 different ST’s are described and ST1-9 shown to 
occur in humans (Stensvold et al. 2012). Overall ST3 remains the dominant human 
ST of Blastocystis with only Thailand reporting ST1 as the dominant ST (Tan 2008). 
The other common ST’s 1, 2, 4 and 6 show large regional variation in prevalence. 
ST4 has generated a lot of interest as it is almost absent from Asia, Middle Eastern 
countries and South America (Alfellani et al. 2013). Multi locus sequence analysis 
(MLST) of the mitochondrial genome of ST4 organisms has shown organisms to be 
almost clonal with much less genetic variation compared the other subtypes 
suggesting ST4 is a relatively recent mutation of the parasite (Clark et al. 2013).  
 
8.3.3 Zoonotic potential 
The zoonotic potential of the parasite has also been explored and with the 
exception of close personal contact with exotic zoo animals (Parkar et al. 2010), non-
human primates (Stensvold et al. 2009a) and pigs (Wang et al. 2014c) there is little 
overlap with the ST’s found in most animals and birds and those reported in human 
infections (Stensvold et al. 2009a). In particular, a recent study has shown a very low 
prevalence of Blastocystis in dogs from Australian pounds and Cambodian rural 
villages (2.3-1.3%), although a higher prevalence was reported in stray city dogs 
from India (24%) (Wang et al. 2013) ST’s observed in dogs varied widely.These 
findings suggest that dogs, at least in Australia, are not an important reservoir for 
infection for humans. Rodents do commonly carry ST4 and these animals are a 
potential reservoir of Blastocystis infection, although ST4 is a minor contributor to 
Blastocystis carriage in humans and is not present at all in many countries (Clark et 
al. 2013).  
 
8.3.4 Subtypes and pathogenicity 
 There is currently no consensus in the literature regarding specific subtypes 
and their pathogenic potential. ST1, 3 and 4 have variously been reported to have a 
higher prevalence in symptomatic patients (Tan et al. 2008; Eroglu et al. 2009; 
Poirier et al. 2011) while other studies have reported no difference (Dogruman-Al et 
al. 2009; Elwakil & Talaat 2009). 
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8.4 Subtyping and transmission within households  
8.4.1 Subtyping for diagnosis of infection (Chapters 2, 5, 6, 7) 
 We performed four clinical studies in Blastocystis-positive patients with IBS. In 
each study three methods of diagnosis of infection were used, namely light 
microscopy identification in wet faecal smears, culture in Jones medium for 48 hours 
and sub-typing using PCR techniques that identified the 18S rRNA gene. This 
allowed the most accurate identification of Blastocystis infection. 
 
 
8.4.2 Transmission of infection within households (Chapter 2) 
 In our first study eleven Blastocystis-positive patients with irritable bowel 
syndrome, seventeen human and eight animal household contacts were monitored 
for Blastocystis carriage before antimicrobial therapy was administered to the 
symptomatic patients. All human household contacts were positive for Blastocystis 
carriage with 94% demonstrating similarity with the ST found in the symptomatic 
patient. All animal household contacts were positive for Blastocystis carriage with 
88% demonstrating similarity with the ST found in the symptomatic patient at the 18S 
rRNA gene. Blastocystis organisms were seen in fewer numbers in the stool of 
animals and the organism was difficult to grow from these specimens.  Despite this 
similarity, due to the large genetic variability found within STs on more variable loci, it 
is not possible to be sure that these organisms were identical on the 18S rRNA 
gene, but it seems likely. These findings suggest that transmission within households 
is common and that infection is easily spread. In conjunction with the later finding of 
low prevalence in dogs in the community pounds (Wang et al. 2013), but a high 
prevalence in our household pets,  I conclude that dogs  are not natural hosts and 
have likely acquired the infection from their human owners or less likely from a 
common environmental source, not present in Queensland dog pounds. 
 
8.4.3 Subtypes and pathogenicity (Chapters 2,5,6,7) 
 Two of our clinical studies looked at symptomatic Blastocystis-positive 
patients only and the later two studies included positive healthy controls as well.  
Blastocystis sub-typing was performed in all these subjects. The largest cohort was 
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documented in Chapter 7 and this included forty symptomatic IBS patients and fifty-
seven healthy positive controls. The ST’s seen in decreasing prevalence in the IBS 
patients were ST3 (31%), ST4 (27%), ST1 (19%) and others (ST’s 2,5,6,7,8) (23%). 
The ST’s seen in decreasing prevalence in the healthy controls were ST3 (29%), 
ST1 (29%), ST4 (14%) and others (ST’s 2, 5, 6, 7, 8) (29%). Although there was a 
trend for ST4 to be more prevalent in our IBS patients compared to healthy controls 
this difference never reached statistical significance. My findings do not support an 
association of specific subtypes with pathogenicity. 
 
 
8.5  Antimicrobial therapy for Blastocystis infection 
8.5.1 Eradication is problematic 
 Multiple different antimicrobials have been reported to be used as eradication 
therapy for Blastocystis infection with widely varying reports of success (Stensvold et 
al. 2010). The most notable of these is metronidazole, used most commonly in 
clinical practice and currently recommended as first line therapy by the Centre for 
Disease Control of USA. It is reported to have clearance rates ranging from 3-100% 
(Stensvold et al. 2010). Although in vitro sensitivity to metronidazole is high (Zierdt et 
al. 1983; Dunn & Boreham 1991), resistance has been reported (Dunn et al. 2012), 
and there are also problems delivering the active drug to the site of interest (likely 
the ileum) and understanding the length of the course of antimicrobial therapy 
needed (predicated upon knowledge of lifecycle parameters that are unknown at 
present). 
 
8.5.2 Why bother? 
 If Blastocystis spp. are proven to cause symptoms then it will be useful to 
have an effective therapy. However, more to the point at this uncertain stage in 
Blastocystis research is, if Blastocystis infection could be reliably eradicated this 
would allow large clinical trials to be performed in symptomatic patients, who could 
be closely monitored for clinical outcomes. In that context it is important to remember 
that Giardia duodenalis was identified in the 1700’s but not confirmed as a pathogen 
until reliable therapy with imidazoles cured both infection and symptoms (Gardner & 
Hill 2001). 
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8.5.3 Clinical pilot study: efficacy of monotherapy with metronidazole or 
trimethoprim/sulfamethoxazole in Blastocystis-positive IBS patients (Chapter 2) 
 Eleven patients were treated with the most commonly recommended mono-
therapies, namely metronidazole (nine patients with 400 mg three times daily) and 
trimethoprim/sulfamethoxazole (two patients intolerant of metronidazole, 160/800mg 
twice daily). These patients were treated for 14 days and faecal samples taken at 
baseline, within 24 hours of completion of therapy and later at 28 and 56 days post-
therapy. No patient cleared the Blastocystis; there was a 100% failure to eradicate at 
the time of completion of the antimicrobial course. The later samples had been taken 
to check on the possibility of re-infection following primary clearance from 
environmental / person or animal sources, but proved unnecessary. We conclude 
that monotherapy with metronidazole for Blastocystis infection should not be 
recommended as first line therapy and a later study has also concurred with this 
statement (Roberts et al. 2014). 
 
8.5.4 Clinical pilot study: efficacy of triple antibiotic therapy in Blastocystis 
positive IBS patients (Chapter 5) 
 Some organisms are difficult to clear with monotherapy, and Helicobacter 
pylori and Mycobacterium sp. are well known examples of infections that are 
managed with triple antimicrobial therapy. We decided to explore this approach and 
gave 10 Blastocystis-positive patients with diarrhoea-predominant IBS diloxanide 
furoate 500 mg three times daily, trimethoprim/sulfamethoxazole 160/80mg twice 
daily and secnidazole 400 mg three times daily for 14 days. These particular drugs 
were chosen based on the following considerations.  
Secnidazole, an imidazole similar to metronidazole, demonstrated moderately 
high antimicrobial inhibitory action in in vitro testing (Dunn & Boreham 1991), no 
documented intrinsic antimicrobial resistance (Mirza et al. 2010) and double the  
serum half-life of metronidazole with  likely more excretion through the gut (Gillis & 
Wiseman 1996). Trimethoprim/sulfamethoxazole has previously been reported to 
have eradication rates ranging from 22-100% (Stensvold et al. 2010). This 
antimicrobial combination works synergistically to disrupt production of the enzyme 
dihydrofolate reductase required for nuclear purine synthesis and is primarly 
excreted in the urine. Blastocystis organisms are likely to synthesize DNA, and 
require this enzyme (Wu et al. 2010). Trimethoprim, but not sulfamethoxazole, has 
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been shown to have moderate antimicrobial inhibitory action in vitro (Dunn & 
Boreham 1991). However, the combination therapy has been shown to have additive 
inhibitory effects in vitro (Mirza et al. 2010). Diloxanide furoate showed no 
antimicrobial inhibitory action in vitro (Zierdt et al. 1983), but it was chosen because 
it is an effective amoebocidal drug that remains intraluminal within the gut and has a 
high safety profile (Gadkariem et al. 2004).  
Faecal specimens were obtained at baseline, within 24 hours and 4 weeks of 
ceasing antibiotics. Six of ten patients (60%) cleared Blastocystis at the end of the 
therapy (with no recurrence at 4 weeks). This was a small pilot study and the main 
aim was to assess antibiotic clearance rates. However, analysis of this small cohort 
showed higher clearance rates in patients with symptoms for less than one year.  No 
association with clearance was found with age, previous antibiotic therapy, faecal 
parasite load, Blastocystis subtype, serum IgA levels or clinical improvement. The 
lack of association of clearance with clinical improvement is not necessarily a 
deterrent to the argument that Blastocystis sp. may cause symptoms. It may be that 
reducing the load of Blastocystis organisms, but without complete clearance, 
resolves symptoms or that the IBS patients who did not improve with clearance had 
IBS unrelated to Blastocystis infection. 
 
8.6 Host responses to Blastocystis infection 
8.6.1  Blastocystis and the host immune system 
 Blastocystis carriage is reported to be higher in immuno- compromised 
people, including immuno-compromised children (Noureldin et al. 1999; Idris et al. 
2010), Human immunodeficiency virus (HIV) infections (Stark et al. 2007), patients 
with haematological malignancies (Tasova et al. 2000; Poirier et al. 2011) or those 
undergoing cancer chemotherapy (Chandramathi et al. 2012; Mirza & Tan 2012). 
However, although diarrhoea was common in these groups of patients Blastocystis 
carriage was not shown to be significantly higher in symptomatic patients (Tasova et 
al. 2000; Poirier et al. 2011).  
 Immunoglobulin A (IgA) secreted into the gastrointestinal lumen is an 
important host defence. Blastocystis organisms and lysates from cell cultures have 
been shown to lyse IgA (Puthia et al. 2005). Additionally, although Blastocystis sp. 
are luminal organisms with only rare reports of opportunistic mucosal invasion, 
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serum antibodies to Blastocystis antigens in every immunoglobulin class have been 
found by many researchers (Zierdt & Nagy 1993; Garavelli et al. 1995; Mahmoud & 
Saleh 2003).  
Antigen interaction occurs between the gut lumen and the submucosal 
immune system and the nature of this interaction with secretory IgA, specific 
Blastocystis faecal and serum antibodies and cytokine T-cell secretion will modulate 
the host’s response to infection. Blastocystis organisms are reported to cause 
increased production of the pro-inflammatory cytokine interleukin (IL)-8 in an 
enterocyte cell culture system (Puthia et al. 2006). IBS patients are also reported to 
have increased prevalence of polymorphisms causing increased production of IL-8 
and reduced production of the anti-inflammatory cytokine IL-10, but the IL-8 
polymorphisms were only reported to be present in the Blastocystis-positive IBS 
patients (Olivo-Diaz et al. 2012). 
 
8.6.2 Serum immunoglobulin A in patients with IBS versus healthy controls 
(Chapter 6) 
 Forty-diarrhoea predominant IBS patients (26 patients positive for Blastocystis 
sp., 14 negative patients) and 40 HC (24 positive, 16 Blastocystis-negative) were 
enrolled in our recent study. Age, gender, ethnicity, season of blood test, ST of 
Blastocystis and serum IgA were recorded. Mean levels of serum IgA were 25-50% 
lower in Blastocystis carriers (p<0.001) but had no relationship to symptoms or the 
formerly mentioned variables. A lower IgA may allow the Blastocystis to establish in 
the gut lumen but does not appear to influence pathogenicity. 
 
8.6.3 Blastocystis specific serum immunoglobulin responses in patients with 
IBS compared to HC (Chapter 6) 
 In this same study (8.6.2) serum samples from the study groups were run 
against Western blots of Blastocystis (WR1, ST4) antigen. This Western blot 
analysis revealed serum IgG antibodies specific for Blastocystis proteins of 17, 27, 
37, 50, 60-65, 75-90, 95-105, and 150 kDa molecular weight (MW). Reactivity to the 
27, 50 and 75-95 kDa proteins were found significantly more frequently in the IBS 
group compared to the HC and correlation was greater with the Blastocystis-positive 
IBS patients compared to the negative IBS patients. Although the difference in 
reactivity between the groups was significant overall, these proteins were recognized 
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by the host immune response in 86-100% of IBS patients and 44-71% of HC. The 
reaction to these Blastocystis proteins in negative patients suggests either a non-
specific cross reactivity with other antigens or prior exposure to Blastocystis 
organisms. 
 
8.6.4 Identifying serum immunoglobulin responses to Blastocystis antigens 
(Chapter 6) 
 Specific immunoglobulin responses to Blastocystis antigens in IBS patients 
have previously been reported at 30kDa (Abou Gamra et al. 2011), 50 and 118 kDa 
(Hegazy et al. 2008), and 60-100 kDa (Rajamanikam & Govind 2013) and these 
reports correlate with our study findings of proteins of interest at 27, 50 and 75-95 
kDa in symptomatic patients. We used specific antibodies, namely a polyclonal 
Blastocystis ST3 antibody (Blastofluor), a monoclonal cytopathic antibody to 
surface legumain (a cysteine protease) of Blastocystis ST7 (MAb1D5), a polyclonal 
anti-human matrix metalloproteinase 9 (Anti-MMP-9) and a control negative 
monoclonal antibody MAb5, to probe the Blastocystis antigens present on the 
Western blot in an attempt to identify the proteins of interest. 
 The Blastofluor antibody result showed a consistent Blastocystis antigen 
pattern in ST3 and ST4 organisms.   
The MAb1D5 antibody reacted with a double protein band around 100kDa 
and also at 27kDa. MAb1D5 has been shown to react mainly at 30, but also at 100 
kDa in a previous study and protein sequencing at this level has identified 
sequences consistent with a cysteine protease (Wawrzyniak et al. 2012). We 
suspect the 27kDa reaction in our study is identical to the 30kDa protein found in 
other studies and that size differences can be accounted for by small differences in 
antigen preparation and Western blotting technique. Cysteine proteases are 
predicted in the Blastocystis genome, identified in Blastocystis lysates and in general 
are well recognised to be associated with mechanisms of pathogenicity in parasites 
(Denoeud et al. 2011). Our results suggest that the 100kDa protein is an intact 
enzyme and the 27kDa protein is a degraded fragment of a cysteine protease. 
The anti-MMP-9 antibody was selected for trial as metalloproteases are found 
on the surface of parasites, are a well recognised pathogenic mechanism for host 
attack, their presence is predicted by Blastocystis genome studies, and anti-MMP-9 
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reportedly reacts with proteins at 50kDa. In our study the anti-MMP-9 reacted with 
Blastocystis antigen at 27, 50 and approximately 80kDa. These results suggest that 
metalloproteases are produced by Blastocystis spp. A subsequent zymogram 
performed with and without a metalloprotease inhibitor (EDTA) showed abolition of 
reaction with a protein around 100kDa with the addition of the inhibitor. We propose 
that the 80 and 50kDa proteins are either intact pro- or active-enzymes and that the 
27kDa protein is a degraded fragment of enzyme. The reactions at 27kDa may be 
due to more than one type of degraded enzyme fragment.  
 
8.7 The faecal microbiome, IBS and Blastocystis carriage 
8.7.1 Introduction to the faecal microbiome, IBS and Blastocystis 
  The faecal microbiome (FM) comprises bacteria, viruses, archaea and 
eukaryotes, the cell count exceeding by 10 times that of its human host. The 3.3 
million FM genes produce micronutrients and neurotransmitters, metabolise food, 
and facilitate immune priming and defence. Metagenomic analysis, using culture-
independent gene sequencing techniques, has allowed insights into the FM that 
were impossible previously (Bonfrate et al. 2013). The FM is altered in various 
disease states and characteristic changes described in IBS are decreased diversity 
of organisms, temporal instability and changes in the dominant bacterial phyla with 
increases in the Firmicutes: Bacteroidetes ratio (Simren et al. 2013). Three different 
FM patterns have previously been described in IBS patients, with no correlation 
found with clinical categories of IBS (Jeffery et al. 2012a). IBS symptoms may have 
multiple causes and we hypothesized that if Blastocystis sp. are one specific cause 
of IBS it may be possible to identify differences in the FM between Blastocystis-
positive and negative-IBS patients. 
 
8.7.2 Differences in faecal microbiota profiles between Blastocystis-positive 
and negative IBS patients (Chapter 7) 
 Forty patients with diarrhoea-predominant IBS (26 Blastocystis-positive and 
14 Blastocystis–negative) and 57 healthy controls (HC) (42 Blastocystis-positive and 
15 Blastocystis-negative) submitted faecal samples for high throughput culture-
independent metagenomic analysis using 16S ribosomal RNA gene sequencing.  
Differences in abundance of bacteria in these IBS and HC groups were evaluated 
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from phylum to genus level. Significant changes in the two dominant phyla, namely a 
rise in Firmicutes and a statistical significant reduction in relative abundance of 
Bacteroidetes (with a threefold increase in the Firmicutes: Bacteoridetes ratio) were 
observed in IBS patients, regardless of Blastocystis infection status. Further 
subgroup analysis showed Blastocystis-positive IBS patients had significant 
reductions in abundance at the phylum level of Actinobacteria (p= 0.015) and 
Firmicutes (p=0.013), and significant increases in Bacteroidetes (p= 0.05), “Other” 
(unidentified bacteria) (p=0.004) and Proteobacteria (p=0.018) compared to 
Blastocystis-negative IBS patients. These changes were reflected in a lower average 
Firmicutes: Bacteroidetes ratio of 6.19 in Blastocystis-positive compared to 9.00 in 
Blastocystis-negative IBS patients. Minor differences at genus level were also seen 
between the IBS groups in Anaerostipes, Blautia and Alistepes spp.  
These significant differences in the FM between Blastocystis-positive and 
Blastocystis-negative diarrhoea-predominant IBS patients suggest that Blastocystis 
carriage either alters the FM directly, or changes in the FM allow Blastocystis to 
flourish. These differences in FM profile may define a separate clinical subtype of 
IBS. 
 
8.8 Limitations of studies 
8.8.1 Acquisition of patients for the clinical studies 
 There are no reliable biomarkers for IBS. The strength of our clinical studies 
was that the IBS patients were selected rigorously and had full clinical screening by 
one person to exclude other causes of symptoms. This allowed the clinical group to 
be as well-defined as possible. This advantage was also a disadvantage as it meant 
the numbers of patients in the clinical groups was small and it took many months to 
recruit patients.  
 
8.8.2 Axenic culture failure (Chapter 3) 
 Axenic cultures could have provided an abundance of Blastocystis antigen 
from different subtypes and increased quantities of antigen for our Western blot 
studies. Axenic cultures are problematic worldwide and we were not able to resolve 
this obstacle and I have provided suggestions for different approaches to axenic 
cultivation in Chapter 3. It may have been to our advantage that consequently only 
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one ST of Blastocystis was used (WR1) as that reduced the variables in the 
experiment. Large quantities of frozen purified Blastocystis antigen were lost in the 
electricity blackout in Gatton that occurred in the devastating 2011 floods. 
 
8.9 A unifying hypothesis and future directions 
8.9.1 A unifying hypothesis 
I propose that in most individuals with normal to high serum levels of IgA the 
Blastocystis parasite is not able to establish a chronic infection. The sIgA, once 
translocated to the gut lumen, directly lyses the parasite. Additionally these IgA 
levels are associated with a faecal microbiome characterised by a greater 
prevalence of aerobic bacteria that is not a supportive environment for the strict 
anaerobe Blastocystis. 
 In individuals with a low serum IgA the parasite is able to establish a chronic 
infection. Lower levels of sIgA mean that the parasite is not lysed immediately and 
Blastocystis is able to survive in the gut lumen.  Lower sIgA levels allow the parasite 
to position itself in the mucosa associated microbiota layer, adjacent to the 
gastrointestinal mucosal surface. Although eukaryotes, such as Blastocystis, 
comprise less than 1% of the faecal microbiome any organism that has closer 
apposition to the mucosal surface will have a proportionately greater opportunity to 
interact physically and immunologically with the host. 
However, even though some individuals are more susceptible to Blastocystis 
infection only a minority of these people will develop symptomatic disease. We know 
that Blastocystis spp. produce many proteases that are highly immunogenic. I have 
shown in this thesis that antibodies to cysteine proteases, and I would propose 
metalloproteases, produced by this enteric organism can be found in the serum of 
healthy and symptomatic patients, suggesting that these are potent antigens. I 
believe the host response to these antigens determines clinical outcome. 
Host responses are likely to vary between individuals. One possible immune 
response that has already been described relates to changes in gut mucosal 
cytokine production. Individuals with genetically determined cytokine polymorphisms 
causing low levels of protective anti- inflammatory IL-10 and high levels of pro-
inflammatory IL-6 are more likely to develop IBS. Only individuals with these cytokine 
changes and in addition high levels of pro-inflammatory IL-8 have IBS and carry 
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Blastocystis. These cytokine polymorphisms will augment the host inflammatory 
response allowing the parasite to damage the host epithelial cells via activated 
cysteine and metallo-proteinases.  
This group of Blastocystis-positive IBS patients can be distinguished from 
other IBS patients by changes in the faecal microbiome and, I propose, by the 
presence of higher titres of specific serum antibodies to the parasite proteases.  
 
8.9.2 Future directions 
Our studies raise questions that could be explored further in many different 
ways and one obstacle that would be useful to overcome is the difficulty with axenic 
cultures.  
Chapter four describes granules exiting from an amoebic form (AF). It may be 
that Blastocystis organisms need to be primed in the gut environment to convert to 
this form and it would be of interest to examine AF’s and these granules with stains 
for genetic material. 
 We need an antimicrobial regimen that achieves high, probably higher than 
90%, eradication rates to allow accurate evaluation of clinical response in treated 
IBS patients. Two recent studies have reported high rates of clearance using oral 
paromomycin, a poorly absorbed aminoglycoside compound that intriguingly has not 
been shown to have any antimicrobial inhibitory action on Blastocystis sp. in vitro 
(Zierdt et al. 1983). The smaller study (Roberts et al. 2014) describes three of three 
patients given paromomycin as second line therapy who all cleared, and the larger 
study (van Hellemond et al. 2013) involves retrospective review of the hospital charts 
of 52 patients treated with paromomycin 500mg three times daily for 5-7 days and 
reports an eradication rate of 77%. The latter study used only microscopic 
examination of faecal smears for diagnosis of Blastocystis infection. Further trials 
using different combinations of antimicrobials are indicated, including consideration 
of topical antibiotic therapy administered via colonic irrigation.  
  We have identified three Blastocystis antigens at 27, 50 and 75-100 kDa, 
recognized by the host immune response and which may be associated with 
pathogenicity. If large amounts of Blastocystis antigen could be produced, the 
proteins at these bands could be sequenced, identified, amplified using recombinant 
protein technology and ELISA kits could be developed to evaluate these reacting 
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proteins in larger numbers of patients with various gastrointestinal diseases, 
including IBS. These proteins may be biomarkers for a specific IBS subgroup.  
It would also be interesting to check cytokine polymorphisms in all patients in 
future clinical studies that would also combine faecal microbiome profiling and serum 
antibody testing. 
 Future studies would benefit from a larger and more diverse sample size of 
subjects and would most likely need to be multicentred. It will be important to include 
patients with other gastrointestinal diseases into the studies to establish if findings 
are specific to Blastocystis carriage, IBS or common non-specific findings in patients 
with damaged intestinal mucosa.
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9.1 Appendix 1   Jones Medium 
 
Distilled water 962.5ml 
Na2HPO4  disodium hydrogen orthophsophate 1.244 g 
KH2PO4  monopotassium phospahte 0.397 g 
NaCl sodium chlordie 7.087 g 
  
Discard 12.5 ml of solution -12.5ml 
  
Prepare 1% yeast solution 
1g yeast extract in 100ml distilled water 
Add the 100 ml yeast 
  
Adjust pH to 7.0 using 1M NaOH sodium hydroxideas required  
  
Autoclave at 121 C for 30 minutes  
 
9.2 Appendix 2   Lockes medium 
Distilled water 1 litre 
Glucose 5 g 
NaCl sodium chloride 16 g 
Calcium Cl calcium chloride 0.4 g 
KCl potassium chloride 0.4 g 
Magnesium chloride 0.02 g 
Sodium phosphate dibasic 4 g 
Sodium bicarbonate 0.8 g 
Potassium phosphate monobasic 0.6 g 
  
Boil this solution, allow to settle overnight, filter through 
Whitmans paper no1 
 
  
Add 0.02% phenol red (1:25, v/v), autoclave, 
Keep at 4 C till use 
 
 
 
9.3 Appendix 3    Biphasic solid and liquid phase 
 
SOLID PHASE 
Beat eggs with Locke solution and then run 
through a gauze filter 
 
4 parts egg:  1 part Locke solution 
?45ml per egg : 12.5 ml Locke solution 
Dispense the ovosuspension into 5ml aliquots 
Into small screw topped jars 
 Put at 30 C slant for 30mins at 80 C 
 Autoclave, then store at 4 C 
 
LIQUID PHASE 
Locke’s solution plus heat inactivated horse 
serum 1: 
 
 Add 4mL liquid phase to solid phase in  
 Pre-reduce 
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Appendix 5.1 Supplementary File 5.1: Clinical Diary of patients 
 
F=mean bowel frequency over 7 days C=mean consistency over 7 days WB=mean well being score over 7 days AB=antibiotic therapy  
F=number of bowel movements per 24 hours 
C=consistency of bowel action scored: 1= very hard 2=hard 3=formed 4=loose 5=watery 
WB= feeling of wellbeing assessed daily scored 1=feels terrible 10=best ever 
Final Clinical score = Improvement in stool frequency (1-7) + improvement in stool consistency (1-7) +improvement in wellbeing (7-1) 
 
 
 
 1 2 3 4 5 6 7  
Time/ 
Patient 
Baseline AB Week 1 AB Week 2 After AB  
Week 1 
After AB 
Week 2 
After AB 
Week 3 
After AB 
Week 4 
Clinical 
Score 
 F C WB F C WB F C WB F C WB F C WB F C WB F C WB  
1 2.6 3.4 6 2.9 3.6 5.6 3.3 3.9 7.4 2.4 3.3 7.4 2.7 3.0 7.4 2.4 3.4 7.9 2.1 3 9 +4.1 
2 1.5 3 5.1 1.3 2.7 5.6 1.1 2.6 6.9 1.3 2.9 6.1 1.4 3.0 7.0 1.3 2.4 7.0 0.9 2.8 6.6 +2.4 
3 3.0 3.3 5.6 2.1 2.7 4.4 3.7 3.0 4.0 3.3 3.1 4.0 2.4 3.0 4.3 2.3 2.7 5.0 2.7 3.3 5.0 -0.3 
4 2.6 3.5 7.2 2.6 3.1 6.9 3.1 3.4 6.8 3.2 3.5 6.9 2.8 3.6 6.9 2.8 3.5 7.0 2.5 3.6 7.4 +0.2 
5 1.6 3.4 7.1 1.3 2.2 8.0 1.0 2.6 8.0 1.3 2.3 8.0 1.4 3.1 8.0 1.3 3.0 8.1 1.0 3.0 8.1 +2.0 
6 1.3 3.4 7.1 1.8 3.3 7.1 1.4 3.7 6.9 1.3 3.5 7.5 1.3 3.5 7.4 1.3 3.2 7.5 1.2 3.1 7.8 +1.1 
7 4.4 4.0 5.9 2.0 2.7 6.0 1.3 2.5 6.0 2.1 3.0 6.9 2.0 2.9 6.6 2.0 2.9 6.7 2.2 2.8 7.0 +4.5 
8 2.6 3.0 7.0 3.0 3.1 6.7 2.7 3.3 7.3 1.3 3.0 7.6 1.4 3.0 7.0 1.6 3.4 7.1 1.6 3.1 7.4 +1.3 
9 1.6 2.0 9.0 2.0 3.0 7.8 4.4 3.0 7.3 4.4 3.0 8.3 2.0 3.0 8.8 1.0 2.2 9.0 2.0 2.2 8.8 -0.8 
10 2.0 2.4 6.7 2.4 3.2 3.6 2.0 2.6 6.4 2.1 2.1 4.1 1.9 2.2 5.2 1.2 2.5 6.5 1.6 2.7 6.0 -0.6 
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